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Abstract  
 T cell immunotherapy is a novel therapeutic strategy that aims to leverage the antigen-
specific nature of a T cell immune response to treat a variety of immunological conditions.  Over 
the past twenty years, T cell immunotherapy has been applied to treat several types of cancer, 
autoimmune conditions, and chronic infections, culminating in the FDA approval of two highly 
effective chimeric antigen receptor (CAR) T cell therapies targeting hematological cancers in 
2017. While the initial success of T cell immunotherapy has been encouraging, identifying 
appropriate antigenic targets and optimizing T cell activation to promote effective responses in 
vivo remain significant challenges. In this dissertation, we discuss the development and 
application of new molecular tools for identifying, isolating, and activating antigen-specific T 
cells, which are directly relevant to the current challenges facing T cell immunotherapy.  
 One of the greatest obstacles to developing a successful T cell immunotherapy is the 
selection of appropriate antigenic targets. T cells naturally recognize antigen-derived peptides 
presented on polymorphic major histocompatibility complex (MHC) proteins, and different 
MHC alleles exhibit different peptide binding specificities. Therefore, peptides that 
promiscuously bind multiple MHC alleles representing a diverse population have significant 
potential in the development of broadly protective peptide-based therapeutics and vaccines. A 
number of high-throughput in silico strategies have been developed to predict peptide-MHC 
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binding; however, the accuracy of these approaches is generally inadequate for the reliable 
prediction of class II peptide-MHC (MHCII) interactions. In contrast, most experimental systems 
designed to measure peptide-MHCII binding emphasize quantitative detail over throughput. In 
this dissertation, we develop and validate a high-throughput screening strategy to evaluate 
peptide binding to four common MHCII alleles. Using this strategy, which we have termed 
microsphere-assisted peptide screening (MAPs), we screened overlapping peptide libraries of 
antigenic viral proteins and identified 12 promiscuously MHCII-binding peptides. Subsequent 
structural analysis indicated that nearly half of these peptides overlapped with antibody 
neutralization sites on the respective viral protein. Together, these results indicate that the MAPS 
strategy can be used to rapidly identify promiscuously binding and immunodominant peptides 
that have therapeutic relevance.    
 Another significant challenge limiting the successful application of T cell immunotherapy 
is expanding a clinically relevant number of therapeutically effective T cells. The effectiveness 
of a T cell response is largely determined by the spatial and stoichiometric organization of 
signals delivered to the T cell during T cell activation. One strategy for promoting an effective T 
cell response is to tune the presentation of stimulatory and costimulatory signals through 
artificial antigen presentation. However, existing technologies have a limited ability to control 
the spatial and stoichiometric organization of T cell ligands on 3D surfaces. In this dissertation, 
we introduce a novel strategy for presenting highly organized clusters of stimulatory and 
costimulatory ligands to T cells using protein-scaffold directed assembly. Using this approach, 
we systematically investigated how the global surface density, local valency, and stoichiometric 
ratio of T cell ligands on a 3D cellular (yeast) surface can be manipulated to tune T cell 
activation. After validating this approach, we further develop more complex scaffold-assembly 
   xiv 
 
schemes to enhance the controllability of isolating and activating antigen-specific T cells. We 
believe that MAPS and artificial antigen presentation using protein-scaffold directed assembly 
provide a robust toolset for identifying, isolating, and activating antigen-specific T cells for T 
cell immunotherapy.  
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Chapter 1. Introduction 
1.1. T Cell Immunity 
 T cells are specialized cells of the adaptive immune system that inspect antigen 
presenting cells (APCs) for signs of disease using a surface protein called a T cell receptor 
(TCR). Each T cell expresses a unique TCR that recognizes a specific peptide (antigen) bound to 
a major histocompatibility complex (MHC) protein. All nucleated cells in the body process and 
present peptides derived from intracellular proteins on class I MHC (MHCI), while certain 
phagocytic cells (macrophages, dendritic cells, and B cells) process and present peptides derived 
from extracellular material on class II MHC (MHCII). Peptide-MHCI (pMHCI) complexes are 
recognized by CD8
+
 cytotoxic T cells, which directly lyse cells presenting the recognized 
antigen. In contrast, peptide-MHCII (pMHCII) complexes are recognized by CD4
+
 helper T 
cells, which secrete immune-modulating cytokines that promote antigen uptake and B cell 
differentiation or attenuate an immune response upon pMHCII recognition. 
1.1.1 Peptide-MHC Binding  
 Because T cell antigen recognition is restricted to MHC-presented peptides, peptide-
MHC binding is a prerequisite to an antigen-specific T cell response. Therefore, understanding 
how peptides are presented on MHC molecules is an important consideration in T cell immunity. 
Both MHCI and MHCII molecules are highly polymorphic heterodimeric proteins, consisting of 
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an alpha chain and a beta chain. MHC polymorphism results in a number of distinct MHCI and 
MHCII alleles, the frequency of which varies between diverse ethnic populations. To date, 
13,680 MHCI alleles and 5,091 MHCII alleles have been identified.
1
 An important consequence 
of this MHC polymorphism is that different MHC alleles exhibit different peptide-binding 
specificities. As a result, peptides that are stably presented on one MHC allele might not be 
presented at all on another MHC allele. 
 
Figure 1.1. Top down representation of peptide-MHC binding. 
Peptide (red) is shown within the peptide-binding groove of MHCI (green) and MHCII (cyan). 
The peptide-MHCI interaction represents HLA-A2 in complex with a 9mer hepatitis B virus 
peptide (UniProt: 5E00).
2
 The peptide-MHCII interaction represents HLA-DR1 in complex with 
the 15mer invariant chain peptide CLIP (UniProt: 3QXA).
3
  
 While both MHCI and MHCII are polymorphic heterodimeric proteins, they differ 
significantly in how they present antigenic peptides. Peptides presented on MHCI are derived 
from cytosolic proteins, which are degraded into 8 – 11 amino acid peptides by the proteasome 
and loaded on MHCI molecules in the endoplasmic reticulum.
4,5
 In contrast, peptides presented 
on MHCII are derived from exogenous proteins, which are endocytosed and degraded into longer 
13 – 25 amino acid peptides by proteases.6 The early endosomes containing the processed 
   3 
 
peptides then fuse with larger endosomes containing MHCII for peptide loading.
5
 For both 
MHCI and MHCII, peptides are bound by interacting with anchoring residues in a region of the 
MHC molecule called the peptide-binding groove. The peptide-binding groove of MHC is 
composed of a beta-sheet floor flanked by two alpha helices (Figure 1.1). The amino acid 
content of the peptide-binding groove is determined by the particular MHC allele, and thus 
different MHC alleles tend to bind different peptides. Because there are many different MHC 
alleles and the frequency of these alleles varies based on genetic history and ethnicity, peptides 
that stably bind multiple MHC alleles are of considerable interest. Such peptides are referred to 
as “promiscuously binding peptides”, and have significant potential for the development of 
broadly protective of peptide-based therapeutics and vaccines.
7–10
 
 Although the general structure of MHCI and MHCII peptide-binding grooves appear 
similar (Figure 1.1), they have one important difference. The peptide-binding groove of MHCI 
is closed at both ends, completely accommodating 8 – 11 amino acid peptides within the groove. 
In contrast, the peptide-binding groove of MHCII is open at both ends, accommodating longer 
and variable length peptides by allowing the peptide to extend outside of the ends of the groove. 
Peptide-MHCII binding is primarily governed by the interactions between a continuous 9mer 
binding core (also referred to as the peptide-biding register, or PBR) within the peptide and the 
peptide-binding groove.
11
 However, because MHCII-presented peptides are longer than nine 
amino acids, peripheral flanking residues (PFRs) outside the 9mer binding core can also affect 
peptide-MHCII binding through complex, secondary interactions with the MHCII molecule.
12,13
  
 Because peptide-MHC binding is necessary for T cell immune responses, developing 
computational tools to accurately predict binding for any peptide-allele combination has been a 
major focus of applied immunological research.
14
 To this end, a wide range of in silico strategies 
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have been pursued including, machine learning methods using artificial neural networks,
15–20
 
matrix based methods using position-specific scoring,
21–23
 and a number of structure-based 
methods
24,25
 including molecular dynamics.
26
 While these methods – and machine learning 
methods in particular – have significantly improved over the past two decades and can now 
accurately predict peptide-MHCI binding, their performance for reliably predicting peptide-
MHCII binding has lagged behind.
27
 The limited accuracy of in silico peptide-MHCII binding 
predictors is largely due to the structural complexities of MHCII antigen presentation. 
Specifically, it is often difficult to identify the optimal 9mer peptide-binding core within longer 
peptides. Additionally, the open-ended nature of the MHCII peptide-binding groove allows the 
peptide considerable conformational freedom, which produces difficult to predict PFR 
interactions. Further, most machine learning and matrix-based methods require peptide 
sequences to be of identical length to accurately predict binding to a particular MHCII allele.
28
 
These methods will therefore underperform when queried with the variable length peptides 
associated with MHCII binding. In contrast, structure-based peptide-MHCII binding predictors 
are not limited to identical length peptides, but these methods are generally slower and restricted 
to the small minority of MHCII alleles with available crystal structures.
29,30
   
 Given the current limitations of in silico peptide-MHCII binding predictors and the fact 
that the most promising of these methods – namely, machine learning – are trained on 
experimental binding data, robust experimental assays measuring peptide-MHCII binding are 
indispensable. A wide range of strategies
31
 for assessing and/or quantifying peptide-MHCII 
binding have been developed including fluorescence polarization assays,
32
 ELISA,
33,34
 and 
bead
35
 and cell-surface
36
 display screening. While each of these experimental assays has its own 
advantages, the vast majority of peptide-MHCII binding assays use competitive-binding methods 
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for quantifying peptide-MHCII binding affinity (represented as IC50). These approaches yield 
high-quality quantitative peptide-MHCII binding data; however, throughput is sacrificed in favor 
of quantitative detail. Because only a fraction of peptides within a given peptide library will bind 
a particular MHCII allele, protein and labor will necessarily be wasted on measuring the peptide-
MHCII binding affinity for non-binding peptides. Therefore, a preliminary peptide-MHCII 
screening system designed to strike a balance between throughput and detail should increase the 
efficiency of more quantitative assays by rapidly segregating binding peptides from non-binding 
peptides. Such a strategy should also allow the rapid identification of promiscuously binding 
peptides with potential therapeutic applications. This idea will be discussed in more detail in 
Chapter 2. 
1.1.2. T Cell Specificity and Phenotype   
 The specific MHC-bound peptide recognized by a TCR is called a T cell epitope. 
Understanding and identifying T cell epitopes is an important aspect of T cell immunity, as it 
provides insight into antigen processing and presentation that can be used to develop peptide-
based vaccines and targeted therapies for a wide range of immunological conditions.
27,37–41
 T cell 
epitope identification began in earnest in 1996 with development of pMHCI tetramers by J. D. 
Altman and colleagues. In this seminal work, it was shown that biotinylated pMHCI incubated 
with fluorescently labeled avidin could produce tetrameric reagents for antigen-specific staining 
of CD8
+ 
TCRs.
42
 CD8
+
 T cells that bound the fluorescently labeled pMHCI tetramers could then 
be detected and sorted using flow cytometry.
 
This technology was expanded to allow the 
identification of CD4
+ 
T cell epitopes with pMHCII tetramers in 1999.
43
 Since then, a number of 
technological advances including photo-cleavable
44,45
 and enzyme-cleavable
46
 peptide exchange, 
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combinatorial pMHC tetramer staining,
47,48
 and T-cell enrichment
46,49
  have allowed for the 
identification of more than 305,000 MHCI-restricted and more than 95,000 MHCII-restricted T 
cell epitopes, according to Immune Epitope Database and Analysis Resource (IEDB).
50
 While 
the rate of progress has been impressive, it is worth noting that the number of T cell epitopes 
identified thus far represents only a small fraction of the total T cell repertoire, which is 
estimated to be at least 2.5 × 10
7
 specificities.
51,52
    
 In addition to simply identifying T cell epitopes, pMHC tetramer staining also allows the 
phenotype of antigen-specific T cells to be studied by co-staining T cells with fluorescently-
labeled antibodies that bind phenotypic and functional markers on the T cell surface.
37,46,47,53–58
 
Recently, this strategy has been used to profile T cells that recognize unique antigens arising 
from tumor-specific DNA-mutations (neoantigens) with the goal of leveraging this tumor-
specificity in targeted therapies.
56,59–61
  
 While pMHC tetramer and phenotypic marker staining is still commonly used for 
profiling antigen-specific T cells, the number of markers that can be detected simultaneously is 
inherently limited by overlapping fluorescence spectra. The development of cytometry by time 
of flight (CyTOF) – which uses isotopically purified heavy metal atoms and mass spectrometry 
instead of fluorophores and photomultiplier tubes
62
 – has allowed the simultaneous detection of 
more than 40 phenotypic markers on the surface of antigen-specific T cells.
63
 This type of deep 
immune profiling is important for two reasons. First, the high-dimensional datasets acquired 
from CyTOF experiments have shifted the long-established bottleneck for T cell phenotypic 
analysis from data collection to data analysis. This shift has produced an interdisciplinary 
renaissance in immunological research, as sophisticated statistical tools and systems approaches 
are needed to deconvolute the highly complex data.
64
 The second important outcome of high-
   7 
 
dimensional T cell phenotypic profiling by CyTOF, is that these studies have expanded our 
understanding of T cell subsets
65
 and revealed profound relationships between T cell specificity, 
phenotype, and function.
48,66,67
 In a landmark 2012 study, Newell and colleagues used CyTOF to 
show that CD8
+ 
T cells exhibit much greater phenotypic and functional complexity than 
previously thought. This complexity provides a large pool of potential CD8
+ 
T cell profiles, 
allowing virus-specific T cells to exhibit distinct phenotypes and functionalities tailored to the 
targeted pathogen.
66
  
 pMHC tetramer staining has produced a wealth of phenotypic and functional data for 
antigen-specific T cells; however, the pMHC-TCR binding affinity necessary for detection by 
tetramer staining is significantly greater than the pMHC-TCR binding affinity necessary for T 
cell activation.
68,69
 This difference in affinity threshold is especially important considering that T 
cells associated with tumor-specific and autoimmune responses tend to bind cognate pMHC with 
low affinity.
70,71
 Further, pMHC tetramer staining has been less successful in the detection of 
low-frequency antigen-specific CD4
+ 
T cells and rare γδ T cells.71,72 As a result, a significant 
fraction of T cell specificities that contribute to a T cell response will not be detected using 
conventional pMHC tetramer staining. One strategy for overcoming the affinity limitation of 
pMHC tetramer staining is to engineer more multivalent complexes that promote greater pMHC-
TCR binding avidity.
71,72
 Multivalent pMHC pentamers, octamers,
73
 dextramers,
74–76
 and 
dodecamers
77
 have all been shown to increase the sensitivity of T cell epitope detection. Among 
these highly multivalent molecules, pMHC dodecamers based on the linkage of four streptavidin 
molecules to a central scaffold have thus far provided the best staining intensity and sensitivity 
with low non-specific signal.
77
 Further applications of highly multivalent pMHC molecules will 
be discussed in Chapter 3, Chapter 4, and Chapter 5.    
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1.1.3. T Cell Activation  
 A T cell immune response is initiated when a TCR binds a cognate pMHC on the surface 
of an APC. After engaging a cognate pMHC, the immunoreceptor tyrosine-based activation 
motifs (ITAMs) on the intracellular domains of the TCR-CD3ζ chains are phosphorylated by the 
tyrosine kinase Lck. The phosphorylated ITAMs then recruit the zeta-chain associated protein 
kinase 70 (ZAP-70), which promotes further activation signaling by phosphorylating the linker 
of activated T cells (LAT). The phosphorylated LAT then serves as docking station where 
signaling complexes assemble and cascade to the T cell nucleus resulting in a transcriptional 
response (Figure 1.2).  
 
Figure 1.2. Schematic of signaling events that produce T cell activation.  
 
 While much is known about the biochemical pathway leading to and following T cell 
activation, the exact molecular mechanism that links pMHC-TCR binding to ITAM 
phosphorylation (TCR triggering) has puzzled immunologists for decades. One of the reasons 
this mechanism has remained elusive is the paradoxical nature of the pMHC-TCR interaction.
78
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pMHC-TCR binding is highly specific and highly sensitive, yet relatively low affinity (KD ~ 1 – 
100 μM) – properties that appear contradictory in the context of protein-protein binding. The 
enigmatic origin or TCR triggering is problematic because a mechanistic understanding of how T 
cells are activated is crucial for optimizing large-scale ex vivo T cell activation processes for 
immunotherapy. Three general theories have been proposed to explain TCR triggering: (1) the 
receptor aggregation model, (2) the receptor deformation model, and (3) the kinetic segregation 
model.
79
  
 The receptor aggregation model of TCR triggering postulates that clustering of TCR 
complexes recruits a critical number of Lck proteins to the immediate proximity of TCR-CD3 
ITAMs following pMHC engagement, leading to ITAM phosphorylation and TCR triggering. 
Early support for this theory came from the observation that multivalent TCR binding via soluble 
pMHC multimers induced TCR triggering while soluble pMHC monomers did not.
80
 It was 
therefore hypothesized that crosslinked TCRs trapped Lck near the engaged TCR-CD3 
complexes, promoting ITAM phosphorylation and TCR triggering. However, it has been difficult 
to explain how multivalent binding of pMHC can induce TCR-CD3 complex aggregation when 
agonist pMHC are present at such low densities on the surface of natural APCs.
79
 To account for 
this discrepancy, it was suggested that an agonist pMHC adjacent to a non-agonist pMHC might 
trigger multivalent TCR engagement via the TCR coreceptor (CD4 or CD8, depending on the T 
cell type). According to this model, the CD4 or CD8 coreceptor of a proximal but unengaged 
TCR could bind an adjacent pMHC-TCR complex forming a “pseudodimer” structure.81 Under 
these conditions, the proximity of the coreceptors and their associated Lck proteins
82,83
 to the 
engaged TCR ITAMs could be sufficient to drive ITAM phosphorylation and TCR triggering. 
While this model is consistent with the striking observation that non-agonist pMHC significantly 
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enhance TCR recognition of agonist pMHC for CD4
+
 T cells,
84
 it does not explain how TCR 
triggering can occur in the complete absence of co-receptors.
85,86
 
Another set of theories suggests that TCR triggering is not caused by receptor 
aggregation alone, but instead by mechanical force transmitted to the TCR following pMHC 
binding.
87–91
 These receptor deformation models postulate that pMHC-TCR binding coupled 
with cell movement applies tensile and shearing forces to the TCR sufficient to induce a 
conformational change in the TCR-CD3 complex that favors activation. Direct evidence of 
conformational changes in the TCR-CD3 complex has been reported;
92,93
 however, the 
significance of these changes with respect to TCR triggering has yet to be shown. One theory 
that supports the receptor-deformation hypothesis is the safety-catch model of TCR 
triggering.
94,95
 The safety-catch model proposes that basic residue rich sequences (BRS) of the 
TCR-CD3 ITAMs have a tendency to associate with acidic lipid vesicles in the plasma 
membrane. Thus, under normal non-activating conditions, TCR-CD3 ITAMs are buried in the 
membrane and protected from phosphorylation. When an agonist pMHC is bound, the pMHC-
TCR binding event causes a conformational change in the CD3 cytoplasmic domain that allows 
the ITAMs to dissociate from the plasma membrane (safety-off), thus exposing them to 
phosphorylation by neighboring Lck.
94,95
 While elegant and supported by experiment data, this 
theory cannot explain the fact that treating T cells with phosphatase inhibitor causes a significant 
increase in ITAM phosphorylation in the absence of receptor engagement.
96
 More recently, it has 
been suggested that TCR triggering may be a result of the cumulative effect of catch bonds 
between pMHC and TCR.
97
 In a 2014 study, it was shown that weak-agonist pMHC have high 
on and off rates, which allows TCRs to rapidly sample pMHCs via slip bonds. In contrast, 
strong-agonist pMHC – which have slower off rates – transmit force to the receptor through the 
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formation of a catch bond. In this study, the magnitude, duration, and frequency of the force 
applied to the TCR by the bound pMHC directly influenced intracellular Ca
2+
 flux, an early 
hallmark of TCR triggering. This model is consistent with the finding that mechanical force on 
the TCR can produce TCR triggering.
91
 However, it should be cautioned that nearly any surface-
displayed protein-protein interaction will result in the application of some mechanical force on 
the engaged receptors, yet not all biochemical reactions that follow are directly caused by that 
application of force. Further, receptor aggregation and mechanical force on the TCR are not 
mutually exclusive events, and both phenomenon could occur in the course of TCR triggering.
98
    
 The final – and currently most well supported – theory of TCR triggering is related to the 
segregation and redistribution of T cell membrane proteins following pMHC-TCR binding. 
According to the kinetic-segregation theory of TCR triggering, a homeostatic equilibrium exists 
between kinase and phosphatase activity on the TCR-CD3 ITAMs by Lck and CD45/148, 
respectively. This equilibrium is disrupted when pMHC-TCR binding reduces the distance 
between the APC and T cell surfaces to ~14 nm.
99
 Because CD45 and CD148 have large 
ectodomains (28 – 51 nm for CD45 and ~55 nm for CD148),100,101 proponents of the kinetic-
segregation model suggest that these phosphatases are segregated from the close-contact zone of 
the pMHC-TCR complex and redistributed to the periphery to better accommodate their large 
size.
102
 This segregation of the phosphatases from the ITAMs of the engaged TCR-CD3 complex 
tilts the local kinase-phosphatase balance in favor of ITAM phosphorylation. The kinetic-
segregation model is well supported by several independent lines of evidence. First, 
approximately 40% of Lck in resting T cells is constitutively active, and no significant increase 
in Lck activity is observed following pMHC-TCR engagement.
103
 This suggests that pMHC-
TCR binding is not required to activate Lck, and therefore, triggering must occur in the context 
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of constant phosphorylation activity. Second, it has been shown that truncating the CD45 
ectodomain in T cells restricts CD45 exclusion and inhibits TCR triggering.
104
 This finding was 
further supported in an elegant 2012 study in which it was shown that pMHC-TCR binding alone 
is necessary and sufficient to drive CD45 segregation and TCR triggering.
105
 Finally, the kinetic-
segregation model is supported by the well-established finding that surface-bound pMHC 
produces more effective TCR triggering than soluble pMHC, and that elongating surface-bound 
pMHC molecules inhibits TCR triggering.
106,107
     
Regardless of the precise molecular mechanism of TCR triggering, pMHC-TCR binding 
is followed by the repopulation of the T cell-APC interface with a number of costimulatory 
molecules and their respective ligands. The cumulative structure of costimulatory molecules at 
the junction of the engaged T cell and APC is called the immunological synapse, and signaling 
from this structure promotes T cell activation and helps determine T cell response.
108
 The 
traditional model of the immunological synapse is a bulls-eye pattern in which agonist pMHC-
TCR and the costimulatory B7-1/2-CD28 interaction form the central supramolecular activation 
cluster (cSMAC). This central cluster is enriched in Lck favoring TCR-CD3 ITAM 
phosphorylation.
109
 The peripheral supramolecular activation cluster (pSMAC) surrounds the 
cSMAC, and is populated by complexes between intercellular adhesion molecule 1 (ICAM-1) 
and lymphocyte function associated antigen 1 (LFA-1), in addition to the CD4 coreceptor for 
CD4
+
 T cells. CD45 phosphatase is thought to be segregated outside the pSMAC in the distal 
supramolecular activation cluster (dSMAC) early in TCR signaling due to its relatively bulky 
ectodomain. In the absence of costimulatory molecules, a mature immunological synapse does 
not develop, and T cells exhibit an anergic phenotype.
110,111
 In this state, T cells do not 
proliferate, secrete IL-2, or become stimulated following additional pMHC-TCR interactions. T 
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cell anergy is thought to play a role in limiting T cell immune responses to prevent autoimmune 
diseases.
111
 As a result, induction of antigen-specific T cell anergy of self-reactive T cells is 
being pursued for the treatment of autoimmune conditions.
112
  
 In addition to promoting T cell activation and immunological synapse formation, 
costimulatory signaling also influences T cell phenotype and function.
113–117
 Therefore, 
modulating costimulatory and inhibitory molecule signaling can be used to tailor the properties 
of T cells for specific therapeutic applications. Early studies of T cell activation reported pMHC-
TCR and B7-1/2-CD28 binding as the minimum requirements for antigen-specific T cell 
activation.
110
 CD28 signaling promotes T cell survival, expansion, and cytokine secretion,
118
 
while also stimulating Lck activity.
119
 In addition to the well-established importance of the B7-
1/2-CD28 interaction, ICAM-1-LFA-1 binding is also thought to play an important role in T cell 
activation. While the ICAM-1-LFA-1 interaction has traditionally been associated with cell 
adhesion,
120
 recent studies have shown that LFA-1 stimulation modulates T cell gene expression 
and can promote differentiation into Th1, Th17, and regulatory (Treg) phenotypes.
115
 Further, 
ICAM-1-LFA-1 signaling sustains elevated levels of intracellular calcium during pMHC-TCR 
binding and promotes the expansion of proliferation-competent memory T cells.
121,122
 The 
costimulatory role of ICAM-1-LFA-1 binding will be explored further in Chapter 3. Another 
important costimulatory interaction – especially in the context of an anti-tumor T cell response –
is 4-1BBL-4-1BB. Recent studies have shown that 4-1BB signaling is more effective than CD28 
signaling for ameliorating T cell exhaustion in therapeutic chimeric antigen receptor (CAR)-T 
cells.
116
 In addition, 4-1BBL-4-1BB binding is thought to play an important role in enhancing 
tumor-specific cytotoxicity by preferentially expanding memory T cells.
123–125
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 Costimulatory signals do not act independently, and T cell costimulation in the body 
involves multiple molecules with complex spatial and stoichiometric organizations. It has been 
shown that a combination of both CD28 and 4-1BB signaling is superior for the long term 
propagation of CD8
+
 T cells than either signal alone.
126
 Similarly, the presentation of various 
combinations of ICAM-1, B7-1 (CD80), B7-2 (CD86), and 4-1BBL improves T cell 
proliferation and activation compared to presentation of each individual molecule.
126–128
 The 
importance of costimulatory ligand stoichiometry was further highlighted in an experiment 
designed to study cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), an inhibitory analog 
of B7-1/2. Here it was shown that not only could CTLA-4 outcompete CD28 for B7-2 
binding,
129
 but also that CTLA-4 could capture bound B7-2 from the opposing cell surface via 
trans-endocytosis. Interestingly, the researchers showed that a 1:8 stoichiometric ratio of CTLA-
4:B7-2 was sufficient for the complete functional depletion of B7-2 from the APC surface.
130
  
1.2. T Cell Immunotherapy  
 Autoimmune disease, cancer, and chronic viral infections all arise from a breakdown in 
the activation and function of antigen-specific T cells. In autoimmune disease, T cells are 
generally overactive, targeting self-antigen on healthy cells and causing significant damage to 
host tissue. In contrast, cancer and chronic viral infections persist from of a fundamental failure 
of T cells to recognize and destroy tumor and infected cells, respectively. One reason for this 
failure, especially in solid-tumor cancers, is widespread immunosuppression in the tumor 
microenvironment. Tumor metastasis occurs, in part, by evading immune detection using a 
variety of soluble (e.g. IL-10 and TFG-β) and surface displayed (PD-L1) immunosuppressive 
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signals. These signals facilitate immune tolerance by, for example, promoting the expansion of 
tolerant Treg phenotypes.
131–133
  
 To circumvent ineffective T cell activation within immunosuppressive environments, 
tumor-specific T cells can be isolated, engineered, and expanded ex vivo in the presence of 
signals that promote a more effective T cell phenotype. This process of modulating T cell 
phenotype and function to achieve a better clinical response is called T cell immunotherapy. As 
our understanding of T cell biology has improved, T cell immunotherapy has gained traction as 
an effective alternative to conventional therapies, and should continue to do so well into the 
future (Figure 1.3). While T cell immunotherapy has been studied and applied to autoimmune 
conditions
134–137
 and chronic viral infections,
138–142
 the primary application of T cell 
immunotherapy has been in the treatment of a variety of cancers.
143,144
 Therefore, we will largely 
focus on T cell immunotherapy in the context of cancer.  
 
Figure 1.3. Academic publications related to T cell immunotherapy since 1985. 
Number of articles containing the words “T cell immunotherapy” published in academic journals 
each year since 1985. Publication counts were determined using Google Scholar.  
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 The first demonstrated successes of T cell immunotherapy were achieved in the mid-
1980s by S.A. Rosenberg’s research group at the National Cancer Institute. In 1986, Rosenberg 
and colleagues showed that tumor infiltrating lymphocytes (TILs) harvested from a tumor and 
expanded ex vivo in the presence of IL-2 could mediate tumor regression in the lungs and livers 
of mice, in conjunction with cyclophosphamide.
145
 Shortly after this finding, ex vivo expanded 
TILs were used in human trials
146
 and shown to mediate tumor regression in the lungs, liver, 
bone, and skin of up to 60% of patients with metastatic melanoma.
147
 By 2002, highly specific 
TILs expanded ex vivo and re-infused in patients with advanced melanoma were shown to 
mediate tumor regression by exhibiting potent activity toward a self-antigen associated with 
melanoma (MART-1).
148
 This study demonstrated that ex vivo expanded TILs recognizing self-
antigen could persist in vivo, and suggested that the adoptive transfer of similar TILs could be 
used to treat a variety of common cancers. While early trials with ex vivo expanded TILs 
highlighted the incredible potential of T cell immunotherapy, these studies also revealed 
significant limitations of this approach. First, TILs need to be harvested from solid tumors, and 
not all tumors are resectable – that is, not all tumors can be safely accessed for harvesting TILs. 
Further, many tumors that are resectable do not yield appreciable TILs. These limitations led to 
the realization that universal approaches and/or off-the-shelf therapeutic T cells would be 
necessary for T cell immunotherapy to be widely applicable and cost-effective.
149
  
1.2.1 Transgenic TCRs 
 The necessity of universal approaches to T cell immunotherapy inspired researchers to 
identify TCRs that recognize common tumor-specific T cell epitopes. Once identified, TCRs 
recognizing these tumor-specific epitopes can be expressed in autologous T cells to establish off-
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the-shelf therapeutic T cells tailored for different types of cancer.
150
 For example, T cell lines 
expressing TCRs that recognize melanoma-associated antigens could be established and used to 
treat skin cancer. Similarly, T cell lines recognizing additional tumor-associated antigens could 
be established and used to treat other common types of cancer. The first demonstration that T 
cells engineered to express tumor-specific transgenic TCRs could mediate tumor regression in 
advanced melanoma patients was reported in 2006 using the HLA-A2 restricted MART-127-35 
epitope.
151
 This work showed that not only could T cells expressing transgenic TCRs persist in 
vivo, but that these T cells could mediate full clinical regression of metastatic melanoma in 
humans. Additional studies using transgenic TCRs recognizing common tumor associated 
antigens – primarily NY-ESO-1, MART-1, and several melanoma associated antigens (MAGE) 
– have improved on this initial success,152–156  and a number of clinical trials are ongoing.149   
 Despite success in the treatment of melanoma, transgenic TCR immunotherapy is limited 
by the fact that many solid tumors down-regulate antigen presentation machinery including 
MHC molecules.
157
 Further, even when antigen presentation machinery is functional, tumors 
presenting the most common tumor associated antigens are often cleared by the immune system 
early in the disease. This elimination of immunogenic tumor cells exerts a selective pressure, 
allowing less immunogenic tumors to escape in a process called immunoediting.
158
 Tumor 
escape through immunoediting has inspired researchers to study neoantigens produced by unique 
mutations using whole-exome sequencing of tumor cells. While this is a relatively novel 
approach, early results have indicated that T cell recognition of patient-specific neoantigens is an 
important factor in the success of clinical immunotherapy.
60,61
 The growing importance of 
neoantigens in cancer immunotherapy casts doubt on the therapeutic potential of off-the-shelf T 
cells expressing transgenic TCRs that recognize generic tumor associated antigens.  
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 Another challenge associated with T cells expressing transgenic TCRs for 
immunotherapy is the potential for off target activity. In one case, 3 of 9 patients injected with T 
cells expressing a transgenic TCR recognizing the melanoma antigen (MAGE)-A3, experienced 
significant mental health changes within 48 hours of injection. Two of these patients lapsed into 
comas and subsequently died while the third recovered but experienced Parkinson’s like 
symptoms over four weeks. Molecular analysis of human brain samples revealed that neurons in 
the brain expressed MAGE-A12, which cross-reacted with the transgenic MAGE-A3-specific 
TCRs.
159
 Off-target cardiovascular toxicity has also been observed with transgenic MAGE-A3-
specific TCRs; however, in this case the cardiovascular tissue targeted did not express any 
MAGE antigen. Instead, the cardiac tissue presented a peptide derived from the striated muscle-
specific protein titin, which bound HLA-A1 and was molecularly similar to the MAGE-A3 T cell 
epitope.
160
 Finally, transgenic TCR therapy is limited to patients that both have tumors that 
present the target antigen and also match the haplotype restriction of the engineered TCR.
149
 
1.2.2. Chimeric Antigen Receptor (CAR) T cells 
 The idea to expand T cell immunotherapy beyond MHC-restricted antigenic targets was 
first introduced by Japanese researchers
161
 at the Institute for Comprehensive Medical Science in 
Toyake in 1987 and more thoroughly explored by Israeli researchers
162
 at the Weizmann Institute 
of Science in 1989. There, Eshhar and colleagues engineered T cells to express a fusion protein 
consisting of the variable domain of an antibody and the constant domain of a TCR. These 
modified T cells exhibited antibody -like specificity while retaining the ability to transmit signals 
that produce T cell activation.
162
 Eshhar and colleagues modified this novel surface receptor into 
a single chain in 1993 by fusing an antibody single-chain variable fragment (scFv) recognizing a 
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target antigen to the intracellular CD3ζ chain.163 T cells expressing the resulting fusion proteins 
were initially called “T-bodies” – a combination of T cell and antibody – but would become 
more widely known as chimeric antigen receptor (CAR) T cells. 
 The first generation of CAR T cells were relatively simple and closely resembled the 
initial “T-body” design of an extracellular scFv fused to an intracellular CD3ζ chain. While 
promising in theory, the preliminary results of first-generation CAR T cells designed to target 
ovarian and renal cancers, lymphomas, and neuroblastomas were disappointing due to limited in 
vivo persistence and modest activity.
164
 These initial limitations were overcome by engineering a 
second generation of CAR T cells, which included the scFv and CD3ζ domains of the first 
generation fused to either the 4-1BB or CD28 endodomain.
165,166
 In a series of 2009 studies, June 
and colleagues demonstrated that CAR T expressing an engineered receptor containing the 4-
1BB endodomain survived longer in vivo and exhibited significantly greater activity against 
leukemia in tumor-bearing mice than first generation CAR T cells.
167
 In a follow up study, June 
and colleagues further demonstrated that anti-mesothelin CAR T cells containing both the 4-1BB 
and CD28 endodomains persisted longer in vivo and exhibited more potent anti-tumor activity 
than CAR T cells expressing either the 4-1BB or CD28 endodomain alone.
168
 At almost the same 
time, Rosenberg and colleagues found that second generation CAR T cells recognizing the B-cell 
surface antigen CD19 could achieve the complete regression of B cell lymphomas in human 
patients.
169
     
 The initial success of second generation CAR T cells in treating CD19
+ 
hematological 
cancers was proven durable in a series of subsequent studies,
170–173
 and in 2017 the first CD19 
CAR T cell therapies were approved by the U.S. FDA. The first of these therapies, 
tisagenlecleucel-T (Kymriah; Novartis), was FDA approved for treating children and young 
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adults (up to age 25) with relapsed or refractory acute lymphoblastic leukemia (ALL), and is 
currently being considered for use in other CD19
+
 hematological cancers. Within months of the 
approval of Kymriah, the FDA approved a second CAR T cell therapy, axicabtagene ciloleucel 
(Yescarta; Kite Pharma/Gilead Sciences), for the treatment of relapsed or refractory B cell 
lymphoma. The alacritous approval of these new therapies was well founded – within months of 
infusion, 83% of patients treated with Kymriah CAR T cells and 51% of patients treated with 
Yescarta CAR T cells experienced complete remission.
174
 While these results are undoubtedly 
impressive, the approved CAR T cell therapies are the most expensive oncology therapies to 
date, with list prices of $475,000 for Kymriah and $373,000 for Yescarta. A major reason for the 
exorbitant costs of these therapies is that, like transgenic TCR therapies, the FDA approved CAR 
T cell therapies rely on genetically modifying autologous T cells. Reducing the cost will 
therefore require off-the-shelf CAR T cells, though whether such cells will be able to deliver the 
same level of safety and efficacy as autologous CAR T cells remains to be seen.
174
   
 The overwhelming success of second-generation CAR T cells in eradicating 
hematological cancers demonstrated two things. First, it showed that CAR T cell therapy is 
incredibly effective when it can be directed at clear antigenic targets (i.e. CD19). Second, it 
established that costimulatory T cell signaling is indispensable for promoting T cell survival in 
vivo and sustaining anti-tumor activity. Despite the promise of second-generation CAR T cells, 
several important challenges remain. Like transgenic TCRs, CAR T cells are prone to over-
activity and off-target activity if the target antigen is not unique to cancer cells. However, 
because CAR T cells bind their cognate antigen with high affinity, this over-activity can lead to a 
life threatening inflammatory response called cytokine release syndrome (also known as a 
“cytokine storm).175,176 Further, while CAR T cell therapies have been successful against 
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hematological cancers like leukemia and lymphoma, similar therapies targeting solid tumors 
have been much less effective.
177
 This is due in part to the immunosuppressive nature of the 
tumor microenvironment and clinical trials investigating CAR T cell therapy in conjunction with 
PD-1/PD-L1 blockades are ongoing.
166
 However, the single greatest challenge in applying CAR 
T cell therapy to solid tumors is the selection and frequent loss of appropriate antigenic targets 
on tumors. Cancer cells are notoriously fickle and evade targeted therapies via immunoediting 
and downregulating the expression of surface antigen.
178
 The difficulty of overcoming immune 
evasion was highlighted recently when CAR T cells targeting a tumor associated variant of 
epidermal growth factor receptor (EGFRvIII) in patients with glioblastoma resulted in tumor-
antigen loss and adaptive resistance.
179
      
1.2.3. T Cell Immunotherapy Challenges  
 The T cell immunotherapy strategies described hitherto have achieved considerable 
success in the past two decades. However, serious challenges must be overcome for T cell 
immunotherapy to reach its full clinical potential. Identifying and selecting appropriate antigenic 
targets – particularly on solid tumors – is among the most significant of these challenges. Most 
antigens presented on solid tumors are also expressed on healthy cells. This is a serious concern, 
especially with CAR T cell therapies, in which off target activity can produce life threatening 
cytokine storms. In fact, minimizing off-target activity is currently the primary factor in the 
selection of CAR T cell antigenic targets.
180
 The desire to minimize off-target activity has led 
researchers to target unique tumor-specific antigens. However, identifying, isolating, and 
expanding a clinically relevant number of T cells recognizing neoantigens is difficult, as these T 
cells represent as little as 0.002% of the peripheral T cell population prior to therapy.
56
 In 
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addition, the targeting of neoantigens is problematic for CAR T cells, as many neoantigens are 
derived from intracellular proteins and their presentation is MHC restricted.
180
     
 Further, all of the discussed T cell immunotherapy strategies involve the ex vivo 
expansion of autologous T cells. T cell phenotype and function change following repeated 
stimulation and often exhibit significantly reduced proliferative capacity, which negatively 
correlates with the treatment efficacy.
143
 A number of studies have demonstrated that 
proliferative capacity and functionality in vivo can be enhanced by carefully modulating the 
costimulatory and soluble signals delivered to T cells during ex vivo activation.
116,181
 However, 
data regarding the optimal combination of costimulatory signals to maximize in vivo efficacy are 
scarce. Achieving a comprehensive understanding of how T cell costimulation translates to 
therapeutic efficacy will require new modular tools capable of precisely organizing signals 
presented to T cells during activation. Systematic investigation of T cell activation using such 
tools should allow the full characterization of the T cell activation design space. This 
characterization should also help identify and evaluate biomarkers that predict success in vivo.  
1.3. Artificial Antigen Presentation 
While autologous APCs have traditionally been used in clinical environments for safety 
reasons, these cells are not always available or desirable for ex vivo T cell expansion. Expanding 
different T cell types requires different molecular signals that may not be present on autologous 
APCs. Further, maintaining multiple cultures of autologous APCs under different conditions for 
each patient and/or application is laborious and expensive. For example, sipuleucel T (Provenge; 
Dendreon Corporation) is an FDA approved therapy that involves culturing autologous APCs 
with a stimulatory fusion protein containing a peptide associated with prostate cancer. While 
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sipuleucel T was shown to increase the median survival time of patients by 4.1 months,
182
 the 
treatment comes at a cost of approximately $93,000.
183
 The high cost of sipuleucel T is reflective 
of the labor-intensive process of culturing autologous APCs. Reducing the costs and increasing 
the accessibility of T cell immunotherapy will therefore require universal systems capable of 
delivering stimulatory and costimulatory signals to T cells using off-the-shelf components.  
 Artificial antigen presentation seeks to reconstitute the fundamental features of APCs – 
namely, stimulatory TCR ligands and costimulatory molecules – on an artificial or engineered 
cell surface. Artificial antigen presentation systems thus represent a cost-effective, scalable, and 
tunable technology for optimizing ex vivo T cell activation and expansion. A wide variety of 
artificial antigen presentation systems have been engineered thus far,
184
 including planar 2D 
systems, engineered cellular systems, and 3D acellular systems. The most appropriate artificial 
antigen presentation strategy depends on the specific application, and together they have greatly 
improved our understanding of how T cell phenotype and function can be influenced by 
modulating stimulatory and costimulatory signaling during T cell activation.  
1.3.1. 2D Artificial Antigen Presentation Systems 
 2D artificial antigen presentation systems are the most tunable type of artificial antigen 
presentation system, as they are amenable to a wide range of patterning techniques and 
conjugation chemistries. 2D artificial antigen presentation systems can be described as either 
static or dynamic, depending on the mobility of the presented ligands. Static presentation 
systems use lithographic patterning of anchor points (usually metal or organic nanoparticles) to 
immobilize T cell ligands on a surface. In contrast, dynamic presentation systems embed ligands 
in fluid lipid bilayers. While each system has its advantages and disadvantages, both are 
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powerful and customizable platforms for studying the molecular organization of proteins during 
T cell activation.  
 The most successful static presentation systems involves di-block micelle assisted 
lithographic patterning of gold nanoparticles.
185
 Lithographic surface patterning with gold 
nanoparticles allows the spatial organization of T cell ligands to be controlled with nanoscale 
precision. Using this approach, it was shown that T cell activation can be finely tuned by 
modulating both the surface density and intermolecular spacing of TCR-ligands.
186–188
 In 
addition, it was recently shown that lithographic patterning can achieve single molecule 
occupancy on each patterned nanoparticle, providing unprecedented control over the spatial 
organization of individual proteins.
189
 Similarly, lithographically patterned surfaces have also 
been used to show that T cell activation is enhanced when costimulatory molecules (in this case 
anti-CD28 antibodies) are segregated from TCR ligands.
190,191
 More recently, all-organic 
lithographic patterning has enabled the live-cell imaging of T cells interacting with patterned 
proteins by total internal reflection and reflection interference contrast microscopy.
192
 Using this 
approach, researchers observed that while TCR clustering is driven by the nanoscale 
organization of TCR ligands, the cell-scale response as measured by T cell adhesion and 
spreading is determined by the global antigen density.
193
 Taken together these studies indicate 
that T cells recognize the organization of T cell ligands at the molecular level, as well as their 
overall surface density. Further, these reports suggest that T cells integrate spatially complex 
multi-scale signals, which shape the functional T cell response. The precision of patterns created 
using lithography is not attainable in cell-cell or dynamic 2D systems. Therefore, static 2D 
artificial antigen presentation systems represent a highly tunable platform for investigating how 
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the nanoscale organization and geometry of immobilized T cell ligands influences T cell 
activation.
194
     
 The primary disadvantage of static presentation systems using lithographic patterning is 
that they do not allow the patterned proteins to move or reorganize during T cell activation. For 
applications that require dynamic antigen presentation, T cell ligands are presented in fluid lipid 
bilayers,
195
 which allow lateral mobility of the embedded T cell ligands during T cell activation. 
A number of different 2D artificial antigen presentation systems using fluid lipid bilayers have 
been engineered, and studies using these systems tend to emphasize the importance of ligand 
mobility in immunological synapse formation and T cell activation.
194
 For example, when T cell 
ligands were embedded in fluid lipid bilayers of heterogeneous membrane fluidity, it was found 
that T cell activation and immunological synapse formation were notably weaker in less mobile 
membranes than more mobile membranes.
196
 Interestingly, additional studies found that when 
pMHC was embedded in fluid lipid bilayers containing barriers to restrict ligand mobility, T cell 
activation was sensitive to the number of pMHC within individual corrals
197
 and was greatest 
when pMHC and TCR clusters were mechanically trapped at the periphery of the cSMAC.
198
 
While the latter result was counterintuitive based on the traditional understanding of the 
immunological synapse as a bulls-eye pattern, it nonetheless supports the notion that T cell 
activation can be modulated by controlling the spatial organization of T cell ligands. 2D artificial 
antigen presentation systems using fluid lipid bilayers have also provided compelling evidence in 
support of the kinetic-segregation theory of TCR triggering, which has important implications in 
the design of future artificial antigen presentation systems.
104,105,199
 For example, if CD45 
exclusion is necessary to sustain stimulatory Lck and ZAP-70 activity, artificial antigen 
presentation systems incorporating surface displayed supramolecular assemblies should consider 
   26 
 
how assembly size might restrict CD45 exclusion. This idea will be discussed in more detail in 
Chapter 4 and Chapter 5. Despite their demonstrated success as research tools, the relatively 
short shelf-life of dynamic 2D antigen presentation systems limits their potential applications.
200
 
In addition, because artificial fluid membranes lack cytoskeletal components, proteins tend to 
aggregate within these bilayers in the absence of membrane organizers.
201
 
 While 2D artificial antigen presentation systems provide unparalleled control over the 
spatial organization of T cell ligands, these systems are not scalable for large-scale ex vivo T cell 
activation. Further, while the interface between T cells and natural APCs is often described as 
2D, it is not clear if T cells primed on a 2D surface will integrate stimulatory and/or 
costimulatory in the same way as 3D surfaces like natural APCs. For example, 2D artificial 
antigen presentation systems exhibit a constant polarity with respect to the orientation of the 
presented antigen, while natural APCs like dendritic cells do not. This constant field of uniform 
antigen on 2D surfaces may underestimate the importance of adhesion and costimulatory 
molecules, which stabilize the T cell-APC interface and enhance TCR signaling. The differences 
between 2D and 3D artificial antigen presentation systems will be discussed in more detail in 
Chapter 3.      
1.3.2. Cell-based and 3D Acellular Artificial Antigen Presentation Systems 
 Like dynamic 2D artificial antigen presentation systems, cellular artificial antigen 
presentation systems generally present antigen in the context of fluid membranes, allowing 
ligand mobility and immunological synapse formation. However in contrast to 2D systems, 
cellular artificial antigen presentation systems present T cell ligands on a living cell surface with 
active cytoskeletal components, which reduces unnatural protein aggregation and more 
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accurately represents natural antigen presentation. Another significant advantage of artificial 
antigen presenting cells (aAPCs) is that once a desired aAPC is engineered, it can be cloned and 
cryopreserved for extended periods of time. Cryopreservation of well-characterized aAPC clones 
is not only convenient, but also helps ensure batch-to-batch consistency, which is an important 
consideration in the application of off-the-shelf aAPCs in a clinical environment. In addition, 
cellular systems generally lack protein purification steps and are relatively stable under 
physiological conditions. 
 aAPCs have been successfully engineered using four cellular platforms: yeast cells,
202
 
insect cells,
203–205
 fibroblast cell lines,
206–208
 and leukemic cell lines.
126,127,209
 Of these various 
cellular platforms, the human leukemic cell line K562 has been among the most popular for 
artificial antigen presentation, as K562 cells do not express native MHC molecules but do 
express an array of adhesion molecules present on natural APCs. Engineered K562 aAPCs 
expressing various combinations of costimulatory molecules allowed the expansion of distinct T 
cell phenotypes.
126
 Importantly, this result suggests that custom aAPCs expressing different 
molecules can be tailored for the optimal expansion of desired T cell subsets.
126
 Despite 
providing a more physiologically accurate surface for presenting antigen to T cells, aAPCs 
generally provide much less control over the spatial and stoichiometric organization of T cell 
ligands. In addition, while clinical grade aAPCs based on leukemic cell lines have worked well 
in small-scale research environments, many medical professionals have reservations about 
infusing T cells and aAPCs derived from a malignant cell line into cancer patients.
210
 
 In contrast to cellular artificial antigen presentation systems, 3D acellular artificial 
antigen presentation systems pose little risk of immunological complications (e.g. graft vs. host 
disease)
211
 when used with primary T cells. The first 3D acellular artificial antigen presentation 
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systems were designed using sepharose
212,213
 and polystyrene beads.
214,215
 These initial systems 
laid the groundwork for a second generation of tunable 3D artificial antigen presentation 
platforms based on magnetic particles
216
 and a range of biocompatible polymers,
217,218
 and 
liposomes.
219–221
 More recently, advanced acellular artificial antigen presentation systems using 
highly multivalent soluble complexes
222–224
 and nanoparticles
225–227
 have been engineered and 
have significant potential as biocompatible therapeutics that can be delivered in vivo.   
 Currently, the most widely used system for activating and expanding T cells are 
Dynabeads
TM
, which are 4.5 μm diameter beads covalently coupled to anti-CD3 and anti-CD28 
antibodies.
228
 Recently, the Dynabeads
TM
 system has been updated to include anti-CD137 (4-
1BB) antibodies as well, as a result of the increasingly understood importance of 4-1BB 
signaling for T cell survival and proliferation.
116
 While these bead-based systems have been 
effective for expanding a clinically-relevant number of antigen-specific T cells ex vivo,
229
 they 
provide little to no control over the spatial organization of T cell ligands. In addition, these 
systems have been associated with poor biocompatibility in vivo as the small particles are 
susceptible to entrapment in lung capillaries.
230–232
 Liposomes and biodegradable particles could 
prove to be an effective alternative for in vivo immunotherapy; however, these materials are less 
stable than polymeric beads
231
 and sustained antigen presentation in vivo or during long-term 
cell culture could be problematic.    
1.4. Project Overview 
 T cell immunotherapy represents a powerful and promising approach for the treatment of 
a wide range of immunological conditions. However, the continued success of T cell 
immunotherapy will require a more thorough understanding of T cell activation and cost-
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effective tools for controlling the T cell activation process. The central theme of this dissertation 
is the development and application of molecular tools for isolating and activating antigen-
specific T cells, with direct applications to T cell immunotherapy. Because this is an inherently 
broad topic, I have organized the following discussion around three sub-themes, which will be 
discussed in Chapter 2, Chapter 3, and Chapter 4, respectively (Figure 1.4).  
 
Figure 1.4. Organization of dissertation. 
  
 The second chapter of this dissertation will introduce a high-throughput strategy for 
rapidly identifying promiscuous peptide-MHCII interactions. This strategy – which we have 
called microsphere-assisted peptide screening (MAPS) – aims to strike a balance between 
throughput offered by in silico prediction algorithms and quantitative detail offered by 
competition-based binding assays. By screening a reference peptide library with known binding 
affinity to four common MHCII alleles, we found that the in silico prediction algorithms 
recommended by IEDB were poor predictors of peptide-MHCII binding, achieving an AUC of 
only 0.632 compared to 0.851 for MAPS. Using MAPS, we then identified seven peptides within 
the rotavirus VP7 protein and six peptides within the Zika virus envelope (E) protein that bound 
to all four MHCII alleles tested. Interestingly, we also found that these promiscuously binding 
peptides overlapped significantly with antibody neutralization sites on each respective protein, 
indicating that these are immunodominant regions. In addition, we observed that the MAPS 
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signal is sensitive to the relative position of the peptide-binding core within the peptide. While 
unexpected, the sensitivity of the MAPS signal to the relative core position should allow for 
more accurate binding core identification when MAPS is used in conjunction with other 
quantitative peptide-MHCII binding assays. Although the peptide-MHCII screening strategy 
described in Chapter 2 was performed using peptide libraries derived from viral proteins, the 
same approach could be applied to screening neoantigen libraries for the design of potential 
peptide-based cancer vaccines and therapeutics.
40
  
 The third chapter of this dissertation will describe a method for using high-affinity 
protein-protein binding to control the spatial and stoichiometric organization of T cell ligands on 
a 3D yeast cell surface. Using these yeast antigen-presenting cells (yAPCs), we explored the role 
of overall ligand surface density, ligand valency, and costimulatory molecule display ratio on T 
cell activation. Interestingly, we observed that the T cell activation threshold is independent of 
local pMHC density – with or without costimulatory molecules – however, in the absence of 
costimulation T cells require six-fold greater pMHC surface density for activation. Further, we 
observed that T cell IL-2 secretion is maximized at a display ratio of 15% pMHC and 85% 
ICAM-1. The systematic investigation of T cell activation described in Chapter 3 could be 
repeated for additional costimulatory molecules to provide a more comprehensive understanding 
of how T cells integrate signals, and how combinatorial costimulation affects T cell phenotype 
and function.  
 The fourth chapter of this dissertation will describe potential strategies for advancing the 
artificial antigen presentation design space using surface displayed 2D multi-scaffold assemblies. 
These supramolecular assemblies are based on scaffold-scaffold complex formation, where an 
anchor scaffold (aScaf) displayed on the yeast cell surface binds a soluble primary scaffold 
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(pScaf) by in vitro loading. By engineering multi-scaffold complexes, both the valency and the 
spatial organization of multiple ligands can be controlled simultaneously and with nanoscale 
precision. However, before directly applying this approach to tuning T cell activation, we sought 
to understand how these large complexes assemble, what parameters affects their overall 
assembly efficiency. To this end, we developed a theoretical and quantitative approach for 
characterizing each aspect of the assembly process. Interestingly, we found that the assembly 
efficiency of these multi-scaffolded complexes is inherently limited by crowding effects on the 
cell surface. These crowding effects were most prominent for the largest aScafs, which suggest 
that assemblies are created via “outside-in” pScaf loading. While these results are presented in 
the context of whole-cell biocatalysis, the mechanistic insights into protein-scaffold directed 
assembly is equally applicable to the design of highly ordered T cell ligand assemblies in the 
future.  
 Finally, the dissertation will conclude with a brief summary of ongoing work as well as 
potential future directions for these projects in Chapter 5.  
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Chapter 2. Rapid Identification of Promiscuous Peptide-class II MHC 
Interactions Using Microsphere Assisted Peptide Screening (MAPS) 
2.1.  Publication Information  
Smith, M. R., Wen, F. Rapid identification of promiscuous peptide-class II MHC interactions 
using microsphere assisted peptide screening (MAPS). (In Prep) 
 The goal of this chapter is to develop and validate a high-throughput screening strategy 
for evaluating peptide-class II MHC interactions. Specifically, we aimed to develop a new 
peptide-MHC screening strategy that strikes a balance between the throughput offered by 
computational peptide-MHC binding predictors and the quantitative detail offered by 
competition-based peptide-MHC binding assays.  
2.2.  Abstract 
A robust CD4
+
 T cell response is predicated on stable peptide-MHCII binding; however, 
predicting if an antigenic peptide will bind to a specific MHCII protein is a significant challenge. 
Despite promising developments in computational tools, peptide-MHCII binding predictors 
continue to lag behind their peptide-MHCI counterparts. The comparatively disappointing 
performance of peptide-MHCII binding predictors is largely a result of three factors: the 
significant allelic diversity of MHCII and the role of this allelic diversity in influencing peptide 
binding, the long and variable length of peptides presented by MHCII, and the complexity of the 
interactions between these longer peptides and the peptide-binding groove of MHCII. Given 
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these complicating factors, peptide-MHCII binding is most often evaluated experimentally using 
competitive binding assays. While these binding assays provide detailed quantitative information 
for peptide-MHCII binding, this detail comes at the expense of throughput, as 8 to 12 point 
titrations (often in triplicate) are generally required to evaluate just a single peptide-MHCII 
combination. Here, we aimed to develop a high-throughput peptide-MHCII screening strategy to 
strike a balance between the throughput offered by computational peptide-MHC binding 
predictors and the quantitative detail and reliability offered by competitive peptide-MHCII 
binding assays. Using this approach – which we have termed microsphere assisted peptide 
screening (MAPS) – we screened antigenic peptide libraries derived from the rotavirus outer 
capsid glycoprotein VP7 and the Zika virus envelope (E) protein for binding to four common 
MHCII alleles including DR1, DR4, DR7 and DR15. Interestingly, the results of this MAPS 
approach revealed a significant overlap between the peptides from the two viral libraries that 
promiscuously bound all four MHCII alleles and the antibody neutralization sites on each 
respective protein. This overlap suggests a deeper relationship between B cell and CD4
+
 T cell 
specificity, which could be relevant to the design of broadly protective vaccines, as well as the 
identification of immunodominant peptide targets for T cell immunotherapy.  
2.3.  Introduction 
 Identifying antigenic targets recognized by T cells (T cell epitopes) is a critical step in the 
development of peptide-based vaccines and therapeutics for treating infectious disease,
48,233
 
cancer,
182,234
 and autoimmune conditions.
39
 Before a T cell can recognize a specific antigenic 
peptide, that peptide must first be presented by a major histocompatibility complex (MHC) 
molecule. Both class I and class II MHC molecules present peptides through interactions 
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between specific peptide residues (called the peptide binding register, or PBR) and the MHC 
peptide-binding groove. MHC molecules are highly polymorphic
1
 and most of the genetic 
diversity is manifested in the peptide-binding groove of different MHC alleles. As a result, 
different MHC alleles generally exhibit different binding specificities.
27
 Because the frequency 
of MHC alleles varies among ethnically diverse populations, immunodominant peptides from 
viral
235
 and tumor
8
 proteins capable of promiscuously binding multiple MHC alleles are of 
considerable interest for broadly protective peptide-based therapuetics.
7
    
 The peptide-binding groove of class I MHC (MHCI) is composed of a single heavy chain 
and is closed at both ends, limiting the size (8 – 11 amino acids) and conformation of binding 
peptides.
4
 In contrast, the peptide-binding groove of class II MHC (MHCII) is formed at the 
junction of a largely conserved alpha chain and a polymorphic beta chain, and is open at both 
ends. The open-ended nature of the MHCII peptide binding groove allows these molecules to 
present longer (13 – 25 amino acids) and more variable length peptides than MHCI.6 Further, in 
addition to MHCII interactions with the PBR, flanking residues on either side of PBR can also 
interact with MHCII molecules.
12,13
 These peripheral peptide-flanking residue (PFR) interactions 
can vary significantly between peptides, depending on their length and composition, and affect 
peptide-MHCII binding. Because of these factors (i.e. allelic diversity, open-ended peptide 
binding groove, and PFR interactions), predicting if a peptide will bind a single MHCII allele, 
much less multiple alleles, is a significant challenge.   
 Over the past twenty years, several in silico strategies have been devised to predict 
peptide-MHC binding, including matrix based methods,
21,22
 structure based methods,
24,25,29
 and 
machine learning methods using artificial neural networks.
16,17,20,236
 The accuracy of in silico 
peptide-MHC binding predictors are measured by the area under (AUC) the receiver operating 
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characteristic (ROC) curve. Currently, machine learning methods using artificial neural networks 
are among the most accurate in silico predictors, achieving an AUC of approximately 0.85 – 0.95 
for peptide-MHCI binding predictions and an AUC of approximately 0.75 – 0.85 for peptide-
MHCII binding predictions.
237
 The accuracy of peptide-MHC binding predictors can often be 
improved by combining the top-performing individual predictors into a consensus method,
18,238
 
which is the strategy recommended by the Immune Epitope Database and Analysis Resource 
(IEDB).
50
 Although in silico peptide-MHCII binding predictors perform well during cross-
validation with standardized datasets, they tend to underperform when applied to new datasets or 
datasets containing peptides of different lengths.
17
 In a study of 21 different peptide-MHCII 
binding predictors, no individual predictor was found to be suitable for the prediction of 
promiscuously binding peptides.
27
 Moreover, these predictors were characterized by high false-
positive rates and even the most accurate could only identify 50% of actual T-cell epitopes from 
four antigenic protein libraries.
27
     
 Given the limited accuracy and high false-positive rate of in silico peptide-MHCII 
binding predictors, a demand exists for high-throughput systems capable of reliably identifying 
promiscuously binding peptides. To this end, a wide range of experimental methods have been 
applied to measure peptide-MHCII binding, including ELISA,
31,239
 fluorescence polarization,
32
 
gel-filtration with radiolabeled peptides,
31,240
 fluorescence resonance energy transfer 
(FRET),
241,242
 surface plasmon resonance (SPR),
243
 cell-surface display,
36
 and bead-based 
methods.
35
 While many of these techniques are well established and yield quantitative peptide-
MHCII binding data, the vast majority tend to sacrifice throughput in favor of quantitative detail. 
For example, competition based assays like ELISA,
31,239
 fluorescence polarization,
32
 and some 
bead-based methods
35
 involve titrating the target peptide for competitive binding with a labeled 
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reference peptide. Although the quantitative binding data derived from these competition assays 
is critical to improving in silico peptide-MHCII binding prediction algorithms, they typically 
involve 8 – 12 point titrations in triplicate for reliable data. As a result, these strategies require a 
significant amount of MHCII protein for evaluating just a single peptide-MHCII interaction. 
Given that a many of the peptides within a library are unlikely to bind a specific MHCII allele, 
up to 36 allocations (12-point titration in triplicate) of MHCII protein may be dedicated to an 
assay in which no peptide binding occurs. The MHCII protein requirement of competitive 
binding assays could be greatly reduced, and the study of peptide-MHCII binding made more 
efficient, if a preliminary screening strategy was used to identify MHCII binding peptides from a 
large library of non-binders using a binary classification scheme. Once identified, these MHCII 
binding peptides could be studied in more detail without spending unnecessary time and 
resources on non-binding peptides.   
 Here, we developed and validated one such preliminary peptide-MHCII binding assay 
called microsphere-assisted peptide screening (MAPS). The MAPS strategy was designed to 
strike a balance between the throughput offered by in silico peptide-MHCII binding predictors 
and the detail provided by competition-based peptide-MHC binding assays. While the MAPS 
strategy was found to be sensitive to the relative position of the PBR within the peptide, it 
significantly outperformed the recommended IEDB in silico peptide-MHCII binding predictors 
(AUC of 0.851 vs. AUC of 0.632, respectively). Moreover, when MAPS was used to screen 
overlapping peptide libraries derived from the rotavirus outer capsid glycoprotein VP7 and the 
Zika virus envelope (E) protein for binding to four common human class II MHC alleles, we 
identified 12 promiscuously binding peptides that bound all four alleles. Of the 12 promiscuously 
binding peptides within the VP7 and Zika virus E protein libraries, IEDB in silico binding 
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predictors accurately predicted only six, suggesting that computational peptide-MHCII binding 
predictors alone remain insufficient for the reliable identification of promiscuous peptide-MHCII 
interactions. Interestingly, three of the seven promiscuously binding peptides from the VP7 
library and two of the five promiscuously binding peptides from the Zika virus E protein library 
were found to overlap with the immunodominant regions of their respective proteins. Taken 
together, these results demonstrate that MAPS is a reliable, high-throughput method for rapidly 
identifying immunologically relevant peptide-MHCII interactions. 
2.4.  Results and Discussion  
2.4.1.  MAPS Strategy and Experimental Design 
 
Figure 2.1. MAPS strategy overview. 
MAPS involves three steps: prepare, load, and analyze. The preparation step involves purifying 
and biotinylating a panel of diverse human MHCII alleles and synthesizing an overlapping DNP-
tagged peptide library. The loading step involves loading the DNP-tagged peptides from the 
library onto each MHCII allele via peptide exchange, and loading the biotinylated, peptide-
exchanged MHCII on streptavidin-coated microspheres. The analysis step involves staining the 
loaded microspheres for the DNP-tagged peptide and analyzing resulting signal using flow 
cytometry. 
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 MAPS is performed in three steps (Figure 2.1). First, a diverse panel of human MHCII 
alleles were designed, expressed, and purified from insect cells. The alpha chain (DRA) of each 
MHCII was fused to a biotinylation site and each beta chain allele (DRB1*01:01 – DR1, 
DRB1*04:01 – DR4, DRB7:01:01 – DR7, DRB1*15:01 – DR15) was fused to the invariant 
chain peptide CLIP, via a thrombin-cleavable linker. The four MHCII alleles chosen – DR1, 
DR4, DR7, and DR15 – are expected to cover approximately 34% of the U.S. population based 
on known MHCII allele frequencies
244
 and demographic data (Figure 2.2a). 
 
Figure 2.2. Analysis of purified panel of human MHCII alleles.  
(a) Frequency of four MHCII beta-chain alleles among different ethnic groups within the U.S. 
population. (b) SAv gel-shift assay verifying biotinylation of each MHCII allele. Disappearance 
of bio-α band in the presence of SAv accompanied by a shift in the SAv band indicates biotin-
SAv complex formation. (c) SDS-PAGE analysis of thrombin-induced cleavage of the CLIP 
peptide. A reduction in the size of the size of the β-chain in the presence of thrombin indicates 
CLIP cleavage.  
 Each alpha-beta heterodimer was purified from High-Five insect cells and biotinylated. 
The degree of biotinylation was assessed by incubating the purified MHCII proteins with soluble 
streptavidin (SAv) and evaluating the complex formation by a streptavidin shift assay using 
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). All alleles were found 
to be >90% biotinylated (Figure 2.2b). In addition to verifying the biotinylation efficiency, the 
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ability of each MHCII allele to undergo peptide exchange via thrombin-induced cleavage of the 
CLIP-linker fusion was also verified. To evaluate peptide exchange, each MHCII allele was 
incubated with thrombin and the CLIP-peptide cleaved constructs were compared to the 
uncleaved constructs using SDS-PAGE (Figure 2.2c). The reduction in the size of the beta chain 
of each allele confirmed thrombin cleavage. 
 We next synthesized three peptide libraries to screen for binding to each MHCII allele. 
Each peptide library consisted of dinitrophenyl- (DNP) tagged 20mers overlapping by 10 amino 
acids. The first peptide library synthesized was derived from the alkyl hydroperoxide reductase 
(AhpC) protein of Burkholderia pseudomallei. This particular peptide library was chosen 
because it was recently screened for binding to a diverse panel of MHCII alleles including DR1, 
DR4, DR7, and DR15.
245
 The AhpC peptides therefore served as a reference library for 
benchmarking the accuracy of the MAPS strategy, as the binding affinity of each peptide MHCII 
allele combination was known. In addition to the reference library, overlapping peptide libraries 
derived from the rotavirus outer capsid glycoprotein (VP7) and the Zika virus envelope (E) 
protein were also synthesized. VP7 and E protein were chosen for screening because each 
represents a major antigenic target on its respective virus, and immune responses against these 
proteins generally correlates with positive outcomes during infection.
246–250
 
2.4.2.  Validating MAPS Strategy with AhpC Reference Library 
 The MAPS strategy was first validated by screening the AhpC reference library of 16 
peptides with known binding affinities for each DR allele (DR1, DR4, DR7, and DR15). Peptide 
exchange was performed for each peptide-MHCII allele combination, and the exchanged pMHC 
were loaded onto SAv-coated microspheres (Figure 2.1). The microspheres presenting the 
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peptide-exchanged MHCII were then stained for the DNP-tagged peptide and analyzed using 
flow cytometry. Peptide-MHCII binding was quantified as the MAPS signal, which was defined 
as the ratio of the median fluorescence intensity (MFI) of the DNP-tagged peptide bound to each 
allele and the MFI of the DNP-tagged peptide incubated with SAv-microspheres alone. Peptide-
MHC interactions with a MAPS signal greater than or equal to five were classified as binding 
peptides. 
 
Figure 2.3. Validation of MAPS strategy with AhpC reference peptides.  
(a) MAPS signal for each peptide in the AhpC reference library plotted with respect to known 
peptide IC50. (b) Relative MAPS signal plotted with respect to the relative position of the HA306-
318 PBR within a 20mer peptide. PFR residues were mutated to alanine. Relative MAPS signal 
represents the MAPS signal of each peptide normalized by the MAPS signal observed for the 
peptide with a relative PBR position of one (c) ROC analysis of MAPS strategy compared to the 
IEDB consensus peptide-MHCII binding predictor for the AhpC reference peptide library. The 
AUC of each curve is provided in the legend. 
 The accuracy of the MAPS strategy was then evaluated by plotting the MAPS signal of 
each peptide-MHCII combination with respect to the peptide’s known IC50 value, as determined 
from a previous study
245
 (Figure 2.3a). The inverse relationship observed between the MAPS 
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signal and known IC50 value indicates that the MAPS signal largely correlates with peptide-
MHC binding affinity. While the MAPS strategy is generally accurate, we observed that MAPS 
missed some known binding peptides within the reference library (i.e. peptides known to bind a 
particular MHCII allele, but exhibited a MAPS signal less than five). To explain these missed 
binders, we hypothesized that the relative position of the 9mer PBR within the 20mer peptide 
might affect the accessibility of the DNP tag during antibody staining. For example, if the PBR is 
located at the N-terminus of a given peptide, the beta-sheet and alpha helices of the peptide-
binding groove might obstruct antibody binding to the DNP tag, resulting in a lower MAPS 
signal. To test this hypothesis, we synthesized 12 DNP-tagged 20mers in which the relative 
position of the PBR from a well-characterized influenza peptide (HA306-318)
 
was shifted from the 
N-terminus (relative PBR position of 1) to the C-terminus (relative PBR position of 12). The 
remaining residues were mutated to alanine to avoid introducing complex PFR interactions.  
 Each peptide was then loaded onto DR1 and MAPS was performed. The MAPS signal 
for each PBR-variant peptide was normalized such that the MAPS signal observed when the 
PBR was at the N-terminus (relative PBR position of 1) was equal to one. As expected, the 
relative MAPS signal was dependent on the position of the PBR within the peptide (Figure 
2.3b). The relative MAPS signal was highest when the PBR was positioned near the middle of 
the 20mer peptide (between residues seven and ten), which resulted in up to 2.5 times greater 
signal than when the PBR was located at the N-terminus. Interestingly, the relative MAPS signal 
decreased approximately 5-fold from its maximum when the PBR was positioned at the C-
terminus of the peptide, suggesting that the accessibility of the DNP tag might also be obstructed 
when the N-terminus of the peptide is significantly overhanging, or that peptides with a C-
terminal PBRs do not MHC as well. 
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 While the MAPS signal is somewhat sensitive to the relative position of the PBR within a 
given peptide, the actual number of missed binding peptides with unique PBRs should be 
minimal when screening overlapping peptides because most unique PBRs will appear twice. In 
addition, although the sensitivity of MAPS to the relative PBR position tends to reduce the 
overall accuracy of this strategy, this sensitivity could have unanticipated advantages. For 
example, MAPS used in conjunction with more rigorous protein-protein binding assays could 
help identify unique PBRs within binding peptides, which is a significant obstacle to improving 
the accuracy of computational peptide-MHCII binding predictions.
236
 
 The AhpC reference library was also screened for predicted binding to each MHCII allele 
using the in silico bioinformatics tools provided by IEDB.
50
 Peptide-MHCII binding was 
predicted using the IEDB recommended consensus method,
238
 which combined the predictions 
provided by the artificial neural network-based method NN-align,
20
 the stabilized matrix method 
SMM-align,
22
 and the combinatorial library method CombLib.
251
 The binding score of the 
consensus prediction was given as a percentile rank, which scores each peptide’s predicted 
binding affinity against the binding affinities of five million random 15mers from the 
SWISSPROT database. Therefore, peptides given a low percentile rank were predicted to be 
strong binders while peptides given a high percentile rank were not predicted to interact strongly 
with that particular MHCII allele. We defined a predicted binder as a peptide with a percentile 
rank of less than or equal to 20, in line with previous studies of promiscuously binding 
peptides.
252
 Because the methods provided by the IEDB database are designed to predict MHCII 
binding of 15mer peptides, each 20mer peptide in the reference library had to be broken down 
into six different 15mers. The low, median, and mean percentile rank of each of these 15mers 
was then recorded to evaluate the binding prediction. The accuracy of the IEDB binding 
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predictions were compared to the experimental results using MAPS by plotting the respective 
ROC curve of each (Figure 2.3c above). Based on this analysis, the AUC for the MAPS ROC 
curve was found to be approximately 0.851, while the AUCs for the IEDB ROCs were 
significantly lower, ranging from 0.540 for the median percentile rank to the 0.632 for the mean 
percentile rank. These results indicate that while the MAPS strategy is susceptible to false-
negatives depending on the relative position of the PBR within a peptide, it significantly 
outperforms the predictions provided by IEDB for 20mer peptide-MHCII binding.  
2.4.3.  MAPS of Rotavirus VP7 Protein 
 
 
Figure 2.4. Overlapping rotavirus VP7 library of DNP-tagged 20mers used for MAPS. 
 
 After validating the MAPS strategy with the AhpC reference library, we synthesized a 
25-peptide library of overlapping 20mers derived from the rotavirus outer capsid glycoprotein 
VP7 (Figure 2.4). Rotavirus is the most common cause of diarrheal disease in children 
worldwide
253
 and remains a significant health challenge in developing countries despite the 
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approval of two rotavirus vaccines.
254,255
 Moreover, genetic analyses of circulating rotavirus 
strains have revealed differences between the dominant antigenic epitopes on VP7 in circulating 
rotavirus strains and the vaccine strains, potentially allowing vaccine-resistant mutants to 
emerge.
246,256
 Given the antigenic drift observed in circulating rotavirus strains and the 
persistence of rotavirus infection across ethnically diverse regions (e.g. sub-Saharan Africa, 
Southeast Asia, etc.), we aimed to identify promiscuously binding peptides within the VP7 
protein, as such peptides might have relevance in peptide-based therapeutics and/or diagnostics.  
 
Figure 2.5. MAPS signal of each rotavirus VP7 peptide for each human MHCII allele. 
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 Each 20mer in VP7 peptide library was loaded onto the four MHCII alleles, and peptide-
MHCII binding was determined by MAPS (Figure 2.5). Promiscuously binding peptides were 
defined as peptides that exhibited a normalized MAPS signal greater than five for all four 
MHCII alleles. Based on this criterion, seven promiscuously binding peptides within the VP7 
protein were identified: VP741-60, VP771-90, VP781-100, VP7111-130, VP7211-230, VP7251-270, and 
VP7301-320 (Figure 2.6a). Of these seven promiscuously binding peptides, only three were 
predicted to bind all four alleles by the mean and median of the IEDB percentile rank prediction, 
while four were predicted to bind all four alleles by the lowest IEDB percentile rank prediction 
(Table 2.1). Further, of the four human MHCII alleles screened, only DR4 was predicted to bind 
all seven promiscuously binding peptides using the IEDB consensus method. These results are 
consistent with the performance of the IEDB peptide-MHCII binding prediction for the AhpC 
reference library, and suggest that in silico strategies alone remain insufficient to reliably predict 
peptide-MHCII binding. 
 
Table 2.1. IEDB consensus method percentile rank of peptide-MHCII binding for 
promiscuously binding VP7 20mers. 
Peptides were defined as binders if the percentile rank below was less than or equal to 20, in line 
with previous studies investigating promiscuous MHCII-binding peptides. 
 
Mean IEDB Rank Median IEDB Rank Low IEDB Rank 
VP7 Peptide DR1 DR4 DR7 DR15 DR1 DR4 DR7 DR15 DR1 DR4 DR7 DR15 
41-60 15.9 9.1 4.0 11.2 13.0 7.0 1.7 10.2 9.6 6.2 0.9 8.7 
71-90 36.9 14.5 21.7 15.9 38.2 13.1 24.0 18.3 28.5 11.0 14.0 4.2 
81-100 54.2 28.1 51.6 68.5 48.0 10.3 47.1 81.6 32.3 2.4 31.4 4.8 
111-130 12.6 2.2 9.0 6.3 12.8 2.0 10.1 5.6 9.5 1.6 2.8 5.6 
211-230 50.1 19.4 57.6 38.9 47.7 17.3 56.4 36.5 47.7 15.5 51.1 32.9 
251-270 45.1 28.4 17.6 29.7 48.8 31.9 18.9 26.3 19.0 9.2 1.7 5.5 
301-320 10.0 4.0 6.5 2.8 10.0 4.0 4.6 2.4 5.6 3.3 3.9 1.3 
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 To explore the potential immunogenicity of the promiscuously binding VP7 peptides, the 
position of each peptide within the VP7 protein was analyzed. VP7 contains three dominant 
antigenic epitopes: 7-1a (BCE 1), 7-1b (BCE 2), and 7-2 (BCE 3),
247
 all of which are located 
near the interface of separate VP7 trimer units. Interestingly, three of the seven promiscuously 
binding VP7 peptides (VP781-100, VP7111-130, VP7211-230) identified by MAPS significantly 
overlapped with these dominant antigenic epitopes (Figure 2.6b). The most striking overlap was 
observed for VP781-100, which included 8 of the 14 residues of BCE 1. Further, VP781-100 and 
VP7111-130 together cover nearly all of BCE 1, overlapping with 12 of the 14 residues (Figure 
2.6c). VP7211-230 – the VP7 peptide associated with the greatest MAPS signal – also overlapped 
with dominant antigenic epitopes, albeit to a lesser extent, sharing 3 of the 6 residues of BCE 2 
and 2 of the 9 residues of BCE 3 (Figure 2.6c).  
 
Figure 2.6. Structural analysis of MAPS-identified promiscuously binding VP7 peptides. 
(a) MAPS signal for each promiscuously binding VP7 peptide. (b) Comparison of the sequence 
overlaps between three dominant B cell epitopes (BCE) on the VP7 protein (top row) and the 
promiscuously binding peptides VP781-100, VP7111-130, and VP7211-230. (c) Amino acid sequence 
and position of each BCE within the VP7 protein. Overlapping residues with promiscuously 
binding VP7 peptides are indicated in red.  
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 The significant overlap between the MAPS-identified promiscuously DR-binding VP7 
peptides and the dominant antibody neutralization sites on the VP7 protein was unexpected and 
its immunological relevance is not immediately clear. It is possible that these particular 
promiscuously binding peptides simply contain “sticky” residues within their primary structure 
that promote non-specific protein-protein interactions. If a peptide exhibits promiscuous binding 
to different MHCII alleles, then it seems reasonable to think that the given peptide might also 
interact promiscuously with other proteins, including immunoglobulins. Alternatively, B cells 
are professional antigen presenting cells, and internalize extracellular material, including viral 
particles, using surface displayed B cell receptors (BCRs). Therefore, it is possible that protein 
fragments that are bound by BCRs are more likely to be presented on B-cell surface displayed 
MHCII than protein fragments that are not bound by BCRs. However, B cell antigen 
internalization and presentation alone does not explain why the peptides capable of binding 
multiple MHCII alleles would be overrepresented in terms of sharing residues with antibody 
neutralization sites. Finally, we cannot preclude the possibility that this overlap between the 
promiscuously binding VP7 peptides and dominant antibody neutralization sites is merely a 
coincidence observed for this particular protein. To determine if this observation is simply a 
coincidence or some phenomenon unique to rotavirus VP7, we synthesized an overlapping 
peptide library for the Zika virus E protein and performed a similar structural analysis. 
2.4.4.  MAPS of Zika Virus Envelope Protein  
 Zika virus is a type of flavivirus, which is a family of structurally similar enveloped 
viruses transmitted by ticks and mosquitoes. Flaviviruses are commonly associated with tropical 
climates and include West Nile virus (WNV), dengue virus (DENV), tick-borne encephalitis, and 
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yellow fever (YFV), among others. The primary antigenic target on flaviviruses – including Zika 
virus – is the envelope (E) protein, which binds to host cell receptors and mediates virus entry.248 
The Zika virus E protein has three domains, EDI (residues 1-52, 132-193, and 280-296), EDII 
(residues 52-132 and 193-280), and EDIII (residues 296-406)
257
 and is highly similar to the E 
protein of other flaviviruses, ranging from 39.5% similarity for tick-borne encephalitis to 57.8% 
similarity for dengue virus 1 (DENV1).
258
  
 Because Zika virus E protein is similar to the E protein of other flaviviruses, antibodies 
that bind E protein are often cross-reactive. However, rather than neutralizing a heterologous 
flavivirus infection, these cross-reactive antibodies tend to exacerbate the infection by promoting 
the internalization and replication of virus in Fc-receptor expressing cells.
259
 This phenomenon, 
known as antibody-dependent enhancement (ADE), can be life threatening and underscores the 
importance of eliciting a highly specific, neutralizing antibody response against E protein in 
areas where multiple flaviviruses circulate. A number of recent studies have shown that 
antibodies targeting the EDIII domain of the Zika virus E protein tend to be potently 
neutralizing
249,250,257
 and less cross-reactive with E protein from other flaviviruses than 
antibodies targeting EDI or EDII.
257
 Therefore, the EDIII domain of Zika virus E protein is of 
special interest for a potential Zika virus vaccine.  
 Although a robust and neutralizing antibody response generally correlates with flavivirus 
immunity, less is known about the contribution of T cells to clearing flavivirus infection. 
However, it is thought that T cells play an important role in clearing flavivirus infections from 
the central nervous system (CNS).
260,261
 In a recent study, it was shown that no antibodies are 
present in the CNS during persistent Zika virus infection in nonhuman primates, and decreased 
Zika viral load in the CNS correlated with the initiation of a CD8
+
 T cell response.
262
 This 
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observation is especially interesting considering that while most individuals infected with Zika 
virus are asymptomatic, serious neurological complications including microcephaly
263
 and 
Guillain-Barre syndrome
264
 have been observed at rates up to 1 in 100 and 1 in 5,000 infections, 
respectively.
265
 Because a robust T cell response to Zika virus could play a role in mitigating 
these neurological complications, the identification of both CD4
+
 and CD8
+
 T cell epitopes 
within Zika virus proteins is an active area of research.
266
  Early findings have suggested that, in 
contrast to other flaviviruses in which T cell epitopes are primarily located on nonstructural 
proteins (NS), T cell epitopes in Zika virus appear to be located on structural proteins including 
E protein.
257,260
 Given the potential importance of E-protein specific T cell responses for 
mitigating neurological complications in Zika virus infection, we aim to apply MAPS to identify 
promiscuously binding peptides within the E protein. In addition, we will also explore any 
overlap between MAPS-identified promiscuously binding peptides and antibody neutralization 
sites on the Zika virus E protein, as these shared residues could highlight immunodominant 
targets for peptide-based therapeutics and/or vaccine development. 
 To identify promiscuously binding peptides within the Zika virus E protein, we 
synthesized an overlapping DNP-tagged peptide library of E protein 20mers (Figure 2.7). As 
with the rotavirus VP7 peptide library, each E protein 20mer (ZikVE) was loaded onto the four 
MHCII alleles and peptide-MHCII binding was determined by MAPS (Figure 2.8). Based on the 
criterion that promiscuously binding peptides exhibit a MAPS signal greater than or equal to five 
for all four MHCII alleles, five promiscuously binding peptides within the E protein library were 
identified: ZikVE51-70, ZikVE131-150, ZikVE191-210, ZikVE311-330, ZikVE351-370 (Figure 2.9a). Of 
the five promiscuously binding ZikVE peptides identified by MAPS, only two were predicted to 
bind all four alleles by the lowest IEDB percentile rank prediction (Table 2.2). Interestingly, 
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only DR4 was predicted to bind all five promiscuously binding peptides, which is consistent with 
the IEDB prediction for the promiscuously binding VP7 peptides. Together these results provide 
further evidence that while the IEDB consensus method for predicting promiscuous 20mer 
peptide-MHCII binding is generally inaccurate, it most accurate for DR4. 
 
Figure 2.7. Overlapping Zika virus E protein library of DNP-tagged 20mers used for 
MAPS. 
 
 
Table 2.2. IEDB consensus method percentile rank of peptide-MHCII binding for 
promiscuously binding ZikVE 20mers. 
Peptides were defined as binders if the percentile rank below was less than or equal to 20, in line 
with previous studies investigating promiscuous MHCII-binding peptides. 
 
Mean IEDB Rank Median IEDB Rank Low IEDB Rank 
ZikVE DR1 DR4 DR7 DR15 DR1 DR4 DR7 DR15 DR1 DR4 DR7 DR15 
51-70 46.4 7.1 30.1 20.4 40.6 4.6 29.8 22.7 30.1 3.0 22.7 4.0 
131-150 3.4 0.7 19.9 1.7 2.5 0.5 20.6 1.7 2.3 0.4 11.1 1.7 
191-210 46.6 15.8 39.9 18.4 44.9 17.5 42.6 17.9 33.3 0.9 6.8 12.2 
311-330 15.0 14.4 20.1 35.6 6.5 9.3 13.5 34.6 1.6 4.0 5.9 24.7 
351-370 12.0 6.3 11.1 9.9 9.4 5.0 11.9 10.9 7.7 3.7 9.3 4.7 
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 In contrast to other flaviviruses and rotavirus, a Zika virus vaccine does not currently 
exist. Therefore, dominant antibody neutralization sites on a vaccine strain cannot be used as 
point of comparison for the structural analysis of the promiscuously binding peptides within the 
Zika virus E protein. However, it is well documented that antibodies binding the EDIII domain 
tend to be potently neutralizing and less prone to ADE than antibodies binding the EDI and EDII 
domains.
257
 Analyzing the position of each promiscuously binding ZikVE peptide within the 
structure of the E protein dimer revealed that one promiscuously binding peptide is within the 
EDI domain (ZikVE131-150), while two are within the EDII  (ZikVE51-70 and ZikVE191-210) and 
EDIII domains (ZikVE311-330 and ZikVE351-370) (Figure 2.9b). 
 While less data is available regarding specific antibody neutralization sites on the Zika 
virus E protein, a 2017 study reported that a neutralizing antibody in Zika-infected individuals 
contacted residues A311, T351, and L352, among others.
249
 These residues can also be found 
within the EDIII promiscuously binding peptides ZikVE311-330 and ZikVE351-370. Moreover, the 
same study also reported that mutating the lysine at residue 394 to alanine eliminated antibody 
binding, suggesting that antibody recognition of K394 is critical for neutralization. While the 
relevant peptide ZikVE391-410 did not fulfil our criterion as a promiscuously binding peptide, it 
exhibited a MAPS signal greater than five for three of the four alleles tested (DR1, DR4, and 
DR7). If we include this quasi-promiscuously binding ZikVE391-410 in our analysis, 8 of the 18 
antibody neutralization sites on the E protein were also present in promiscuously binding ZikVE 
peptides. Similarly, another study reported that antibodies contacting residues M68, S70, V153, 
T315, and P354 (among others) were potently cross neutralizing to Dengue and Zika virus. In 
addition to the T315 and P354 residues found in the promiscuously binding EDIII peptides 
ZikVE311-330 and ZikVE351-370, M68 and S70 are found in the promiscuously binding EDII 
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peptide ZikVE51-70. In total, 6 of the 16 E protein antibody neutralization sites described in this 
study are also present in the MAPS-identified promiscuously binding ZikVE peptides. Therefore, 
as with the promiscuously binding VP7 peptides, we observed considerable overlap between the 
MAPS-identified promiscuously binding ZikVE peptides and antibody neutralization sites on the 
Zika virus E protein.   
 
Figure 2.8. MAPS signal of each Zika virus E protein peptide for each human MHCII 
allele. 
 
 While the data gathered thus far are insufficient to definitively preclude coincidence, the 
significant overlap between MAPS-identified promiscuously binding peptides and antibody 
neutralization sites for both the rotavirus VP7 protein and Zika virus E protein suggests a deeper 
relationship between BCR binding and antigen presentation to CD4
+ 
T cells. This phenomenon 
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of paired antigen specificity between B cells and T cell has been observed before,
267,268
 and 
might be caused by the fact that B cell receptor (BCR) bound residues are protected from 
degradation during B-cell antigen processing.
269
  
 
Figure 2.9. Structural analysis of MAPS-identified promiscuously binding peptides in the 
Zika virus E protein dimer.  
(a) MAPS signal for each promiscuously binding E protein peptide. (b) Structural analysis of 
promiscuously binding peptides within the E protein dimer. The E protein domains are color 
coded in the top row (EDI – red, EDII – yellow, and EDIII – green) and the location of each 
MAPS-identified promiscuously binding peptide is shown in the bottom row.  
A similar phenomenon was observed in a recent study that found CD4
+
 T cells preferentially 
target the same structural proteins (e.g. E protein) as B cells during Dengue infection.
270
 
Moreover, as in the present study, researchers observed significant overlap between regions of 
the Dengue E protein recognized by CD4
+
 T cells and those targeted by IgG molecules. 
Together, these results suggest that virus-specific B cells bind, internalize, and present structural 
proteins on MHCII during virus infection, which preferentially expand CD4
+ 
T cells of the same 
or similar specificity.
270
 An interesting outcome of shared B/T cell specificity is the possibility of 
predicting CD4
+
 T cell epitopes from known antibody neutralization sites and vice versa.
271
 
Regardless, the observed overlap between antibody neutralization sites and CD4
+
 T cell epitopes 
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highlights the importance of MHCII restriction – and the corresponding utility of peptide-MHCII 
screening strategies like MAPS – in the design and development of vaccines.271  
 Although we have not yet (work in progress) independently confirmed that the 
promiscuously binding ZikVE peptides are actual CD4
+
 T cell epitopes, a 2018 study
266
 found 
that ZikVE51-70, ZikVE131-150, and ZikVE191-210 existed as CD4
+
 T cell epitopes in HLA-DR4 
transgenic mice primed with 25 μg of recombinant Zika envelope protein. Similarly, ZikVE131-150 
and ZikVE311-330 were also shown to be CD4
+
 T cell epitopes in HLA-DR1 and HLA-DR15 
transgenic mice, respectively.
266
 Further, when mice were challenged with Zika virus infection, 
CD4
+
 T cell response to ZikVE351-370 was among the strongest as measured by IFNγ ELISpot. 
These results indicate that each of the promiscuously binding E protein peptides identified using 
MAPS have been shown to be true T cell epitopes in either humans or animal models. Moreover, 
while the aforementioned study included DR1, DR4, and DR15, we can confirm that these 
peptides (ZikVE51-70, ZikVE131-150, ZikVE191-210, ZikVE311-330, and ZikVE351-370) also bind DR7, 
which provides broader coverage to Hispanic and African American populations (10.5% and 
9.8%, respectively).  
2.5.  Conclusions and Outlook 
 Viral infections and their vaccination are often studied in the context of a neutralizing 
antibody response; however, CD4
+
 T cells also play an important role in viral immunity.
272
 
Therefore, identifying T cell epitopes is an important part of understanding how viral antigens 
are processed and presented, as well as predicting what viral protein fragments are likely to be 
recognized by T cells. A thorough understanding of T cell epitopes derived from viral proteins 
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should help in the development of both diagnostic tools and peptide-based vaccines and 
therapeutics.
9,273,274
  
 However, before a T cell epitope can be identified the cognate peptide must be loaded 
onto an MHC molecule. Because peptide-MHC binding is a prerequisite for T cell epitope 
discovery, it is necessary to first evaluate whether a particular peptide is capable of binding a 
particular MHC allele. While computational tools have come a long way in the past two decades 
– especially for peptide-MHCI binding prediction – reliably predicting peptide-MHCII binding 
remains a challenge.
238
 This is largely because the open-ended peptide-binding groove of MHCII 
molecules allows for the presentation of longer peptides than MHCI. Longer peptides coupled 
with open-ended binding grooves allow for a greater number of possible peptide conformations 
within MHCII, the optimum of which is difficult to predict. This difficulty is further complicated 
by secondary interactions between flanking residues at the peripheries of the peptide PBR and 
the MHCII molecule. In addition, MHCII are characterized by substantial allelic diversity, which 
is manifested in different peptide-contacting residues within the peptide-binding grooves of 
different MHCII alleles. This MHCII polymorphism results in MHCII molecules exhibiting a 
wide range of peptide-binding specificities, depending on the particular MHCII allele. Therefore, 
MHCII allelic diversity must be carefully considered in the development of therapeutic products 
if they are to be applicable to an ethnically diverse population.  
 Here we report the development and validation of MAPS – a high-throughput screening 
strategy for rapidly identifying promiscuously MHCII-binding peptides. Using this approach, we 
identified seven and five 20mer peptides derived from the rotavirus VP7 protein and the Zika 
virus E protein, respectively, capable of strongly binding four common class II MHC alleles. 
Moreover, a structural analysis of these promiscuously binding peptides within their respective 
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proteins revealed substantial overlap with dominant antibody neutralization sites, indicating that 
these peptides correspond to immunodominant regions of each viral protein, and are thus strong 
candidates for diagnostic and peptide-based vaccines. In addition, these findings contribute to a 
body of knowledge
269–271
 that suggests a more complex and important relationship between the B 
cell and CD4
+
 T cell specificity.  
  In addition to independently confirming that the MAPS identified promiscuously binding 
peptides are T cell epitopes by tetramer staining, we also plan to quantify peptide-MHCII 
binding affinity using conventional assays.
32
 This quantitative peptide-MHCII binding data will 
then be reported so that it can be included in large datasets that are used to train predictive 
peptide-MHCII binding algorithms. The identification of promiscuously binding peptides is 
particularly interesting in the context of training predictive peptide-MHCII binding algorithms, 
as these peptides necessarily exhibit physical characteristics that allow binding to diverse MHCII 
alleles. Further investigation of the chemical and structural similarities between promiscuously 
binding peptides should help elucidate molecular signatures that promote their promiscuous 
binding and improve the accuracy of predictive algorithms.   
 While quantitative binding data is critical to improving the accuracy of computational 
peptide-MHCII binding predictors, this data alone provides an incomplete picture of peptide-
MHCII binding. Identification of the 9mer PBR core that facilitates the principle interaction 
between a peptide and an MHCII molecule is also important. In fact, PBR identification is one of 
the greatest challenges associated with predicting peptide-MHCII binding.
28
 Although the MAPS 
strategy described here was designed to rapidly identify promiscuously binding peptides, the 
method used to detect peptide binding was found to be sensitive to the relative position of the 
PBR core within 20mer peptides (Figure 2.3b). While this unforeseen sensitivity complicates the 
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translation of the observed MAPS signal to peptide-MHC binding affinity, it does provide some 
insight into the location of the PBR. As a result, MAPS coupled with quantitative measurements 
of peptide-MHCII binding affinity might provide a basis for the informed prediction of the PBR 
within a 20mer peptide. Moreover, our data suggests that the accuracy of such a prediction will 
likely improve if the PBR is located near the extreme ends of the peptide, where the MAPS 
signal is most sensitive (Figure 2.3b).  
 The central theme of this dissertation is the development and validation of molecular 
tools with applications in T cell immunotherapy. Like any tool, MAPS is designed for a specific 
task; namely, a simple and high-throughput method for identifying peptides that promiscuously 
bind to multiple MHCII alleles. In addition to identifying promiscuously binding peptides from 
antigenic viral protein libraries, MAPS also provided insight into immunodominant regions of 
these viral proteins that could be targeted by both B cells and CD4
+ 
T cells during viral 
infections. While we demonstrated the utility of the MAPS strategy in the context of viral 
immunity, this approach is also applicable to the high-throughput screening cancer neoantigens 
for cancer immunotherapy.  
2.6.  Materials and Methods  
2.6.1. Protein Design, Expression, and Peptide Synthesis 
 Human MHCII proteins were assembled by isolating the extracellular domains of the 
alpha chain HLA-DRA (UniProt: P01903, residues 26-216) and each beta chain allele: HLA-
DRB1*01:01 (UniProt: P04229, residues 30-227), HLA-DRB1*04:01 (UniProt:P13760, residues 
30-227), HLA-DRB1*07:01 (UniProt: P13761, residues 30-227), HLA-DRB1*15:01 (UniProt: 
P01911, residues 30-227). The leucine zipper dimerization motifs Fos and Jun were fused to the 
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C-terminus of the DRA and DRB1 chains, respectively, as described elsewhere.
275
 The 15 amino 
acid AviTag
TM
 (GLNDIFEAQKIEWHE) was fused to the C-terminus of the Fos dimerization 
motif on the DRA chain to allow for biotinylation and a 6X-Histidine tag was fused to the C-
terminus of the complete recombinant DRA chain for purification. The N-terminus of each 
DRB1 chain was fused to the invariant chain CLIP87-101 peptide via a thrombin-cleavable linker 
to allow for peptide exchange, as described elsewhere.
276
 The C-terminus of the Jun-dimerization 
motif of each DRB1 was fused to a 6X-Histidine tag for purification. Finally, the N-terminus of 
each dimeric chain was fused to the baculovirus gp64 signal peptide and ligated into separate 
baculovirus transfer vectors pAcGP67A (BaculoGold Baculovirus Expression System, 
Pharmingen BD Biosciences, San Jose, CA). The DNA sequence of each construct was verified 
by Sanger sequencing.  
 Spodoptera frugiperda (SF9) insect cells were transfected with transfer vectors carrying 
the recombinant DRA chain and each recombinant beta chain (DR1, DR4, DR7, and DR15) with 
linearized Baculovirus DNA (Pharmingen BD BaculoGold Biosciences, San Jose, CA) using 
Cellfectin II (Invitrogen) according to the manufacturer’s protocol. Low-titer P0 viral stocks 
carrying the recombinant DRA and DRB1 genes were isolated from the transfection supernatant 
and amplified separately in SF9 cells to create high-titer P1 viral stocks. Each human MHCII 
heterodimer was expressed by co-infecting High-Five cells at a density of 2.0 M/mL with equal 
volumes of high-titer P1 DRA and DRB1 baculovirus stocks. MHCII protein was harvested 72 h 
after infection and purified using affinity chromatography with Ni-NTA beads according to the 
manufacturer’s protocol (Qiagen). SDS-PAGE analysis was performed to evaluate protein purity. 
 Approximately 0.5 mg of each peptide used in this work was chemically synthesized by 
Sigma-Aldrich (Woodlands, TX). Each peptide was designed to be 20 amino acids long and was 
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fused to an N-terminal dinitrophenyl (DNP) tag. Peptide libraries covering the B. pseudomallei 
alkyl hydroperoxide reductase (AhpC) protein (UniProt: Q63T73 residues, 1 – 180), the rotavirus 
outer capsid glycoprotein VP7 (UniProt: P11853 residues 41 – 320), and the Zika virus E protein 
(UniProt: A0A024B7W1 residues 291 – 794) were designed such that each 20mer peptide 
overlapped with the preceding peptide in the sequence by 10 amino acids. DNP-tagged variants 
of DR1-binding peptide the HA306-318 were synthesized were also synthesized to determine how 
relative PBR position affects MAPS signal. Peptides in the libraries that could not be chemically 
synthesized were not included in the MAPS analysis, and explain any non-consecutive sequences 
in Figure 2.4 and Figure 2.7.  
2.6.2. Biotinylation and Peptide Exchange  
 After purifying the human MHC-CLIP proteins, the DRA chain of each heterodimer was 
biotinylated. Biotinylation reactions were performed with the AviTag
TM 
biotinylation kit 
(Avidity LLC, Aurora, CO) according to the manufacturer’s protocol. Biotinylation reactions 
were performed at room temperature overnight. The biotinylation efficiency for each allele was 
assessed using a streptavidin gel-shift assay. Briefly, biotinylated MHC-CLIP proteins were 
buffer exchanged into HEPES buffered saline (HBS) and incubated with excess streptavidin for 
1 h at 30 °C. The complexes were then analyzed using SDS-PAGE, and biotinylation efficiency 
was evaluated by estimating the fraction of the biotinylated DRA chain that shifted following 
incubation with streptavidin.  
 Peptide exchange was performed similar to previously published methods,
46
 with some 
modifications. Prior to peptide exchange, the CLIP87-101 peptide fused to each DR beta chain was 
cleaved. CLIP87-101 cleavage was performed by incubating the MHC-CLIP protein with 
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restriction grade thrombin (Novagen, Madison, WI) for 2 h at 37 °C at a concentration of ten 
units per milligram of protein. Thrombin-induced CLIP87-101 cleavage was confirmed using SDS-
PAGE (Figure 2.2c). Following CLIP87-101 cleavage, peptide exchange was performed by 
transferring the empty DR alleles into peptide exchange buffer containing 50 mM sodium citrate 
pH 5.2, 1% octylglucoside, and 100 mM NaCl. DR alleles were then incubated with 25 molar 
excess DNP-tagged peptides for 16 h at 37 °C. Peptides were diluted in a solution of 50% 
DMSO in HBS to minimize precipitation prior to loading. After 16 h, the peptide exchange 
reaction was neutralized by adding 1/5 volume of 1 M Tris pH 8.0.     
2.6.3. MAPS and Flow Cytometry  
 Following peptide exchange, 2 μg of each exchanged MHCII was incubated with 100,000 
streptavidin-coated microspheres (Bangs Laboratories, Fishers, IN) in 1% bovine serum albumin 
(BSA) for 1 h at room temperature. In parallel, an equivalent amount of DNP-tagged peptide 
used in the peptide exchange reaction was incubated with streptavidin-coated microspheres in the 
absence of MHCII for calculating the MAPS signal. After loading, the microspheres were 
washed in 1% BSA and stained with 2 ng/μL of rat anti-DNP antibody (Clone LO-DNP-2, 
Invitrogen, Waltham, MA) for 30 min at room temperature. Stained microspheres were washed 
in 1% BSA and stained with 2 ng/μL of secondary goat-anti-rat PE (Invitrogen, Waltham, MA) 
for 30 min at room temperature. The stained microspheres were then washed twice in 1% BSA 
and resuspended in 500 μL for analysis by flow cytometry.  Flow cytometry was performed by 
gating on the population of single microspheres and analyzing the median fluorescence intensity 
(MFI) from the DNP fluorescent staining. The MAPS signal was determined by normalizing the 
peptide-MHC DNP MFI by the MFI of the peptide incubated with the microspheres alone. This 
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normalization accounted for non-specific binding of peptides to the streptavidin-coated 
microspheres. Peptide-MHC interactions exhibiting a MAPS signal greater than or equal to five 
were defined as binding interactions.   
2.6.4. IEDB peptide-MHCII Binding Prediction  
 IEDB peptide-MHCII binding predictions were performed by entering each 20mer 
peptide sequence and predicting its binding to DRB1*01:01, DRB1*04:01, DRB1*07:01, and 
DRB1*15:01 using the IEDB recommended prediction method. The output data was broken 
down into six 15mers for each 20mer sequence provided. The IEDB consensus method
238,251
 was 
used to predict peptide MHCII binding, which provided a binding percentile rank for each 
15mer. The percentile rank binding score was calculated by comparing the predicted peptide-
MHCII binding affinity of the target peptide against 5 million random 15mers from the 
SWISSPROT database. Accordingly, a low percentile rank indicated a high predicted binding 
affinity while a high percentile rank indicated a low predicted binding affinity. The mean, 
median, and low percentile rank were calculated from the six 15mers derived from each single 
20mer sequence, and analyzed separately. Peptides were said to be binders if the percentile rank 
was less than or equal to 20, in accordance with a previous study concerned with promiscuously 
binding peptides.
252
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Chapter 3. Protein-Scaffold Directed Nanoscale Assembly of T Cell Ligands: 
Artificial Antigen Presentation with Defined Valency, Density, and Ratio  
3.1.  Publication Information  
Smith, M. R., Tolbert, S. V., Wen, F. Protein-Scaffold Directed Nanoscale Assembly of T Cell 
Ligands: Artificial Antigen Presentation with Defined Valency, Density, and Ratio. ACS Synth. 
Biol. 7(6), 1629 – 1639. 2018. 
 The goal of this chapter is to demonstrate that T cell activation can be finely tuned by 
controlling the spatial and stoichiometric organization of T cell ligands on the surface of a yeast 
cell. To our knowledge, this is the first study demonstrating that the nanoscale organization of T 
cell ligands on the surface of a living cell can be controlled using supramolecular assembly 
engineering based on cohesin-dockerin binding. Stephanie Tolbert assisted in expressing and 
purifying the proteins used in this study.  
3.2.  Abstract.  
 Tuning antigen presentation to T cells is a critical step in investigating key aspects of T 
cell activation. However, existing technologies have a limited ability to control the spatial and 
stoichiometric organization of T cell ligands on 3D surfaces. Here, we developed an artificial 
antigen presentation platform based on protein scaffold-directed assembly that allows fine 
control over the spatial and stoichiometric organization of T cell ligands on a 3D yeast cell 
63 
 
surface. Using this system, we observed that the T cell activation threshold on a 3D surface is 
independent of peptide-major histocompatibility complex (pMHC) valency but instead is 
determined by the overall pMHC surface density. When intercellular adhesion molecule 1 
(ICAM-1) was coassembled with pMHC, it enhanced antigen recognition sensitivity by 6-fold. 
Further, T cells responded with different magnitudes to varying ratios of pMHC and ICAM-1 
and exhibited a maximum response at a ratio of 15% pMHC and 85% ICAM-1, introducing an 
additional parameter for tuning T cell activation. This protein scaffold-directed assembly 
technology is readily transferrable to acellular surfaces for translational research as well as large-
scale T-cell manufacturing. 
3.3.  Introduction  
 In nature, T cells are activated by binding peptide-major histocompatibility complex 
(pMHC) and costimulatory molecules displayed on the surface of antigen presenting cells 
(APCs). These T cell ligands form complex multi-component assemblies with both the micro- 
and nanoscale organization. The spatial and stoichiometric organization of these assemblies 
plays an important role in promoting T cell expansion and determining T cell phenotype and 
function.
117,277
 Therefore, identifying the spatial and stoichiometric parameters of T cell ligand 
assemblies that promote robust T cell activation is critical to reveal molecular insights that can 
be applied to translational immunotherapy.  
 A variety of artificial antigen presentation systems have been developed to control the 
spatial organization of T cell ligands including modified fluid lipid bilayers
194,197,198,278,279
 and 
patterned coverslips.
279–281
 Nanolithographic patterning of TCR ligands (e.g. anti-CD3, anti-
TCR, and pMHC) on glass coverslips has been used to determine a minimum pMHC surface 
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density of 90 – 140 pMHC/μm2 for T cell activation.186,189 Above this threshold, T cell response 
can be fine-tuned by controlling the global TCR-ligand surface density.
186–188
 The nanoscale 
organization of TCR-ligands can be quantified as TCR-ligand valency, and has also been shown 
to affect T cell activation.
81,223,282–284
 When two soluble pMHC molecules are crosslinked by a 
peptide linker, T cell activation is inversely correlated with the linker length (5 nm – 9 nm).282 
Other studies demonstrated that T cell activation can be further enhanced several-fold by 
increasing the degree of valency of soluble TCR ligands up to 10 for anti-CD3
223
 and up to 300 
for pMHC.
283
 Despite reports that soluble multivalent pMHC complexes enhance T cell 
activation, it is unclear if T cells respond similarly to surface-bound multivalent pMHC.
285
 Given 
that class II pMHC arrive at the plasma membrane of dendritic cells in sub 100-nm 
microclusters
286
 and TCR on resting T cells are similarly aggregated,
287
 there is reason to believe 
that surface-bound multivalent pMHC may enhance T cell activation through avidity effects. 
 The overwhelming majority of artificial antigen presentation systems that allow the 
nanoscale tuning of TCR ligand organization are 2D. While 2D systems are powerful research 
platforms amenable to elegant imaging and signaling studies, their planar geometry represents a 
significant departure from 3D cell-cell interactions in nature. For example, planar systems 
provide sustained interfacial contact between T cells and a relatively unidirectional antigen-
presenting surface, while 3D cell-cell interactions do not. In addition, 2D artificial antigen 
presentation systems may have limited scalability in T cell manufacturing due to their lower 
antigen-presentation surface area per unit than 3D systems. Most current large-scale ex vivo T 
cell activation is performed in bioreactors using anti-CD3/anti-CD28 coated beads. Recent 
advances in the design of patchy particles
288,289
 have enabled the regular patterning of 3D 
surfaces; however, the resolution of this approach is currently limited to ~3 μm diameter (1/6th  
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the diameter of the microsphere)
288
 patches. This patterning resolution is too coarse to probe how 
T cells respond to nanoscale ligand organization.  
 In addition to controlling the spatial organization of T cell ligands, artificial antigen 
presentation systems have also been designed to control the composition of different T cell 
ligands. In contrast to the aforementioned planar systems, the ones designed to control the 
composition of costimulatory and adhesion molecules during antigen presentation are often cell 
lines, and thus 3D. Studies have shown that presentation of intercellular adhesion molecule 1 
(ICAM-1) by both cells and acellular beads accelerates the production of IL-2 and IFN-γ by 
CD4
+
 T cells.
115
 Similarly, 4-1BBL presentation on engineered cells has been shown to enhance 
the expansion of functional CD8
+
 T cells more effectively than anti-CD28.
123
 The presentation of 
multiple costimulatory molecules such as various combinations of ICAM-1, CD80, CD86, and 4-
1BBL further improves T cell proliferation and activation.
126–128
 While insights gained from 
manipulating costimulatory signals have already been translated to improved clinical designs of 
therapeutic T cells,
172
 most studies to date have focused on simply combining 
costimulatory/adhesion molecules with little control over their valency or ratio. This is 
technically challenging on cell surfaces. Even with synthetic systems, this control has thus far 
been limited to biotin-avidin based presentation methods such as anti-CD3/anti-CD28 coated 
beads
290
 and stochastically clustered anti-CD3/anti-CD28/anti-LFA-1 on neutravidin anchored in 
liposomes.
221
 Therefore, the extent to which T cell activation can be tuned by simultaneously 
modulating the stoichiometric ratio and valency of pMHC and adhesion/costimulatory molecules 
during antigen presentation remains unclear.  
 Here, we describe a modular artificial antigen presentation system that provides control 
over the spatial and stoichiometric organization of immunological proteins on a 3D yeast cell 
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surface using protein-scaffold directed assembly. These yeast antigen-presenting cells (yAPCs) 
enabled for the first time the systematic and quantitative investigation of how nanoscale protein 
organization on a 3D surface influences T cell activation. This work presents a new strategy for 
tuning antigen presentation on 3D surfaces by controlling the valency, density, and ratio of T cell 
ligands. The underlying principle of scaffold-directed assembly based on high affinity protein-
protein interactions described here can be readily applied to acellular 3D surfaces, such as 
polystyrene and magnetic microparticles and hydrogels,
291
 greatly expanding its potential 
applications. 
3.4.  Results and Discussion 
3.4.1.  Molecular Design for Patterning Cell Surface with Defined pMHC Valency and 
Density 
 pMHC spatial organization can be controlled by manipulating both the occupancy of 
nanoscale pMHC clusters on a surface (i.e. pMHC valency) and the global pMHC density across 
the entire surface. To control pMHC valency and the global pMHC surface density, yeast cells 
were engineered to assemble pMHC on surface-displayed multivalent protein scaffolds (Figure 
3.1). Yeast cells were chosen as a model antigen presenting system for their inability to activate 
T cells in vitro
41,205,292
 and the versatile genetic tools available that allow proteins to be displayed 
on the yeast cell surface.
292–297
 Modular cohesin units from the CipA protein
298
 of Clostridium 
thermocellum were recombined to create custom protein scaffolds containing a tunable number 
of binding sites ranging from one (yAPC1) to five (yAPC5) (Coh1 – Coh5 in Figure 3.1). 
Cohesin units bind strongly to cognate protein units called dockerins. To organize pMHC on the 
yeast-displayed cohesin scaffolds, a cognate dockerin domain
299
 from C. thermocellum was 
fused to the alpha-chain of the class II MHC HLA-DR1 (Figure 3.2). The pMHC-dockerin 
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fusion allows the protein scaffolds to direct the supramolecular assembly of pMHC on a 3D 
surface (Figure 3.2b). pMHC valency is controlled through the number of cohesin units in the 
protein scaffold. For example, yAPC5 represents a yeast cell displaying protein scaffolds with 
five cohesin units, and therefore presents five pMHC molecules per protein scaffold (Figure 3.1, 
bottom right). These multivalent protein scaffolds included an N-terminal Aga2 fusion which 
forms a disulfide linkage to Aga1 on the yeast cell surface
294
 (Figure 3.2a) allowing the pMHC 
surface density to be tuned by treating yeast cells with a reducing agent. The protein scaffolds 
also included a C-terminal V5 epitope tag for detection and molecular quantification. 
 
Figure 3.1. Schematic depicting yAPC system assembly and tunability. 
yAPC was engineered to accommodate pMHC with valency between 1 (yAPC1) and 5 (yAPC5). 
Scaffold spacing and corresponding global pMHC surface density can be tuned to generate 
yAPCs with a broad range of pMHC surface densities. pMHC was expressed as a heterodimer 
stabilized by a leucine zipper. The N-terminus of the pMHC beta-chain (DRB1*01:01) was fused 
to the peptide. The C-terminus of the pMHC alpha chain (DRA) was fused to a dockerin-domain 
from C. thermocellum, which specifically associates with corresponding cohesin domains (Coh1-
Coh5) from C. thermocellum expressed as yeast-surface displayed, Aga2-fused cohesin 
scaffolds. 
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3.4.2. Protein-scaffold Directed Assembly of pMHC on a Cell Surface 
 To verify the specific binding of dockerin-fused pMHC with cohesin-derived protein 
scaffolds, soluble forms of the protein scaffolds (sAPCs) and dockerin-fused pMHC were 
expressed and purified in E. coli and insect cells, respectively (Figure 3.3a). The binding affinity 
of soluble protein scaffold (sAPC1) and dockerin-fused pMHC was measured using surface 
plasmon resonance (SPR) and found to be approximately 10 nM (Figure 3.4a). This value is 
consistent with reported binding affinities for other enzyme-dockerin fusions,
300
 suggesting that 
the fusion of this dockerin to pMHC does not significantly change the affinity of the cohesin-
dockerin interaction. Excess dockerin-fused pMHC was incubated with the sAPCs and complex 
formation was assessed by a Native-PAGE shift assay. The Native-PAGE analysis showed a 
complete shift of each sAPC band accompanied by the appearance of bands with increasing 
molecular weight in the order of sAPC1 to sAPC5 (Figure 3.3 b and c), indicating complete 
complex formation between soluble protein scaffolds and dockerin-fused pMHC. 
 
Figure 3.2. Schematic depicting the construction and assembly of recombinant pMHC and 
yeast-displayed scaffold.  
(a) The N-terminus of the pMHC beta-chain (DRB1*01:01) is fused to the well-studied 
hemagglutinin peptide (HA306-318). The C-terminus of the pMHC alpha-chain (DRA) is fused 
to a dockerin-domain from C. thermocellum which specifically associates with corresponding 
cohesin-domains from C. thermocellum. (b) Yeast surface displayed Aga2-fused cohesin 
scaffolds direct the assembly of the recombinant dockerin-fused, multivalent pMHC complexes. 
A valency of three is shown as an example here. 
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 To enable the assembly of pMHC on the cell surface, yeast cells were transformed with 
the plasmid encoding the multivalent, Aga2-fused and V5-tagged protein scaffolds. After protein 
induction, the transformed yAPC1 – yAPC5 were loaded with pMHC, and co-stained with 
fluorescent antibodies recognizing the pMHC and the V5 tag, respectively. The resulting 
fluorescent signals were then analyzed using flow cytometry to assess the pMHC occupancy of 
each surface-displayed scaffold (Figure 3.3d). The average pMHC occupancy of each yAPC 
scaffold was measured by analyzing the ratio of the pMHC signal to protein scaffold signal. 
These ratios were then normalized based on the valency of yAPC5.  
 
Figure 3.3. Scaffold-directed assembly of recombinant pMHC achieves expected pMHC 
valency.  
(a) SDS-PAGE analysis and (b) Native-PAGE analysis of recombinant pMHC and soluble 
cohesin scaffolds. (c) Native-PAGE shift assay shows dockerin-fused pMHC forming complex 
with soluble cohesin-scaffolds (right). (d) Flow-cytometry dot plot showing pMHC display level 
plotted against scaffold display level for yeast presenting scaffolds of different valency. (e) The 
average number of pMHC per scaffold determined by the ratio of the median fluorescence 
intensity (MFI) of the bound pMHC and the MFI of the displayed scaffold. Data represent mean 
± SD  (n = 3). Student’s t-test indicated any pair within dataset have p < 0.05. 
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 The observed pMHC valency of each protein scaffold construct agreed with its designed 
stoichiometry, indicating that each cohesin module stably binds a dockerin-fused pMHC (Figure 
3.3e). A yeast cell control presenting no scaffold (pYD1 in Figure 3.3e) was also incubated with 
pMHC and analyzed in the same way. No pMHC signal was detectable indicating that pMHC 
display is protein-scaffold dependent. The apparent binding affinity between yeast surface-
displayed protein scaffolds and pMHC was measured to be 5.70 ± 1.75 nM using a flow-
cytometry binding assay (Figure 3.4b), which was comparable to the binding affinity measured 
by SPR (10.00 ± 5.06 nM). 
 
Figure 3.4. Dockerin-fused pMHC cohesin binding assays.  
(a) Biacore 3000 response curves from immobilized dockerin-fused pMHC and flowing sAPC1. 
(b) Flow-cytometric apparent binding affinity curve between yAPC1 and dockerin-fused pMHC. 
The average binding affinities determined from the assays in (a) and (b) were 10.00 nM and 5.70 
nM, respectively. 
3.4.3.  T Cell Activation by Multivalent pMHC Assembly   
 To ensure the functionality of the multivalent pMHC assembly, the recombinant 
dockerin-fused pMHC protein was first used to elicit dose-dependent, antigen-specific T cell 
activation. Dockerin-fused HLA-DR1 in complex with the influenza antigenic peptide
301
 HA306-
318 (DR1-HA) was used to activate HA1.7 cells, a murine transgenic T cell hybridoma expressing 
a human α/β TCR that recognizes the DR1-HA.302 Dockerin-fused HLA-DR1 in complex with 
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the invariant chain peptide
46
 CLIP87-101 (DR1-CLIP) was used as a negative control for antigen 
specificity. DR1-HA and DR1-CLIP were titrated and adsorbed in a 96-well polystyrene plate 
and incubated with HA1.7 T cells for activation. After 18 hours, IL-2 level in the supernatant 
was quantified using ELISA. As shown in Figure 3.5a, HA1.7 T cells responded to immobilized 
pMHC proteins in an antigen-specific, dose-dependent manner, indicating that the recombinant 
dockerin-fused pMHC is functional.  
 
Figure 3.5. Dockerin-fused pMHC activate HA1.7 T cell hybridoma.  
(a) T cell response to dockerin-fused pMHC presenting either agonist HA peptide (DR1-HA) or 
null CLIP peptide (DR1-CLIP) titrated and immobilized in activation plate. Activation index is 
the ratio of T cell IL-2 secretion over basal IL-2 signal from unstimulated control. (b) T cell 
response to soluble pMHC with varying valency assembled on soluble scaffold (sAPC). Soluble 
pMHC monomer (no sAPC) was included as a negative control. Activation was performed using 
either 10 ng or 20 ng pMHC. Statistical significance was determined with respect to sAPC1. (c) 
T cell response to dockerin-fused pMHC loaded on yeast displayed scaffolds (yAPC1 – yAPC5). 
yAPC1 – yAPC5 loaded with DR1-HA have statistically insignificant difference in activation, 
but all are statistically different from the negative control, pYD1. For a – c, data represent mean 
± SD (n = 3, Student’s t-test, *p<0.05, **p < 0.01, ***p < 0.001, not significant (ns)). 
 Soluble multivalent pMHC has long been known to activate T cells by cross-linking 
TCRs while soluble monomeric pMHC is incapable of inducing T cell activation.
80,87,223,303
 To 
validate the pMHC-scaffold assembly scheme and test the ability of our soluble multivalent 
pMHC complexes to activate T cells, equal amounts of pMHC were loaded on sAPC1 – sAPC5, 
and the soluble pMHC-sAPC complexes were incubated with HA1.7 T cells for activation. An 
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equivalent amount of soluble pMHC monomer (i.e. no sAPC in Figure 3.5b) was included as a 
negative control. After 18 hours, T cell activation was assessed by quantifying IL-2 in the 
supernatant using ELISA. In agreement with previous studies, soluble pMHC monomer and 
pMHC-sAPC1 complexes failed to induce T cell IL-2 secretion (Figure 3.5b). Moreover, as the 
pMHC multivalency increased, the degree of T cell activation also increased, suggesting high 
pMHC multivalency on soluble complexes is more effective in cross-linking TCRs than low 
pMHC multivalency. 
 
Figure 3.6. Loaded pMHC signal on unsorted yAPC.  
Data represent mean ± SD (n = 3). 
 To further test the functionality of the protein-scaffold directed pMHC assembly on the 
yeast cell surface, dockerin-fused DR1-HA and dockerin-fused DR1-CLIP were loaded onto the 
surface of yAPC1 – yAPC5. The resulting yAPCs were then incubated with the HA1.7 T cells at 
a 10:1 ratio for 18 hours, and the IL-2 secretion was quantified using ELISA. Each yAPC 
construct presenting agonist DR1-HA produced measurable IL-2 secretion while each yAPC 
construct presenting DR1-CLIP did not (Figure 3.5c). The yeast cell displaying no protein 
scaffold (pYD1 in Figure 3.5c) was also included for both DR1-HA and DR1-CLIP, and neither 
produced measurable IL-2 secretion. These results suggest that the yeast cells do not non-
specifically activate the T cells, and pMHC organized on yeast-displayed protein scaffolds can 
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induce antigen-specific T cell activation. Interestingly, pMHC valency did not significantly 
influence the IL-2 secretion by T cells as yAPC1 – yAPC5 induced comparable T cell activation 
after 18 h. This observation could be a result of the natural variation in protein scaffold 
expression producing similar global pMHC surface densities on each yAPC construct (Figure 
3.4d and Figure 3.6).  Therefore, we next aimed to tune the pMHC surface density on the yAPC 
constructs. 
3.4.4.  FACS-facilitated Tuning of Global pMHC Surface Density 
 To control the global pMHC surface density, we stained pMHC-loaded yAPC1 – yAPC5 
with   anti-His fluorescent antibodies and used FACS to isolate yAPC populations with 
homogeneous pMHC surface densities. As shown in Figure 3.7a, four gates corresponding to 
four different pMHC surface densities were used to sort yAPC1 – yAPC5.  
 This allowed the same pMHC surface density to be obtained for each pMHC valency. 
The sorted yAPCs were reanalyzed using flow cytometry to confirm that the pMHC surface 
density was indeed consistent between yAPC1 – yAPC5 (Figure 3.7b). Fluorescence 
quantitation beads were used to convert fluorescence intensity into the average pMHC surface 
density for each yAPC population using Equation 3.1 below (Figure 3.7c). This process was 
repeated using yAPCs treated with varying concentrations of Tris(2-carboxyethyl)phosphine 
hydrochloride (TCEP) prior to pMHC loading. TCEP treatment releases a fraction of protein 
scaffold from the yeast cell surface, broadening the range of possible pMHC surface densities 
(Figure 3.8). 
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Figure 3.7. Fluorescence activated cell sorting (FACS) of yAPC based on pMHC surface 
density.  
(a) pMHC-loaded yAPC sorted into populations with different pMHC surface densities (low – 
R4, high – R7). (b) Sorted yAPC1 (top), yAPC3 (middle), yAPC5 (bottom) populations analyzed 
using flow cytometry (left to right R4 – black, R5 – red, R6 – cyan, R7 – purple. (c) 
Quantification of pMHC surface density of sorted populations. All yAPC were subjected to the 
same treatment, yAPC2 and 4 are not shown for simplicity.   
 
 
Figure 3.8. Average pMHC surface density after TCEP treatment. 
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3.4.5.  Relationship between pMHC Surface Density and Protein Scaffold Spacing 
 To calculate pMHC surface density, quantitative flow cytometry was performed using 
fluorescence quantitation beads. Specifically, yAPCs loaded with pMHC were stained with 
Alexa Fluor 647-labeled anti-His antibody and the resulting median fluorescence intensity (MFI) 
was measured on a flow cytometer. Note that each pMHC molecule has two His tags (Figure 
3.2a). In parallel, fluorescence quantitation beads labeled with known numbers of molecules of 
equivalent soluble fluorophore (MESF) were analyzed by flow cytometry to convert MFI to the 
number of pMHC per yAPC surface (Figure 3.9). The function relating MESF to MFI was 
determined independently for each experiment. Yeast cells were assumed to be spheres of radius 
R = 2 μm (ref304 and Figure 3.10) and the pMHC surface density was calculated as: 
𝑝𝑀𝐻𝐶 𝑆𝑢𝑟𝑓𝑎𝑐𝑒 𝐷𝑒𝑛𝑠𝑖𝑡𝑦 =  
𝐴∗𝑀𝐹𝐼𝑦𝐴𝑃𝐶+𝐵
2𝛽∗4𝜋𝑅2
                                            (3.1) 
where MFIyAPC represents the MFI of pMHC-loaded yAPC, β represents the degree of 
fluorescence labeling of the anti-His antibody, and A and B are the slope and intercept, 
respectively, provided by the MESF vs. MFI function shown in Figure 3.9.  
 
Figure 3.9. Example MESF vs. MFI standard curve.  
Curve is used to define relationship between MESF and quantitation bead MFI, allowing 
calculation of pMHC surface density.   
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 Next, the protein scaffold surface density ρ (i.e. number of protein scaffold / yAPC 
surface area) was calculated by dividing the pMHC surface density by the valency of each yAPC 
construct. Because the protein scaffold was assumed to be randomly distributed across the cell 
surface (Figure 3.10), the probability that a protein scaffold is s distance away from its nearest 
neighbor was calculated using the Poisson distribution 
𝑃(𝑠) = 2𝜋𝑠𝜌𝑒−𝜋𝜌𝑠
2
. Integrating this function from zero to infinity provides the average protein 
scaffold distance to nearest neighbor (i.e. protein scaffold spacing), ?̅?:   
?̅? =
1
2√𝜌
                                                                   (3.2) 
 
Figure 3.10. Confocal microscopy of yAPC1, yAPC3, yAPC5.  
Scaffold protein is stained with Alexa Fluor 647 (AF647) (top) and its expression is 
approximately uniform across yAPC surface. Fluorescent and DIC overlay shown in bottom. The 
scale bar in each figure is 2 μm. 
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3.4.6. Minimum pMHC Requirement for T Cell Activation 
 After generating yAPC populations with defined pMHC surface densities and valencies, 
these well-characterized yAPCs were used to determine how global pMHC surface density, 
protein scaffold spacing and pMHC valency influence the T cell activation threshold. T cell 
activation was assessed by measuring IL-2 in the supernatant after 18 hours and plotted as a 
function of protein scaffold spacing for each pMHC valency (yAPC1 – yAPC5) (Figure 3.11a). 
In agreement with previous results obtained using 2D systems,
188
 monovalent pMHC (i.e. 
yAPC1) spacing was found to inversely correlate with T cell activation. This inverse correlation 
was also observed for higher valencies (yAPC2 – yAPC5); however, the decrease was more 
gradual suggesting that increased pMHC valency can compensate for greater protein scaffold 
spacing.  
 
Figure 3.11. T cell response to global pMHC surface density and local pMHC valency.  
(a) T cell IL-2 secretion plotted against average scaffold spacing for each yAPC. Regression 
lines fitted using log-log transformation and linear regression. (b) Using the regressions fitted in 
(a), the minimum scaffold spacing required for T cell activation plotted for each pMHC valency. 
The shaded regions represent 95% confidence intervals. (c) Assuming uniform scaffold 
distribution, the minimum, global pMHC density/μm2 required for T cell activation plotted as a 
function of pMHC valency. The shaded regions represent 95% confidence interval. (d) 
Regression of T cell activation index plotted against average scaffold spacing showing lines of 
constant pMHC surface density. 
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 To interpolate the T cell activation threshold, linear regression was performed on the log-
log transformed data set of activation index and protein scaffold spacing for each yAPC (see 
methods for details). Using these regression equations, the protein scaffold spacing at which IL-2 
secretion became undetectable (i.e. equal to unstimulated T cells) was determined. This scaffold 
spacing threshold depended linearly on pMHC valency, ranging from ~ 19.6 nm for yAPC1 to ~ 
49.2 nm for yAPC5 (Figure 3.11b). The pMHC surface density threshold was then calculated 
for each yAPC construct using Equation 3.2, and was found to be independent of pMHC valency 
(Figure 3.11 c and d). 
 Although we observed that the T cell activation threshold is independent of pMHC 
valency on the yeast cell surface, at high pMHC surface densities yAPC5 appeared to enhance T 
cell response (Figure 3.11d), indicating that pMHC valency may have a secondary effect on T 
cell activation. While these results agree with previous studies using ligands anchored on 2D 
surfaces,
186
 they differ from our results using soluble multivalent pMHC complexes (Figure 
3.5b) as well as previous studies,
223
 suggesting that T cells respond to TCR ligand valency 
differently in soluble and surface-bound contexts. This notion is supported by the well-
established finding that surface-anchored monomeric pMHC induces T cell activation while 
soluble monomeric pMHC does not.
80,87,223,303
 It is also possible that the relatively weak 
relationship between T cell activation and pMHC valency on the yeast cell surface observed in 
this study is due to the limited pMHC valencies tested. Here, the maximum pMHC valency 
investigated was five; however, TCRs in nature are clustered at a valency of 7 – 20 following 
pMHC engagement.
305
 Therefore, further investigation using higher valency scaffolds (e.g. 
yAPC6, yAPC7, etc.) would be necessary to determine the extent to which pMHC valency on a 
3D surface might enhance T cell response. 
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 The observation of a minimum pMHC requirement for T cell activation is consistent with 
previously published findings using lithographically patterned surfaces.
186
 However, the 
minimum pMHC surface density required for T cell activation on the 3D yAPC surface was 
significantly higher than that required on 2D planes (Table 3.1). This discrepancy is likely 
related to the geometric differences between 2D and 3D systems. In the absence of adhesion and 
costimulatory molecules, pMHC must function as both the adhesion and stimulatory ligand. The 
“adhesion” role of pMHC is less important for 2D antigen presentation surfaces as their planar 
geometry allows for sustained interfacial contact between T cells and the antigen-presenting 
surface. In contrast, such contact is not assured when T cells are activated by pMHC presented 
on a 3D surface. Therefore, greater pMHC surface densities are required for antigen presentation 
on a 3D surface to maintain productive T cell-APC contacts leading to full T cell activation. 
 Given the abundance of costimulatory and adhesion molecules that participate in T cell 
activation in vivo, we hypothesized that the T cell activation threshold could be reduced by 
presenting ICAM-1 with pMHC. Further, based on our ability to tune T cell IL-2 secretion by 
manipulating the spatial organization of pMHC, we believed that T cell IL-2 secretion could also 
be controlled by manipulating the pMHC-ICAM-1 display ratio. To test these hypotheses, we co-
assembled pMHC and ICAM-1 on yAPCs. 
3.4.7.  Protein-scaffold Directed Co-assembly of pMHC and ICAM-1  
 The extracellular domain of ICAM-1 was fused to the same C-terminal dockerin as the 
pMHC to allow for co-assembly on the yAPC-displayed scaffolds. Dockerin-fused ICAM-1 was 
analyzed using SDS-PAGE to verify purity and size (Figure 3.12 a and b). The apparent binding 
affinity of dockerin-fused ICAM-1 for the yAPC cohesin-scaffold was measured using a flow-
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cytometry based binding assay (Figure 3.12c) and found to be slightly higher than the dockerin-
fused pMHC (5.60 nM for the pMHC vs. 1.21 nM for ICAM-1). The slightly higher binding 
affinity of ICAM-1 could be a result of its elongated structure, which may be less prone to steric 
hindrance than the bulkier heterodimeric pMHC.  
 
Figure 3.12. Construction and characterization of dockerin-fused ICAM-1.  
(a) Schematic showing the design of recombinant ICAM-1. (b) SDS-PAGE analysis of purified 
dockerin-fused ICAM-1. (c) Flow-cytometry apparent binding affinity curve between yAPC1 
and dockerin-fused ICAM-1.The average binding affinity determined from the assay in (c) was 
1.21 nM. 
 The effect of pMHC-ICAM-1 co-assembly on T cell activation was assessed by loading 
various ratios of pMHC and ICAM-1 on unsorted yAPC1, yAPC3, and yAPC5. The fractional 
occupancy of pMHC and ICAM-1 on the surface of yAPCs was determined by flow cytometry 
(Figure 3.13), and the characterized yAPCs were used for T cell activation. For pMHC-ICAM-1 
co-assembly, T cell activation increased sharply as the fraction of pMHC increased from 0 to 
15% and then gradually decreased up to 100% pMHC (Figure 3.14a). This optimum assembly 
ratio of approximately 15% pMHC, 85% ICAM-1 was observed for each yAPC construct, and 
thus deemed independent of valency (Figure 3.14a). This optimum suggests that 15% pMHC is 
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sufficient to trigger widespread TCR signaling, which not only initiates T cell activation but also 
promotes stronger LFA-1-ICAM-1 binding by inducing a conformational change in LFA-1.
306–
310
 This synergistic interaction led to a ~ 3-fold increase in maximum T cell activation despite 
presenting ~ 6-fold less pMHC (Figure 3.14a vs. Figure 3.11a). It is worth noting that in 
addition to mediating intercellular adhesion, ICAM-1-LFA-1 binding has also been shown to 
sustain intracellular calcium flux that is required for T cell activation.
122
 As a result, ICAM-1 
exhibits characteristics of both adhesion and costimulatory molecules,
115,311
 which might explain 
the synergy that produced the ~ 3-fold increase in T cell activation by the pMHC-ICAM-1 co-
assemblies.  
 
Figure 3.13. Determining fractional ICAM-1 display ratio using flow cytometry.  
(a) Flow cytometer histogram corresponding to ICAM-1 signal observed for yAPC1 loaded with 
various pMHC:ICAM-1 mass ratios (red: 75:25; purple: 50:50; blue: 25:75; gray: 0:100). (b) The 
actual fractional ICAM-1 occupancy was found by dividing the MFI for each mass-loading ratio 
by the MFI observed when only ICAM-1 was loaded (0:100). 
 The T cell activation threshold for the pMHC-ICAM-1 co-assembly was determined by 
first loading yAPC1, yAPC3, and yAPC5 with 15% pMHC and 85% ICAM-1 (Figure 3.15a). 
The loaded yAPCs were then stained with a fluorescent anti-His antibody and sorted to isolate 
homogenous yAPC populations with defined total ligand surface densities (Figure 3.15b). T cell 
activation by these yAPC populations was assessed by measuring IL-2 secretion after 18 h using 
ELISA and plotted against the global pMHC surface density (Figure 3.14b). Similar to the 
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results for T cell activation by pMHC alone (Figure 3.11c), the pMHC surface density threshold 
for the co-assembly did not depend on valency (Figure 3.14c and d and Figure 3.16). 
 
Figure 3.14. T cell response to yAPC displaying the coassembly of pMHC and ICAM-1.  
(a) T cell response to unsorted yAPC1, yAPC3, and yAPC5 loaded with various ratios of pMHC 
and ICAM-1. (b) T cell activation index plotted against global pMHC surface density for sorted 
yAPC1, yAPC3, and yAPC5 loaded with 85% ICAM-1 and 15% pMHC. The yAPCs were 
sorted based on fixed overall protein display levels. (c) Solid lines represent 
 
 
Figure 3.15. ICAM-pMHC co-display characterization.   
(a) Optimum surface occupancy of 85% ICAM-1 can be reproducibly obtained for yAPC1, 
yAPC3, and yAPC5. (b) yAPC codisplaying ICAM-1 and pMHC were sorted to isolate 
populations with defined total protein display levels (Middle: R4, R5, R6). Uniformity of sorted 
yAPC total protein display level was verified by flow cytometric analysis (right). Plots shown 
are of yAPC1 for simplicity. For (a), data represent mean ± SD  (n = 3). 
 As we hypothesized, the presence of ICAM-1 reduced the pMHC surface density 
threshold for T cell activation approximately 6-fold to 92 – 122 pMHC/μm2, which is 
comparable to that reported for planar systems (Table 3.1). This observation supports our 
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hypothesis that sustained intercellular contact is critical for efficient T cell activation, and that 
ICAM-1 mediates this contact more effectively than pMHC alone on 3D antigen-presenting 
surfaces. In addition to maintaining intercellular contact, fine-tuning the stoichiometric ratio of 
adhesion and stimulatory T cell ligands may also be useful in directing T cells towards an 
optimum phenotype. For example, ICAM-1 has been shown to drive CD4
+
 T cells towards a Th1 
phenotype
114,312
  and additional studies of other costimulatory molecules may provide insights 
that are relevant to the design of future T cell immunotherapeutics and their large-scale 
manufacture.   
 
Figure 3.16. Activation index plotted with respect to pMHC surface density for yAPC 
codisplaying 85% ICAM-1 and 15% pMHC.  
(a) T cell activation index plotted with respect to pMHC surface density when stimulated by 
yAPC1, yAPC3, and yAPC5 displaying 85% ICAM-1. Solid lines represent logarithmic 
regression lines and dashed lines correspond to 95% confidence intervals for the regressions.  (b) 
Total (left) and valency-independent (right) T cell activation index plotted with respect to pMHC 
surface density. Solid line represents valency-independent logarithmic regression line and dashed 
lines correspond to 95% confidence intervals for the regression. (c) Logarithmic regression lines 
overlay for T cell activation index vs. pMHC surface density for yAPC1 (blue) yAPC3 (red) 
yAPC5 (green) and all yAPC combined (black) displaying 85% ICAM-1.   
84 
 
 In this work, we developed a novel strategy for controlling the valency, surface density, 
and stoichiometric ratio of T cell ligands on a 3D yeast cell surface using protein-scaffold 
directed assembly. Using the engineered yeast as artificial antigen presentation cells, we 
observed that the T cell activation threshold is determined by a minimum global pMHC surface 
density and independent of pMHC valency. Further, we found that T cell activation is maximized 
when pMHC and ICAM-1 are co-assembled with a presentation ratio of 15% and 85%, 
respectively. In addition to increasing the magnitude of T cell activation, co-assembly of 85% 
ICAM-1 enhanced T cell sensitivity to antigen by 6-fold. Taken together, these results suggest 
that adhesion molecules like ICAM-1 play an especially important role in 3D antigen 
presentation, as they maintain productive intercellular contacts necessary for T cell activation. As 
a result, the stoichiometric ratio between adhesion and stimulatory molecules should be carefully 
considered when designing future 3D antigen presenting systems. Finally, we believe the 
platform technology described here has applications beyond T cell antigen presentation, as it can 
be used for nanoscale patterning of any proteins of interest on any surfaces of interest. 
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Table 3.1. T cell activation thresholds observed for various antigen presentation systems. 
TCR 
Ligand 
Costimulatory 
Ligand 
Activation 
Readout 
Patterning 
Technique 
Spacing 
Threshold 
Density 
Threshold 
Reference 
pMHC None Contact area, 
IL-2 secretion Lithography 
100 – 150 
nm 90 – 140/μm
2 186 
aCD3 
(OKT3) aCD28 
IL-2 secretion, 
Proliferation Lithography > 150 nm N/A 
187
 
aCD3 
(UCHT1 
Fab
2
) 
ICAM-1 pY intensity Lithography 34 – 69 nm N/A 188 
aCD3 
(UCHT1 
Fab) 
ICAM-1 pY intensity Lithography 100 nm 115/μm2 189 
pMHC None IL-2 secretion 
Scaffold-
directed 
assembly 
18 – 21 nm* 550 – 650/μm2 This work 
pMHC ICAM-1 IL-2 secretion 
Scaffold-
directed 
assembly 
45 – 52 nm* 92 – 122/μm2 This work 
*Spacing threshold determined for monovalent yAPC1 
 
3.5.  Conclusions and Outlook  
 Controlling T cell activation is a fundamental aspect of T cell immunotherapy, as T cell 
activation leads to T cell expansion, differentiation, and the execution of effector functions. Over 
the past twenty years, researchers have shown that T cell activation can be controlled by the 
manipulating spatial organization of TCR ligands and costimulatory molecules. A number of 
studies have shown that focal patterning of TCR ligands surrounded by costimulatory ligands  
resembling the immunological synapse produces more potent T cell stimulation than 
colocalization of the same molecules.
190,194,198,281
 Similarly, a series of studies using 
lithographically patterned surfaces have clearly shown that T cell activation can be finely tuned 
by controlling the spatial distribution of TCR ligands on a patterned surface.186–189,193 While such 
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studies have provided invaluable insight into the molecular and signaling mechanisms that 
produce T cell activation,
104,105,108
 they have largely relied on 2D, planar antigen presentation 
surfaces. The geometry of such systems stands in sharp contrast to the 3D geometry of antigen 
presenting cells in the body. For example, planar systems present antigen such that the molecules 
are all oriented in the same direction (i.e. perpendicular to the surface) and provide sustained 
interfacial contact between T cells and the surface through gravity. In contrast, the orientation of 
antigen presented on 3D APCs in the body is much less uniform, and interfacial contact between 
T cells and antigen presenting cells is mediated by molecular interactions without assistance 
from gravity. Thus far, technological limitations have restricted the control over the spatial 
organization of T cell ligands on 3D surfaces to large, multi-micron diameter patches.
288
 As a 
result, the extent to which insights (e.g. minimum pMHC requirement for activation, optimum 
ratio of TCR ligands and costimulatory molecules, effect of pMHC/TCR ligand valency, etc.) 
gained using planar systems are transferrable to 3D cell-cell interactions is not well understood.  
 Here, we developed a modular artificial antigen presentation system based on cohesin-
dockerin binding that provides nanoscale control over the spatial organization of T cell ligands 
on a 3D yeast cell surface. Using this system, we showed that the minimum pMHC requirement 
for T cell activation is approximately six-fold greater on a 3D surface than on a planar surface, in 
the absence of costimulatory and adhesion molecules (Table 3.1). This result suggests that 
sustained interfacial contact is an important parameter for T cell activation, and that planar 
antigen presentation systems underestimate the pMHC surface density required for T cell 
activation on 3D surfaces in the absence of costimulatory and/or adhesion molecules. Further, 
using yAPCs we found that T cell activation intensity as measured by IL-2 secretion is 
independent of pMHC valency and instead determined by the overall pMHC surface density. 
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This observation stands in contrast to our results using soluble multivalent pMHC (Figure 3.5b) 
indicating that T cells integrate soluble and surface-displayed pMHC signals differently.  
 
Figure 3.17. Schematic of dockerin-fused costimulatory molecules and their potential uses.  
These molecules have been engineered for expression in insect cells and will be used with 
functionalized cohesin scaffolds in the next phase of our comprehensive study on how the spatial 
and stoichiometric organization of T cell ligands affects T cell phenotype and function.  
 Using this system, we also found that T cells are maximally activated by yAPCs 
presenting 15% pMHC and 85% ICAM-1, exhibiting up to six-times greater IL-2 secretion than 
when activated by pMHC alone. This observation reveals that T cell activation can be controlled 
by modulating the stoichiometric ratio of pMHC and costimulatory/adhesion molecules, in 
addition to controlling the spatial organization of T cell ligands. Taken together, these results 
demonstrate that modular artificial antigen presentation based on protein-scaffold directed 
assembly allows for the systematic investigation of how the spatial and stoichiometric 
organization of T cell ligands affects T cell activation.  
 Building on this concept, we have designed and engineered a panel of additional 
dockerin-fused costimulatory/coinhibitory molecules including PD-L1, OX40L, B7-1, and 4-
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1BBL (Figure 3.17). Using these molecules, we plan to conduct additional experiments, 
continuing our investigation of how the stoichiometric ratio of pMHC and costimulatory T cell 
ligands influences T cell activation, phenotype, and effector function. To accomplish this goal, 
we plan to couple our analysis of cytokine secretion with T cell proliferation assays and more 
detailed, high-dimensional phenotypic analysis using cytometry by time of flight (CyTOF). 
Together these tools should provide a comprehensive strategy for understanding how T cells 
integrate and ultimately respond to combinations of costimulatory/inhibitory signals of varying 
magnitudes.  
 Given the importance of T cell phenotype and effector function in T cell immunotherapy, 
robust molecular tools capable of finely tuning the signals that shape these parameters has 
significant therapeutic and research potential. We believe that the cohesin-dockerin based protein 
assembly strategy introduced in this chapter offers a robust toolset for modulating antigen 
presentation to T cells on 3D surfaces. Moreover, when coupled with high-dimensional 
phenotypic analysis via CyTOF, systematic studies of T cell activation using highly organized 
cohesin-dockerin based assemblies will provide a more comprehensive understanding of how T 
cells integrate stimulatory and costimulatory signals. Such studies should yield valuable insight 
for the development of next generation of off-the-shelf artificial antigen presenting cells to tailor 
to the phenotype and function of T cells for specific immunotherapeutic and research 
applications.  
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3.6.  Materials and Methods 
3.6.1.  Design of pMHC, ICAM-1, and Cohesin Scaffolds  
 Recombinant pMHC fusion proteins were assembled by first isolating the extracellular 
domains of HLA-DRA (UniProt: P01903, residues 26-216) and HLA-DRB1*01:01 (UniProt: 
P04229, residues 30-227). The leucine zipper dimerization motifs Fos and Jun were fused to the 
C-terminus of the extracellular DRA and DRB1 chains, respectively, in lieu of the native 
transmembrane domains as described.
313
 A dockerin domain from C. thermocellum (UniProt: 
A3DH67, residues 673-741) was fused to the C-terminus of the DRA construct via a 6X-
Histidine tag. Two forms of the DRB1 chain were engineered. One DRB1*01:01 construct was 
fused to the invariant chain CLIP87-101 peptide via a cleavable thrombin linker as described
276
 and 
one DRB1*01:01 construct was fused to the well-characterized influenza antigen HA306-318 via 
the same cleavable thrombin linker. The C-terminus of both DRB1*01:01 constructs were fused 
to a 6X-Histidine tag for purification and detection. The N-terminus of each dimeric chain was 
fused to the baculovirus gp64 signal peptide and ligated into separate baculovirus transfer 
vectors pAcGP67A (BaculoGold Baculovirus Expression System, Pharmingen BD Biosciences, 
San Jose, CA). The integrity of each DNA sequence was confirmed using Sanger sequencing.  
 The murine intercellular adhesion molecule 1 (ICAM-1) was designed similarly. The 
DNA sequence coding the extracellular domain of ICAM-1 (UniProt: P13597, residues 28-485) 
was fused to the same C. thermocellum dockerin as DRA via a 6X-Histidine tag for purification 
and detection. The N-terminus of the ICAM-1 was fused to the baculovirus gp64 signal peptide 
and ligated into the baculovirus transfer vector pFastBac1 (Bac-to-Bac Baculovirus Expression 
Systems, Life Technologies). Separate baculovirus expression systems were used for pMHC and 
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ICAM-1 because of the discontinuation of the BaculoGold linearized baculovirus DNA. The 
difference did not affect protein expression.  
 Protein scaffolds were designed by recombining the sequences coding for the first three 
cohesins of the CipA cellulosome from C. thermocellum. Soluble protein scaffolds are denoted 
with the prefix “s”APC and yeast-displayed scaffolds are denoted with the prefix “y”APC. 
sAPC1/yAPC1 consisted of Coh1 (UniProt: Q06851, residues 29-182), sAPC2/yAPC2 consisted 
of Coh1 and Coh2 (UniProt:  Q06851, residues 29-322), and sAPC3/yAPC3 consisted of Coh1, 
Coh2, and Coh3 (UniProt: Q06851, residues 29-183 and residues 560-704). sAPC4/yAPC4 and 
sAPC5/yAPC5 contained the sAPC3 sequence fused to additional cohesins through a G-S-S-S 
linker (sAPC4: Coh1, Coh2, Coh3, and Coh1; sAPC5 Coh1, Coh2, Coh3, and Coh1, Coh2). All 
soluble protein scaffolds were ligated into the bacteria expression plasmid pET28a (Novagen) 
with a kanamycin resistance selectable marker. Yeast-displayed scaffolds were ligated into a 
modified form of the yeast surface display plasmid pYD1 (Invitrogen) with ampicillin resistance 
and tryptophan auxotrophic selectable markers and fused to an N-terminal Aga2 domain and a C-
terminal V5 epitope tag for detection. All plasmids were propagated in the E. coli strain Mach1. 
All plasmids were sequenced using Sanger DNA sequencing for verification. 
3.6.2.  Baculovirus Transfection and pMHC, ICAM-1 Purification  
 Spodoptera frugiperda (SF9) insect cells were co-transfected with either the DRA or 
DRB1 baculovirus transfer vectors and linearized Baculovirus DNA (Pharmingen BD 
BaculoGold Biosciences, San Jose, CA) using Cellfectin II (Invitrogen) according to the 
manufacturer’s protocol. The recombinant DRA and DRB1 baculoviruses generated from 
transfection were amplified separately in SF9 cells to create high-titer P1 viral stocks. pMHC 
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was expressed by co-infecting High-Five cells at a density of 2.0 M/mL with equal volumes of 
high-titer DRA and DRB1 baculovirus stocks. Multiplicity of infection was optimized as 
described.
205
 Recombinant pMHC was harvested after 72 h and purified using affinity 
chromatography with Ni-NTA beads according to the manufacturer’s protocol (Qiagen). The 
ICAM-1 baculovirus transfer vector was transformed into the E. coli strain DH10Bac (Bac-to-
Bac Baculovirus Expression Systems, Life Technologies). Bacmid recombination was 
established via blue/white colony screening and PCR recombination checks as described in the 
manufacturer’s protocol. Recombinant baculovirus DNA was purified using PureLink HiPure 
Plasmid miniprep kit (Invitrogen). ICAM-1 bacmid was used to transfect SF9 cells with 
Cellfectin II. The recombinant baculovirus generated from transfection was amplified in SF9 
cells to obtain a high-titer P1 baculovirus stock. ICAM-1 was expressed by infecting High-Five 
cells at a density of 2.0 M/mL with high-titer ICAM-1 baculovirus stock. Recombinant ICAM-1 
was purified in the same way as pMHC. SDS-PAGE analysis was performed to verify protein 
purity (Figure 3.12b). 
3.6.3.  Scaffold Purification and Scaffold-Directed Protein Complex Assembly  
 Plasmids coding for the soluble protein scaffolds were used to transform the E. coli strain 
BL21. Soluble protein scaffold expression was induced by addition of 0.1 mM IPTG in LB 
media when the BL21 culture reached an OD600 between 0.6 and 0.8. The induced-BL21 were 
cultured for 16 h at 16°C. Soluble protein scaffold was harvested by lysing the BL21 via 
sonication and performing affinity chromatography on the lysate using a 5 mL HisTrap column 
(GE Healthcare Life Sciences). The purified soluble protein scaffolds were analyzed using SDS-
PAGE (Figure 3.3a) to verify protein purity.  
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 To verify the scaffold-directed assembly of recombinant dockerin-fused pMHC, 
approximately 1.0 μg of each soluble protein scaffold construct (sAPC1 – sAPC5) was incubated 
with excess pMHC in 50 mM Na3PO4 at 30°C over 2 h. pMHC was added step-wise every 30 
minutes over the 2 h incubation time. Complex formation was assessed by Native-PAGE 
analysis. Briefly, the protein-complexes were run on an 8% Tris-Glycine gel at 130V for 2 h 15 
min and stained using SimplyBlue SafeStain. Protein-complex formation was assessed by 
observing a total shift of the soluble protein scaffold band.  
 Plasmids coding for yeast-displayed scaffolds were used to transform the S. cerevisiae 
strain EBY100. Transformants were selected by plating on tryptophan-dropout media. 
Transformed yeast were cultured to an OD600 of 4.0 in tryptophan-dropout media and then 
scaffold-expression was induced by transferring the yeast to galactose-rich media for 48 h at 
20°C. After induction, 500,000 of each yAPC (yAPC1 – yAPC5) were incubated with excess 
pMHC in 0.5% bovine serum albumin (BSA) at 4°C overnight. The yAPC were then washed 
twice with 0.5% BSA and co-stained with anti-His conjugated to PE (BioLegend) and anti-V5 
conjugated to Alexa Fluor 647 (Invitrogen) for 1 h. The co-stained cells were then analyzed 
using flow cytometry. pMHC valency was determined by analyzing the ratio of pMHC (His) to 
scaffold (V5) median fluorescence intensities.  
3.6.4. Fluorescent Activated Cell Sorting (FACS) 
 yAPC1 – yAPC5 were prepared for FACS by initial fixation with 0.1% 
paraformaldehyde (PFA) for 15 minutes at room temperature. Fixation did not affect pMHC 
loading or T cell response. After fixation, the yAPC were washed 3 times with 0.5% BSA and 
then loaded with excess pMHC in 100 μL 0.5% BSA at 4°C overnight. The yAPC were washed 
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3X with 0.5% BSA, stained with Alexa Fluor 647-conjugated anti-His (clone AD1.1.10, BioRad 
Antibodies) for 1 h at room temperature, and resuspended in 1 mL 0.5% BSA for FACS. The 
fluorophore to protein ratio (F/P) of the anti-His antibody was 3.1 and was provided by the 
manufacturer. Sorting was performed using a MoFlo Astrios (Beckman Coulter Life Sciences, 
Indianapolis, IN) cell sorter. Briefly, three or four gates were drawn based on distinct pMHC 
surface densities (as determined by the anti-His staining) and yAPC1 – yAPC5 cells were sorted 
using these gates. The median fluorescence intensity was converted into median pMHC per cell 
using Quantum
TM
 Alexa Fluor® 647 Fluorescence Quantitation Beads (Bangs Laboratories, 
Fishers, IN). The uniformity of the sorted yAPC populations was confirmed by analyzing a 
fraction of the sorted yAPC using flow cytometry. For activation experiments requiring lower 
pMHC surface density than possible through standard induction, yAPC were pretreated with 0.1 
mM – 0.5 mM TCEP for 10 minutes at room temperature. This mild TCEP treatment decreased 
the number of surface displayed scaffolds by reducing a fraction of the Aga1-Aga2 disulfide 
bonds anchoring each scaffold to the yeast cell surface. Cells were washed thoroughly with 0.5% 
BSA following TCEP treatment and then treated as described previously.  
 FACS involving pMHC-ICAM-1 co-assembly was performed by first fixing yAPC1, 
yAPC3, and yAPC5 with 0.1% PFA for 10 minutes at room temperature. Following fixation, 
each yAPC was loaded with 85% ICAM-1 and 15% pMHC in 100 μL 0.5% BSA at 4°C 
overnight. The display ratio of 85% ICAM-1 and 15% pMHC was confirmed by staining a small 
fraction of each yAPC for ICAM-1 (clone YN1/1.7.4 BioLegend) and analyzing the samples 
using flow cytometry. ICAM-1 and pMHC loaded yAPC1, yAPC3, and yAPC5 were then 
washed and stained for both ICAM-1 and pMHC with Alexa Fluor 647-conjugated anti-His 
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(clone AD1.1.10, BioRad Antibodies) and sorted and characterized in the same way as yAPC 
presenting pMHC alone.  
3.6.5.  T Cell Activation 
 T cell activation assays were performed in 96 well tissue culture plates at 37°C and 5% 
CO2. Activation plates were blocked prior to activation with 1% BSA overnight at 4°C to 
minimize non-specific immobilization of pMHC during activation. Murine HA1.7 T cell 
hybridoma
314
 were cultured to a density of 2.0 M/mL in IMDM (Invitrogen) supplemented with 
10% fetal bovine serum for activation. Once at this density, 200,000 HA1.7 T cells were applied 
to the activation wells in 200 μL IMDM. In experiments involving sorted yAPC, 100,000 yAPC 
were used for activation. In experiments involving immobilization of pMHC for activation, 
pMHC was immobilized overnight at 4°C in 1% BSA. In experiments involving sAPC-pMHC 
complexes for activation, the sAPC-pMHC were assembled 2 h prior to activation in 1% BSA in 
volume of approximately 7 μL and added to 200 μL IMDM for activation. The activation 
supernatant was collected after 18 ± 2 h and analyzed using Ready-Set-Go IL-2 ELISA 
(eBiosciences, San Diego, CA) according to the manufacturer’s protocol. The ELISA plate was 
developed for 10 minutes and the IL-2 secretion was measured by recording the absorbance at 
650 nm (A650). To ensure consistency between experiments, a T cell activation index was 
calculated by dividing the A650 from activation wells by the A650 of the unstimulated controls. 
Thus, activation index indicates the multiple of IL-2 secretion over unstimulated T cells.     
3.6.6.  Regression Equations for T Cell Activation   
 T cell activation index was plotted against the average scaffold spacing for each yAPC 
construct. For each yAPC data set, activation index and scaffold spacing were logarithmically 
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transformed and fitted using linear regression with a fixed slope of -2. The regression equations 
thus provided a valency-dependent constant for each yAPC curve. T cell activation thresholds 
were then calculated by solving for a scaffold spacing that corresponded to a T cell activation 
index of 1.0 for each yAPC. The scaffold spacing thresholds were then used to calculate the 
corresponding pMHC surface density to determine the global pMHC density thresholds for each 
yAPC. For pMHC-ICAM-1 co-assembly experiments, the regression equation for T cell 
activation vs. pMHC surface density was determined by logarithmically transforming the values 
for pMHC surface density and performing linear regression on the transformed dataset. The 
minimum pMHC surface density requirement for measurable T cell IL-2 secretion was found by 
finding the pMHC surface density that corresponded to a T cell activation index of 1.0.   
3.6.7.  Statistical Analysis 
 Statistical analysis was performed using the Student’s t test. All error bars are 
representative of the mean ± standard deviation of triplicate experiments unless otherwise noted. 
*P < 0.05, **P < 0.01, ***P < 0.001. 
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Chapter 4. Advancing the Artificial Antigen Presentation Design Space: 
Characterizing 2D Multi-Scaffold Complex Assembly 
4.1 Publication Information. 
*Smith, M. R., *Gao, H., Yee, C. M., Bugada, L. F., Ponnandy, P., Roth, C., Mutukuri, D., Lee, 
L., Ziff, R. M., Lee, J., Wen, F. Elucidating structure-performance relationships in whole-cell 
cooperative enzyme catalysis: role of multi-enzyme assembly efficiency, enzyme density and 
enzyme proximity in cellulose hydrolysis. 2018. (In revision.)  
 The goal of this chapter is to explore how multi-scaffold complexes assemble on the 
yeast cell surface, and explore the implications of assembly efficiency on artificial antigen 
presentation. While this work will be published in the context of biocatalysis, the quantitative 
approach to characterizing yeast-surface displayed supramolecular assemblies is directly 
applicable to engineering highly organized assemblies of T cell ligands for artificial antigen 
presentation. Mason Smith and Hui Gao contributed equally as first authors on this manuscript. 
Hui Gao and Cori Roth designed the proteins used in this study while Luke Bugada, Deepika 
Mutukuri and Lester Lee assisted in their expression and purification. Christine Yee and Prabhu 
Ponnandy performed the enzyme activity assays and fermentation experiments, respectively. 
Professor Robert Ziff assisted in developing a statistical model for aScaf surface distribution.  
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4.2. Abstract 
 Multi-protein complexes inspired by nature have received attention in a number of fields 
including whole-cell biocatalysis, artificial antigen presentation, and biosensor engineering. 
Despite considerable interest, efforts to harness the full potential of multi-protein assemblies 
have been based on trial and error rather than rational design due to the lack of quantitative tools. 
This empirical approach has created a gap in our understanding of how these supramolecular 
complexes assemble, and what parameters affect assembly efficiency. Here, we developed 
quantitative experimental tools that enabled the first quantitative investigation of multi-scaffold 
assemblies on the yeast cell surface. Combined with a statistical model, we revealed that multi-
scaffold assembly efficiency is limited by molecular crowding on the yeast cell surface, and this 
crowding effect is more prominent for larger scaffold constructs. This work raises interesting 
questions regarding the optimum design of supramolecular assemblies, including a tradeoff 
between multi-scaffold assembly efficiency and the expression level of surface displayed 
scaffolds.  
4.3. Introduction  
 In Chapter 3, we showed that the spatial and stoichiometric organization of T cell 
ligands on a yeast cell surface could be finely controlled by protein-scaffold directed assembly 
using cohesin-dockerin binding. However, the assemblies we have described thus far are 
relatively simple and do not closely resemble the immunological synapse. One strategy for 
increasing the complexity of protein assemblies – and potentially mimicking the structure of the 
immunological synapse – is to create 2D multi-scaffold complexes using surface displayed 
anchor scaffolds (aScafs) and addressable primary scaffolds (pScafs) (Figure 4.1).
315–317
 These 
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complex multi-scaffold assemblies are formed by fusing a dockerin to either the N- or C-
terminus of the pScaf protein. The pScaf-dockerin fusion protein can then assemble with surface 
displayed aScafs via in vitro loading to create 2D multi-scaffold complexes capable of binding 
dockerin-fused ligands. Because cohesin-dockerin binding is largely species-specific, the 
molecular organization of ligands assembled on 2D aScaf-pScaf complexes can be further 
controlled by engineering chimeric pScafs and aScafs composed of cohesin modules with 
different binding specificities (Figure 4.1).
293,299,318,319
 More than 19 distinct cellulosomal 
species (i.e. microbes that utilize cohesin-dockerin binding) have been identified to date,
320
 
providing diverse library of orthogonal cohesin-dockerin binding pairs that can be used to 
construct a myriad of molecular architectures.  
 
Figure 4.1. 2D multi-scaffold complex architectures.  
 
 While we have discussed cohesin-dockerin binding in the context of artificial antigen 
presentation, this interaction has traditionally been used to organize cooperative enzyme 
assemblies for the efficient hydrolysis of lignocellulosic biomass.
320–322
 Lignocellulosic biomass 
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is among the most abundant renewable carbon sources on Earth and represents a sustainable 
feedstock for the production of materials, value-added chemicals, and biofuels.
323–331
 The 
primary component of lignocellulosic biomass is cellulose, a polysaccharide that locks β-1,4-
linked glucosyl units in a highly compact crystalline structure.
332
 Completely hydrolyzing 
cellulose to glucose requires three types of enzymes: endoglucanases, exoglucanases (or 
cellobiohydrolases), and β-glucosidases,332–334 which exhibit enzyme-enzyme synergy through 
their cooperative activities.
335–337
 When these enzymes are organized on surface displayed 
scaffolds they also exhibit proximity synergy, which further enhances the overall activity.
319,338
 Realizing the full potential of surface-displayed multi-scaffold complexes – in both 
biocatalysis and artificial antigen presentation – will require a more complete understanding of 
how these proteins assemble, and how the assembly architecture relates to its function. For 
example, the extent to which pScafs and ligands saturate their respective binding sites on 
surface-displayed multi-scaffold assemblies is rarely reported in the literature due to a lack of 
quantitative tools. This is especially important in biocatalysis, where a lack of quantitative 
characterization complicates the comparison of biocatalyst designs, as one design may have 
considerably higher assembly efficiency or enzyme density than another. In the context of 
artificial antigen presentation, full spatial and stoichiometric characterization of the T cell ligand 
assembly is crucial to reproducing optimum presentation patterns. Further, because quantitative 
tools and protocols are rarely utilized for characterizing surface-displayed protein assemblies, it 
is often difficult to decouple the contribution of different structural parameters to the output. For 
example, without the quantitative characterization of the yAPCs described in Chapter 3, it 
would be difficult to determine the individual contribution of T cell ligand valency and overall T 
cell ligand surface density on T cell activation. Likewise, reliably evaluating the role of structural 
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parameters like aScaf expression level, overall enzyme density per cell, and the size of multi-
scaffold enzyme assemblies on overall biocatalyst activity is not possible without quantitative 
tools.    
 Here we engineered yeast to present 2D multi-scaffold complexes using aScafs binding 
one (aScaf1), two (aScaf2), and three (aScaf3) pScafs, with each pScaf designed to bind four 
unique ligands. With these constructs, we developed a quantitative approach to characterize the 
assembly of each yeast-surface displayed 2D multi-scaffold assembly. This quantitative 
approach revealed that aScaf-pScaf assembly is limited by the molecular crowding of aScafs on 
the yeast cell surface. To better understand this result, we developed a statistical model of aScaf 
spatial organization based on a Poisson distribution. Using this model, we found that neighboring 
aScafs must be separated by some critical distance – which is dependent on aScaf size – for 
aScaf-pScaf binding to occur. We then used the critical distance values provided by the model to 
predict aScaf-pScaf assembly efficiency as a function of aScaf expression level. The statistical 
model agreed well with the experiment results, with both indicating that large aScaf designs are 
more sensitive to surface crowding during aScaf-pScaf assembly than small aScaf designs. 
Further, our model predicts that the total ligand surface density is maximized when aScaf-surface 
crowding allows only 1/e (~37%) of expressed aScaf to bind pScaf. Taken together, these 
observations suggest that aScaf-pScaf assembly is performed in an “outside-in” manner, in 
which the most distal aScaf cohesin sites are occupied first and, once occupied, limit pScaf 
access to the internal cohesin sites. While this work will be published in the context of whole-
cell biocatalysis, the mechanism of surface-crowding limited assembly described here has 
important implications for the design of complex surface displayed assemblies in a variety of 
fields including artificial antigen presentation.  
101 
 
4.4. Results and Discussion  
4.4.1. Design of 2D Multi-scaffold Complex  
 Yeast cells were engineered to express anchor scaffold proteins (aScafs) as C-terminal 
fusions with the a-agglutinin subunit Aga2 for Aga1-Aga2 yeast-surface display (Figure 
4.2a).
299,339,340
 Three different aScafs were engineered composed of one (aScaf1), two (aScaf2), 
or three (aScaf3) type II cohesins derived from C. thermocellum
341
 to accommodate a 
corresponding number of primary scaffold proteins (pScafs). The surface-displayed aScafs were 
also fused to a C-terminal V5 epitope tag for detection and quantification.  
 
Figure 4.2. Schematic of surface-displayed 2D multi-scaffold assembly.  
(a) Yeast were designed to display anchor scaffold proteins (aScafs) accommodating one 
(aScaf1), two (aScaf2), or three (aScaf3) addressable scaffold proteins (pScafs) through type II 
cohesin-dockerin binding. (b) Representation of aScaf3 2D multi-scaffold assembly. Chimeric T 
cell ligands can be assembled on the pScaf through species-specific type I cohesin-dockerin 
interactions, as indicated by color-coding.    
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 The pScaf was designed to function as an addressable scaffold protein, binding the 
surface-displayed aScafs and four unique ligands through its type II dockerin and four type I 
cohesins, respectively (Figure 4.2b). Each of the four type I cohesins was derived from a 
scaffoldin protein of a different cellulolytic microbe: CipA of C. thermocellum, ScaB of R. 
flavefaciens, CipC of C. cellulolyticum, and CbpA of C. cellulovorans (Table 4.1). The pScaf 
protein was also fused to a c-Myc epitope tag for detection and quantification.  
 
Table 4.1. Description of recombinant proteins used in this study. 
Protein Description Accession number
a
 
Expression 
vector 
Tag 
aScaf 
Scaffold protein containing 
one, two, or three type II 
cohesins from scaffoldin 
OlpB displayed on S. 
cerevisiae surface  
WP_020458018 
pYD1 
c-Myc 
pScaf 
Scaffold protein containing 
four of type I cohesins, one 
CBM, and a type II dockerin 
from different organisms 
CipA:WP_020458017; 
ScaB: Q9AE52;  
CbpA: AAA23218; 
CipC: AAC28899; 
CBM:WP_020458017; 
Type II dockerin: 
WP_020458017 
pET28a V5 
a 
The accession numbers appear in the DDBJ/EMBL/GenBank nucleotide sequence databases. 
4.4.2. Quantitative Characterization of aScaf-pScaf Assembly  
 The successful assembly of the 2D multi-scaffold complexes is predicated on robust 
aScaf surface expression, which we evaluated using confocal microscopy. To detect aScaf 
surface expression, yeast cells expressing aScaf1, aScaf2 or aScaf3 were stained with 
fluorescently labeled anti-V5 antibody. As shown in Figure 4.3a, aScaf expression was detected 
for all three constructs and appeared uniform across the entire cell surface. Further, yeast 
displaying aScaf1 appeared to show the highest aScaf expression level while aScaf3 appeared to 
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show the lowest, suggesting that aScaf expression level on the yeast cell surface is a function of 
protein size.  
 
Figure 4.3. Confocal microscopy and quantitative flow cytometric analysis of aScaf-pScaf 
assembly on the yeast cell surface. 
 (a) Confocal microscope images of four yeast constructs stained for aScaf (green, anti-V5-
AF647) and pScaf (red, anti-c-Myc-AF488). Vector control (AGA2-V5) included a V5 epitope 
tag but no type II cohesins. (b) Quantification of the number of aScaf on the surface of each 
yeast construct. (c) Quantification of the number of pScaf assembled on each of the four yeast 
constructs. (d) The average number of pScaf assembled by aScaf1, aScaf2, and aScaf3. (e) The 
aScaf-pScaf assembly efficiency for aScaf1-pScaf, aScaf2-pScaf and aScaf3-pScaf. Data are 
represented as the mean of at least two independent experiments and error bars signify standard 
deviation.  
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 After confirming aScaf surface display, the average number of aScaf per cell was 
quantified using flow cytometry. Quantitative flow cytometry has been routinely used to quantify 
the surface density of mammalian proteins by staining the target protein with fluorescently 
labeled monoclonal antibodies and comparing the median fluorescence intensity (MFI) to that of 
standard beads with known numbers of molecules of equivalent soluble fluorophore 
(MESF).
342,343
 
 Using the same principle, we stained the V5 epitope tag of each aScaf design, and the 
aScaf expression level was then quantified by comparing its MFI to that of standard beads. In 
agreement with confocal microscopy observations, aScaf expression level was found to depend 
strongly on the aScaf size, ranging from ~103,000 for aScaf1 to ~63,000 for aScaf3 (Figure 
4.3b). Further, the Aga2-V5 fusion protein, which was the smallest protein displayed on a yeast 
cell surface in this study, had an expression level of ~143,000. Taken together, these results 
further suggest that aScaf surface display is limited by either protein transport or increased 
metabolic burden associated with aScaf size.   
 To mitigate complications in protein transport and/or ease yeast metabolic burden, we 
expressed and purified the pScaf from E. coli rather than co-expressing it in yeast. In vitro 
loading of purified pScaf under saturating conditions ensured that multi-scaffold assembly was 
not influenced by protein transport or expression limitations. The purity and size of pScaf protein 
was verified using SDS-PAGE (Figure 4.4) prior to loading onto yeast cells displaying the 
aScafs. The aScaf-pScaf assembly was then evaluated by co-staining the cells with fluorescently 
labeled anti-V5 and anti-c-Myc antibodies (binding the aScaf and pScaf, respectively). 
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Figure 4.4. SDS-PAGE analysis of pScaf purified from E. coli. 
 
  Confocal microscopy showed that the pScaf was detected on all three aScaf constructs, 
but not on the control expressing the Aga2-V5 fusion, indicating that aScaf-pScaf assembly is 
specific and aScaf-dependent (Figure 4.3a). Quantitative flow cytometry further revealed that 
the number of pScafs per cell increased modestly as the aScaf size increased from ~54,000 per 
cell on aScaf1 to ~75,000
 
per cell on aScaf3 (Figure 4.3c). The number of pScafs per aScaf also 
increased as the number of pScaf binding sites (i.e. type II cohesins) on the aScaf increased, 
corresponding to: 0.53, 0.69 and 1.19 for aScaf1, aScaf2 and aScaf3, respectively (Figure 4.3d). 
Using this data, the aScaf-pScaf assembly efficiency was calculated by normalizing the number 
of pScaf per aScaf with respect to the theoretical maximum (i.e. one pScaf per aScaf1, two 
pScafs per aScaf2, and three pScafs per aScaf3). Interestingly, the aScaf-pScaf assembly 
efficiency observed for each of the three constructs was relatively low, ranging from a minimum 
of 34% for aScaf2 to 53% for aScaf1 (Figure 4.3e). Given that loading was performed with a 
saturating amount of pScaf protein, we hypothesized that aScaf-pScaf assembly might be limited 
by aScaf crowding on the yeast cell surface.  
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4.4.3. Modeling 2D Multi-scaffold Complex Assembly  
 
Figure 4.5. Statistical model of aScaf spatial distribution on yeast cell surface.  
a) Visual representation of aScaf distribution across the yeast cell surface for aScaf1, aScaf2, and 
aScaf3. (b) Poisson distribution representing the spatial arrangement of aScaf as the distance to 
nearest neighbor. Each line represents this distribution for a different aScaf expression level 
(6.25k – 100k per cell). (c) Visual representation of crowding-limited assembly hypothesis. 
When the distance between neighboring aScafs is less than the critical distance (rcrit), aScaf-
pScaf assembly does not occur (left). When the distance between neighboring aScafs is greater 
than rcrit, aScaf-pScaf assembly occurs (right).   
 To further explore our hypothesis that aScaf-pScaf assembly efficiency is limited by 
aScaf crowding on the yeast cell surface, we modeled the spatial arrangement of each aScaf on 
the cell surface using the Poisson distribution (Equation 4.1 and Figure 4.5a). Integrating this 
distribution allowed the percentage of total aScaf to be plotted with respect to its distance to 
nearest neighbor (Equation 4.2). When the aScaf expression level is high (e.g., 100k per cell), the 
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distribution of aScaf distance to nearest neighbor is tight, and the average distance between 
aScafs is relatively short. In contrast, when the aScaf expression level is low (e.g., 6.25k per 
cell), the distribution of aScaf distance to nearest neighbor is broader, and the average distance 
between aScafs is farther (Figure 4.5b). Based on this distribution, if aScaf-pScaf assembly 
efficiency is determined solely by aScaf surface crowding, then there should be a minimum 
aScaf distance to nearest neighbor (critical distance) below which aScaf-pScaf binding does not 
occur (Figure 4.5c).  
 
Figure 4.6. Confocal microscopy of yeast aScaf expression following TCEP treatment. 
Confocal microscope imaging of aScaf distribution following TCEP treatment. Scale bar 
represents 2 μm.  
 To test the crowding-limited assembly hypothesis, we needed to investigate aScaf-pScaf 
assembly over a range of aScaf expression levels. This was done by treating each of the aScaf 
constructs with various amounts of TCEP, which reduces a fraction of the disulfide bonds 
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anchoring the surface-displayed aScafs. TCEP treated aScafs were qualitatively analyzed by 
confocal microscopy to confirm that aScaf surface distribution appeared random (Figure 4.6). 
 
Figure 4.7. aScaf-pScaf assembly characterized for various aScaf expression levels.  
(a) Number of assembled pScaf per cell plotted with respect to aScaf1, aScaf2, and aScaf3 
expression level. (b) aScaf-pScaf assembly efficiency plotted with respect to aScaf expression 
level for aScaf1, aScaf2, and aScaf3. aScaf-pScaf assembly efficiency was normalized based on 
a maximum assembly efficiency of 100%. Data are plotted as the mean from at least two 
independent experiments. Error bars signify standard deviation.  
 Following confocal microscopy, each TCEP treated aScaf was loaded with pScaf and 
aScaf-pScaf assembly was characterized using quantitative flow cytometry (Figure 4.7a). 
Because of the sensitivity limitation of quantitative flow cytometry, aScaf-pScaf assembly 
efficiency was normalized to 100% for the highest aScaf-pScaf assembly observed for each 
aScaf construct. This normalization only modestly increased the observed aScaf-pScaf assembly 
efficiencies, and was used for the subsequent analyses. While the aScaf1-pScaf assembly 
efficiency was weakly dependent on aScaf1 expression level, the aScaf2-pScaf and aScaf3-pScaf 
assembly efficiencies exhibited a strong inverse correlation with aScaf expression level (Figure 
4.7b). This result is consistent with our hypothesis that aScaf-pScaf assembly is limited by 
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crowding effects, as aScaf assembly was more efficient when there were fewer aScaf proteins 
present on the surface. Moreover, the shape of the aScaf-pScaf assembly efficiency curves in 
Figure 4.7b revealed that the aScaf3-pScaf assembly efficiency is the most sensitive to aScaf 
expression level, indicating that aScaf surface crowding is more prominent for larger aScaf 
constructs. This observation suggests that aScaf-pScaf assembly occurs in an “outside-in” 
manner (Figure 4.8a).  
 
Figure 4.8. Statistical model of aScaf-pScaf assembly based on aScaf surface crowding. 
(a) Visual representation of “outside-in” aScaf-pScaf assembly mechanism. (b) Theoretical 
aScaf-pScaf assembly efficiency plotted as a function of aScaf expression level for various 
critical distances. (c) Theoretical number of pScaf assembled on aScaf1, aScaf2, and aScaf3, 
plotted with respect to aScaf expression level and for various critical distances (top curve – 6 nm; 
bottom curve – 18 nm).   
 After experimentally characterizing the aScaf-pScaf assembly efficiency with respect to 
aScaf expression level, we aimed to elucidate the critical distance required for aScaf-pScaf 
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binding of each aScaf design. Using the Poisson distribution (Equation 4.2), we plotted the 
theoretical aScaf-pScaf assembly efficiency as a function of aScaf expression level for different 
critical distances (Figure 4.8b). These curves indicate that if the critical distance for a particular 
aScaf design is small (i.e. 6 nm), aScaf-pScaf assembly efficiency is weakly dependent on aScaf 
expression level. In contrast, if the critical distance for a particular aScaf design is large (e.g. 18 
nm), the aScaf-pScaf assembly efficiency is strongly dependent on aScaf expression level. In 
statistical terms, the concavity of the aScaf-pScaf assembly efficiency curve is representative of 
the aScaf critical distance. aScafs characterized by large critical distance will have more concave 
assembly curves, indicating pronounced sensitivity to crowding effects.  
 
Figure 4.9. Determining critical distance for aScaf-pScaf assembly.  
(a) Number of pScaf per cell for aScaf1, aScaf2, and aScaf3, plotted with respect to aScaf 
expression level. Solid lines represent best-fit curves generated by solving for the most 
representative critical distance for each aScaf dataset. Dashed lines represent theoretical curves 
for other critical distance values. (b) Critical distance required for aScaf-pScaf assembly for 
aScaf1, aScaf2, and aScaf3. (c) aScaf-pScaf assembly efficiency plotted with respect to aScaf 
expression level for aScaf1, aScaf2, and aScaf3. Solid lines represent best-fit curves in (a). Data 
are represented as the mean of at least two independent experiments. Error bars signify standard 
deviation.  
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 Using the assembly efficiency curves in Figure 4.8b, the theoretical number of pScafs 
assembled on each aScaf construct was determined as a function of aScaf expression level for 
various critical distances (Figure 4.8c). Interestingly, these curves suggest that if aScaf-pScaf 
assembly is limited by aScaf surface crowding, increasing aScaf expression level beyond a point 
will actually result in a net reduction in the number of pScaf per cell.  
 The critical distance for each aScaf construct was determined by fitting the integrated 
Poisson distribution (Equation 4.2) to the aScaf-pScaf assembly data in Figure 4.7a by varying 
the critical distance in a least-squares regression (Figure 4.9a). As expected, this curve fitting 
revealed that the critical distance was dependent on aScaf size, ranging from 7.9 nm for aScaf1 
to 14.0 nm for aScaf3 (Figure 4.9b). After determining the critical distance for each aScaf 
design, the corresponding aScaf-pScaf assembly efficiency curve was plotted as a function of 
aScaf expression level (Figure 4.9c). The theoretical aScaf-pScaf assembly efficiency curves fit 
the experimental data well, especially for aScaf2 and aScaf3. Consistent with our previous 
observations, these curves indicate that the largest aScaf design (namely, aScaf3) is the most 
sensitive to crowding effects while the smallest aScaf design was the most robust to aScaf 
surface crowding.  
 Using these aScaf-pScaf assembly efficiency curves and assuming a constant 70% pScaf-
ligand assembly efficiency for each design, the predicted number of ligands assembled per cell 
was plotted as a function of aScaf expression level (Figure 4.10a). Based on crowding limited 
aScaf-pScaf assembly, the maximum possible ligand display level on aScaf1 is ~259,000, which 
is achieved at an aScaf expression level of ~257,000 (Figure 4.10a). The maximum possible 
ligand display level for aScaf2 is ~300,000, which is achieved at an aScaf expression level of 
~146,000. Interestingly, under crowding-limited aScaf-pScaf assembly, aScaf3 is only predicted 
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to display a maximum of ~252,000 ligands per cell at an aScaf expression level of ~81,000, 
which is lower than both aScaf1 and aScaf2. While unexpected, this result has significant 
implications for the design and application of surface-displayed 2D multi-scaffold assemblies. 
For example, applications that seek to achieve the maximum ligand loading using 2D multi-
scaffold assemblies should be wary of engineering large aScaf proteins, as the critical distance 
associated with these constructs will require a greater amount of cell surface area for efficient 
loading.  
 
Figure 4.10. Total ligand loading predicted based on surface-crowding limited 2D multi-
scaffold complex assembly. 
(a) Total ligand loading based on surface-crowding limited aScaf-pScaf assembly plotted with 
respect to aScaf expression level for aScaf1, aScaf2, and aScaf3. (b) Total ligand loading plotted 
with respect to crowding-limited aScaf-pScaf assembly efficiency. Dashed line represents 
maximum possible ligand display level, which occurs at 37% aScaf-pScaf assembly efficiency 
for all constructs. For all graphs, best-fit critical distance values of 7.9 nm, 10.5 nm, and 14.0 nm 
were used for aScaf1, aScaf2, and aScaf3, respectively.   
Another interesting implication of crowding-limited aScaf-pScaf assembly is that the 
total ligand display level is maximized for each aScaf design at an aScaf expression level that 
corresponds with an aScaf-pScaf assembly efficiency of 1/e (or ~37%) (Figure 4.10b). These 
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results suggest that when the aScaf expression level is higher than this optimum, each additional 
aScaf protein crowds out previously accessible aScaf proteins, rendering them inaccessible to 
pScaf binding. This phenomenon results in a net reduction in the number of possible pScafs – 
and corresponding ligands – assembled per cell. In contrast, when aScaf expression level is 
below this optimum, the spatial distribution of aScaf across the yeast cell surface is suboptimal – 
that is, the total yeast cell surface area is not being used efficiently for pScaf binding. As a result, 
more aScafs can be added to the surface without crowding effects dominating, increasing the 
number of possible pScafs and ligands assembled per cell, but at the expense of multi-scaffold 
assembly efficiency. These results highlight the clear tradeoff that arises from aScaf crowding: 
increasing aScaf expression level (from 0 to optimum) causes an increase in total ligand density 
while reducing the assembly efficiency.  
4.5. Conclusions and Outlook 
 2D multi-scaffold assemblies provide an elegant method for finely controlling the spatial 
and stoichiometric organization of ligands on a cell surface. While these assemblies have 
traditionally been studied in the context of whole-cell biocatalysis,
293,319
 they have significant 
potential in artificial antigen presentation, as complex molecular architectures can be engineered 
to mimic the structure and composition of the immunological synapse. Despite their potential, 
the molecular principles that govern how 2D multi-scaffold complexes assemble, and the 
mechanisms by which the assembly architecture influences its overall function are not well 
understood due to a lack of quantitative tools. Here, we developed experimental and theoretical 
approaches to quantify each step of a multi-scaffold assembly process. This work presents the 
first quantitative study of cellulosomal structure assembly and revealed that aScaf-pScaf 
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assembly is limited by aScaf molecular crowding, which should provide guidance for design of 
future cell-surface displayed protein assemblies.  
 Using quantitative flow cytometry, we observed that aScaf-pScaf assembly efficiency is 
dependent on aScaf expression level. This result suggests that aScaf surface crowding limits 
aScaf-pScaf assembly efficiency, and therefore aScafs must be separated from their nearest 
neighbor by a minimum distance for pScaf binding to occur. The molecular basis of this 
crowding effect is likely related to the random distribution of aScafs across the yeast cell surface. 
If aScaf surface distribution is random, then some areas of the yeast cell surface will have more 
aScafs than other areas. As the aScaf expression level increases, some of these more populated 
areas will become so crowded that early pScaf binding events block a surrounded aScaf from 
accessing a pScaf in the bulk solution. We simulated this phenomenon by modeling aScaf 
expression on the yeast cell surface as a Poisson distribution and found that aScaf critical 
distance was dependent on aScaf size (aScaf1 – 7.9 nm, aScaf1 10.5 nm, aScaf3 14.0 nm) 
meaning larger aScafs are more sensitive to crowding-limited pScaf assembly.  
 The dependence of aScaf-size on surface crowding likely arises from an “outside-in” 
mechanism of aScaf-pScaf assembly. Under “outside-in” assembly, the most distal cohesin on 
aScafs are closest to the “bulk” solution, and thus likely to bind pScafs before cohesins closer to 
the cell surface. As more of the distal cohesins become occupied by pScafs, neighboring partial 
assemblies begin to obstruct the diffusion of soluble pScafs from the bulk solution to the interior 
cohesins, resulting in additional aScaf-pScaf assembly inefficiency. Therefore, at the same aScaf 
expression level, aScafs composed of more cohesins would have lower aScaf-pScaf assembly 
efficiency than aScafs composed of fewer cohesins.  
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 Interestingly, inefficient aScaf-pScaf assembly caused by surface crowding is not 
necessarily an impediment to achieving a high cellular ligand density. Instead, our model 
predicts that total ligand density is maximized when surface crowding allows only 37% of 
expressed aScaf to bind pScaf (i.e. 37% aScaf-pScaf assembly efficiency). At first, this result 
may seem counterintuitive as one might assume that high assembly efficiency correlates with 
higher ligand density. However, because aScaf crowding limits aScaf-pScaf assembly efficiency, 
high assembly efficiencies are only possible at relatively low aScaf expression levels. While 
increasing aScaf expression level reduces aScaf-pScaf assembly efficiency, the additional aScafs 
(up to ~257,000 aScaf1 per cell, ~145,000 aScaf2 per cell, and ~81,000 aScaf3 per cell) provide 
more pScaf binding sites – and thus ligand binding sites – than are lost by inefficient assembly 
(Figure 4.10b).  
 Achieving the aScaf expression level necessary for maximum ligand display presents 
other challenges given the considerable metabolic burden such expression levels impose. 
Although we were able to achieve a maximum expression level of ~103,000 for the smallest 
aScaf used in this study (aScaf1), this is was only possible by expressing the pScaf separately 
and assembling the 2D multi-scaffold complexes in vitro. If all the components of the assembly 
(aScaf, pScaf, and potentially each unique ligand) were expressed in a single cell, the maximum 
attainable aScaf expression level would like be significantly reduced, given the increased 
metabolic burden associated with expressing each protein. Nevertheless, the tradeoff between 
ligand density and aScaf-pScaf assembly efficiency observed in this study highlights an 
unanticipated consequence of molecular crowding during a stochastic protein assembly process. 
 While 2D multi-scaffold assemblies have significant potential in artificial antigen 
presentation, the size of these supramolecular complexes may introduce additional 
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complications. Multi-protein assemblies “built-up” from the cell surface are not generally found 
on natural or engineered APCs and the presence of these large assemblies will like affect the 
spatial distribution of proteins at the T cell interface. In Chapter 1, we introduced the kinetic-
segregation theory of TCR triggering, which postulates that size-based exclusion of phosphatases 
from the T cell-APC interface drives ITAM phosphorylation (Figure 4.11a). A number of 
studies have demonstrated that restricting phosphatase exclusion from the engaged TCR – 
including by elongating TCR ligands – significantly reduces kinase activity, and thus inhibits T 
cell activation.
104–107
 Therefore, it is possible that surface-displayed 2D multi-scaffold assemblies 
loaded with TCR ligands will increase the space between an antigen presenting surface and the T 
cell membrane, reducing size-driven segregation of CD45 from the cSMAC (Figure 4.11b).  
 
Figure 4.11. Effect of 2D multi-scaffold assemblies on size-based CD45 segregation. 
(a) The kinetic-segregation theory of TCR triggering hypothesizes that ITAM phosphorylation is 
driven by the size-based segregation of bulky phosphatases (CD45) from the immediate 
proximity of an engaged TCR. The absence of phosphatases tilts the basal balance of kinase-
phosphatase activity on the TCR ITAMS in favor of phosphorylation and TCR triggering occurs. 
(b) Large 2D multi-scaffold assemblies could increase the distance between the antigen 
presentation surface and the T cell membrane, which would reduce CD45 segregation and thus 
inhibit TCR triggering.    
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 Going forward, we plan to apply the insights gained in this study to investigate how the 
structure of 2D multi-scaffold assemblies can be tuned to control T cell activation. While a series 
of studies will be necessary to determine what – if any – size assembly inhibits TCR triggering 
through reduced CD45 segregation, we believe that 2D multi-scaffold assemblies offer new 
opportunities in the artificial antigen presentation design space. In contrast to conventional 
patterning technologies associated with planar artificial antigen presentation, 2D multi-scaffold 
assemblies provide extraordinary control over the spatial and stoichiometric arrangement of T 
cell ligands on any nearly antigen presentation surface imaginable. Further, these assemblies 
enable the construction of highly ordered supramolecular structures composed of multiple of T 
cell ligands, which can be designed to resemble the immunological synapse. Using orthogonal 
cohesin-dockerin binding pairs, scaffold-based assembly can direct the assembly of molecules 
associated with cSMAC (i.e. pMHC) to the center of the complex and simultaneously direct 
molecules associated with the p/dSMAC (i.e. ICAM-1) to the distal regions of the complex 
(Figure 4.11b).  
4.6. Materials and Methods 
4.6.1. Strains, Media and Reagents 
 The S. cerevisiae strain EBY100 (Invitrogen, Carlsbad, CA) was used for aScaf 
expression and 2D multi-scaffold assembly. The E. coli strains (Invitrogen) Mach1 and BL21 
(DE3) were used for recombinant DNA engineering and protein expression, respectively. All 
recombinant yeast and E. coli strains are summarized in Table 4.1. C. thermocellum DSM1237, 
C. cellulovorans, C. cellulolyticum and R. flavefaciens were purchased from ATCC (Manassas, 
VA) and cultured anaerobically following ATCC protocols. Recombinant EBY100 cells were 
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cultured using SC-Trp medium: 1.67 g/L yeast nitrogen base without amino acids, 5 g/L 
ammonium sulfate (Difco Laboratories, Detroit, MI), 20 g/L glucose, 15 g/L adenine 
hemisulfate, and 0.64 g/L complete supplement mixture without tryptophan (MP Biomedicals, 
Solon, OH). Induction of aScaf expression on yeast cell surface was performed in YPG media 
(1% yeast extract, 2% peptone, 2% galactose). E. coli was cultured in Luria-Bertani (LB) 
medium containing 50 μg/mL kanamycin. Unless otherwise indicated, all chemicals were 
purchased from Sigma-Aldrich (St. Louis, MO).  
4.6.2. Plasmid Construction, Protein Expression and Protein Purification 
 The aScaf and pScaf expression cassettes were cloned in pYD1 (Invitrogen, Carlsbad 
CA) and pET28a (Novagen, WI, USA), respectively. Sources of all protein sequences and 
primers used in this study are listed in Table 4.1. All plasmids were constructed using either 
homologous recombination in EBY100 or restriction-enzyme digestion and ligation in Mach1. 
aScaf surface expression was induced by incubating EBY100 strains transformed with pYD1-
Aga2-V5, pYD1-aScaf1, pYD1-aScaf2, pYD1-aScaf3 in YPG for 60 hours at 20˚C. pScaf 
protein expression was induced by incubating BL21 (DE3) transformed with pET28a-pScaf, in 
LB with 0.1 mM isopropyl-β-D-thiogalactopyranoside (IPTG) overnight at 16 °C. The pScaf 
protein was then purified from BL21 (DE3) cell lysate using fast protein liquid chromatography 
(FPLC) with a HisTrap HP column (GE healthcare, Fairfield, CT). The 6×His tag on pScaf was 
cleaved using thrombin (EMD Millipore, Billerica, MA) according to the manufacturer’s 
protocol following purification.  
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4.6.3. Quantitative Characterization of 2D Multi-scaffold Assembly  
 aScaf-pScaf assembly was performed by incubating 1.0 µM pScaf with 1.0×10
6
 yeast 
displaying each aScaf design overnight at 4 
o
C in 50 mM PBS buffer (pH 7.4) containing 1.0% 
BSA. After incubation, cells were washed and co-stained using anti-V5-AF647 (Invitrogen) and 
anti-c-Myc-PE (Invitrogen) at 2 ng/μL of each antibody for one hour on ice. aScaf-pScaf 
assembly was assessed qualitatively using an Olympus FV-1200 confocal microscope (Olympus, 
Melville, NY) with a 60x objective. The yeast-cell displayed assemblies were then co-stained 
with anti-V5-AF647 and anti-c-Myc-AF647 (R&D Systems, Minneapolis, MN) at 2 ng/μL of 
each antibody for one hour on ice. Co-stained cells were then analyzed using flow cytometry and 
the MFI of each component was recorded. The number of aScaf and pScaf present on the yeast 
cell was determined using quantitative flow cytometry with Quantum
TM
 Alexa Fluor 647 and 
Quantum
TM
 R-PE fluorescence quantitation beads (Bangs Laboratories, Fishers, IN). Briefly, 
quantitation beads with four densities of molecules of equivalent soluble fluorophore (MESF) 
were analyzed by flow cytometry, and the MFI corresponding to each distinct density of 
fluorophores was determined. Using these data, MESF (provided by the manufacturer) was 
plotted with respect to MFI and linear regression was performed to derive a relationship between 
fluorescence intensity and fluorophore number. The number of aScaf and pScaf on each co-
stained yeast cell was then determined using linear regression equation corresponding to the 
appropriate fluorophore.  
4.6.4. Modeling aScaf Spatial Distribution on Yeast Cell Surface and 2D Multi-scaffold 
Assembly 
 aScaf spatial distribution on the yeast cell surface was modeled as a Poisson distribution 
in which the probability (P) that one aScaf had a distance to nearest neighbor of r is:  
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𝑃(𝑟) = 2𝜋𝑟𝜌𝑒−𝜋𝑟
2𝜌              (4.1) 
where ρ represents the aScaf surface density (i.e. aScaf expression level/ yeast surface area). 
Yeast cells were assumed to be spheres with a radius of 2 μm based on confocal imaging and a 
previous study.
344
 The fraction of total aScaf (faScaf) with a distance to its nearest neighbor equal 
to or smaller than r is then found by integrating Equation 4.1 with respect to r: 
𝑓𝑎𝑆𝑐𝑎𝑓 = ∫ 2𝜋𝑟𝜌𝑒
−𝜋𝑟2𝜌𝑟
0
𝑑𝑟 = 1 − 𝑒−𝜋𝑟
2𝜌                (4.2) 
 The critical distance for aScaf1, aScaf2, and aScaf3 was determined by solving Equation 4.2 for 
an r value that best fit the experimental data in Figure 4.9 using non-linear least squares 
regression. After determining the rcrit for each aScaf, the theoretical aScaf-pScaf assembly 
efficiency was determined with respect to aScaf expression levels (i.e. different ρ values) by 
solving Equation 4.2 to for faScaf with r > rcrit at each aScaf expression level. The number of 
pScaf per aScaf was then found by multiplying the pScaf-aScaf assembly efficiency at a given 
aScaf expression level by the number of cohesins in each aScaf (i.e. 1 for aScaf1). The number 
of ligand per aScaf was similarly predicted as a function of aScaf expression level assuming 70% 
assembly pScaf-ligand assembly efficiency.   
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Chapter 5. Future Directions 
 T cell immunotherapy currently faces two significant challenges: difficulty identifying 
and isolating T cells recognizing appropriate antigenic targets and difficulty sustaining a robust 
and effective T cell response in vivo. In this dissertation, we have presented a set of quantitative 
and high-throughput molecular tools that are designed to address these limitations by enabling 
the rapid identification of immunologically relevant T cell epitopes and the fine-tuning of T cell 
activation through highly controlled artificial antigen presentation. Here, we will discuss future 
directions and ongoing research projects using these tools, and provide an outlook for the 
research area as a whole.  
5.1. Enhanced Antigen-Specific T cell Detection 
 While the MAPS strategy introduced in Chapter 2 allows for the rapid detection of 
promiscuously binding and potentially immunodominant T cell epitopes, MAPS alone is not 
capable of isolating T cells recognizing these epitopes. As discussed in Chapter 1, antigen-
specific T cells are traditionally isolated by staining the peripheral T cell population with 
fluorescently labeled pMHC tetramers and performing fluorescence activated cell sorting 
(FACS).
42,71
 This strategy has significantly improved our understanding of antigen-specific T 
cell phenotype and function; however, the binding affinity threshold for pMHC tetramer staining 
is insufficient to detect the entire T cell repertoire. The affinity limitation of pMHC tetramer 
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staining is especially problematic when the goal is to isolate self-reactive or tumor-reactive T 
cells, as these TCRs cells tend to bind their respective antigen with very low affinity.
70,71
 One 
strategy that has been pursued to increase the detection limit of antigen-specific T cells is to 
engineer highly multivalent pMHC molecules that bind TCR with greater binding avidity.
71,72
 A 
number of such pMHC multimers have been engineered to date,
73–77
 and the sensitivity of T cell 
epitope detection generally correlates with the degree of pMHC multivalency.
77
 Therefore, we 
are currently exploring the development of our own design of highly multivalent pMHC 
molecules for sensitive T cell epitope detection using protein-scaffold directed assembly.  
 
 
Figure 5.1. Schematic of bsAPC protein design. 
 
 In Chapter 3, we showed that soluble scaffolds (sAPCs) could be loaded with pMHC to 
create complexes with well-defined pMHC valency (Figure 3.3c). Further, we showed that these 
soluble multivalent pMHC complexes activated T cells in a valency-dependent manner (Figure 
3.5b), suggesting that TCR crosslinking and triggering by soluble complexes is strongly 
dependent on pMHC valency. Building on this approach, we modified the sAPC design to 
include an N-terminal biotinylation site (Figure 5.1). The resulting biotinylated sAPCs (bsAPCs) 
could then be tetramerized using fluorescently labeled SAv to create even higher valency 
complexes, which we have called ultramers (Figure 5.2a). For example, ultramers formed using 
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bsAPC3 provide a total of 12 pMHC binding sites while ultramers formed using bsAPC6 provide 
a total of 24 pMHC binding sites.  
 
Figure 5.2. Schematic of pMHC ultramer formation and its use for antigen-specific T cell 
detection. 
(a) pMHC ultramers are formed by incubating pMHC-loaded bsAPC scaffolds with fluorescently 
labeled SAv. (b) Percent of ultramer positive T cells when stained with various concentrations of 
ultramer formed with bsAPC1 or bsAPC3. (c) MFI of ultramer positive T cells when stained 
with various concentrations of pMHC ultramers formed with bsAPC1 or bsAPC3. Each point 
represents the mean of three independent trials and error bars represent standard deviation of the 
mean.   
 When used for antigen-specific T cell staining, pMHC ultramers formed with bsAPC3 
significantly outperformed pMHC ultramers formed with bsAPC1 (functionally equivalent to 
tetramers) (Figure 5.2b-c). This observation is consistent with a recent study using pMHC 
dodecamers and provides further evidence that increasing the valency of fluorescent pMHC 
multimers increases the staining sensitivity.
77
 Based on the idea that pMHC valency enhances 
staining sensitivity, a follow up study was performed using ultramers formed with bsAPC1, 
bsAPC3, and bsAPC6. While ultramers formed with bsAPC3 and bsAPC6 outperformed 
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ultramers formed with bsAPC1 in terms of T cell staining sensitivity, no significant difference 
was observed between ultramers formed with bsAPC3 and bsAPC6 (Figure 5.3). This could be 
due to the fact that the TCR being detected in these assays (HA1.7) binds its cognate pMHC 
(DR1-HA) with a sufficiently high affinity, such that the pMHC-TCR binding avidity is not 
significantly enhanced by increasing pMHC valency beyond 12. Additional studies using 
ultramer staining of peripheral antigen-specific T cells will be needed to determine if ultramers 
based on bsAPC6 can increase the detection limits of antigen-specific T cells beyond that of 
pMHC dodecamers.  
 
Figure 5.3. pMHC ultramer detection of antigen-specific T cells. 
Frequency of ultramer positive T cells observed when staining with pMHC ultramers formed 
using bsAPC1, bsAPC3, or bsAPC6. Ultramers were loaded with either DR1-HA (agonist 
pMHC) or DR1-CLIP (negative control). Each point represents the mean of three independent 
trials and error bars represent standard deviation.    
5.2. Highly Organized Acellular Artificial Antigen Presentation  
In Chapter 3, we showed that yeast antigen presenting cells (yAPCs) could be used to 
finely tune T cell activation by controlling the spatial and stoichiometric organization of T cell 
ligands on surface-displayed scaffolds. While yAPCs provide a robust cellular platform for 
artificial antigen presentation, their microbial nature precludes their use in a clinical 
environment. Fortunately, functionalized sAPCs – like the bSAPCs described in Section 5.2 – 
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allow organized protein-scaffold directed assemblies to be presented on a wide range of 
biocompatible surfaces. As we continue to explore applications of protein-scaffold directed 
artificial antigen presentation, we plan to transition to a biocompatible platform like 
biodegradable SAv-coated microparticles and/or nanoparticles. In addition to providing a more 
clinically relevant activation surface, acellular platforms allow the investigation of important 
physical parameters not possible on yeast including activation-surface rigidity,
345–347
 size,
227,285
 
and shape.
218,225
  
 
 
Figure 5.4. Systematic investigation of T cell activation using highly organized protein 
assemblies. 
Systematic investigation of T cell activation can be performed in four steps. First, a panel of 
assemblies presenting various stoichiometric ratios of a target costimulatory molecule (or 
molecules) and pMHC are formed. Assemblies will be loaded on protein scaffolds, which are 
fixed to biocompatible particles. These assembly-displaying particles are then used to activate T 
cells. T cell activation is assessed by measuring cytokine secretion and monitoring T cell 
expansion. Finally, the phenotype of the expanded T cells is examined using CyTOF. This data is 
then analyzed and integrated with existing data, the costimulatory molecule assembly is 
exchanged, and the process is repeated.  
Regardless of the specific presentation platform, our primary research goal is to 
systematically investigate how the spatial and stoichiometric organization of T cell ligand 
assemblies influences T cell activation. We have previously observed that CD4
+
 T cell IL-2 
secretion is maximized when the cells are stimulated with yAPCs presenting 85% ICAM-1 and 
15% pMHC (Figure 3.14a). Based on this result, it is reasonable to assume that manipulating the 
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stoichiometric ratio of other costimulatory ligands could be used to optimize other T cell 
responses (e.g. T cell proliferation, Th1 polarization, etc.). Therefore, we plan to continue these 
studies going forward, expanding the scope of our investigation to include T cell proliferation 
capacity and T cell phenotype using high-dimensional tools like CyTOF (Figure 5.4). By 
including these additional outputs in our study of T cell activation, we can gain a deeper and 
more holistic understanding of how T cell signal integration translates to different functional 
responses. Further, this systematic approach to investigating T cell activation by high-
dimensional phenotypic analysis could elucidate biomarkers or – patterns of biomarkers – that 
correlate with either effective or ineffective T cell phenotypes for a particular immunotherapeutic 
application. Once optimal presentation patterns are understood (e.g. optimum ICAM-1 pMHC 
ratio), we can shift our focus to the development of off-the-shelf aAPCs custom engineered to 
elicit specific T cell responses.          
5.3. Final Thoughts   
 T cell immunotherapy is a broad and interdisciplinary research area involving 
immunology, biostatistics, computer science, molecular biology, and engineering. Given the 
scope of T cell immunotherapy research, the tools described in this dissertation represent just one 
of many strategies for addressing some of the more intractable challenges in the field. Further, as 
our understanding of T cell biology – and the immune system more broadly – improves, new 
challenges will certainly emerge, as others are resolved. Therefore, I will conclude with a brief 
discussion of where I believe the field is headed, and what tools and strategies are likely to be 
important in the future.  
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 In this dissertation, we have focused on tools related to CD4
+
 T cell identification and 
activation. In contrast, most immunotherapy research focuses exclusively on activating and 
expanding CD8
+
 T cells. CD8
+
 T cells execute effector functions directly on the targeted cell, 
and thus are indispensable for most types of T cell immunotherapy; however, CD4
+
 T cells play 
an important role in sustaining a CD8
+
 T cell response, as well as activating B cells. In fact, a 
number of studies have suggested that the presence of CD4
+
 T cells promotes more robust anti-
tumor CD8
+
 T cell responses,
138,348–351
 and that CD4
+ 
T cells alone can also mediate tumor 
regression.
352
 These findings highlight the fact that the functional relationship between CD4
+
 T 
cells and CD8
+
 T cells is not fully understood. Therefore, researchers should avoid rigid and 
potentially superficial categorization and instead investigate how the synergistic activity of CD4
+
 
and CD8
+
 T cells can be leveraged to achieve an optimal T cell response.  
 While rapid development and FDA approval of CAR T cell therapy speaks to its 
therapeutic potential, the most broadly efficacious immunotherapies developed to date are 
immune checkpoint inhibitors.
353
 Immune checkpoint inhibitors are monoclonal antibodies that 
bind to inhibitory proteins like PD-L1 and CTLA-4, effectively blocking T cells from integrating 
the signals that attenuate T cell activation. Because immunosuppression within the tumor 
microenvironment continues to pose a significant challenge for cell-based immunotherapies in 
solid tumors, a combination of checkpoint inhibitors with such therapies should improve overall 
treatment efficacy. Similarly, as computational and technological advances improve the science 
of protein engineering, combining deliverable therapies with cell-based approaches should also 
provide new methods for disrupting immunosuppression in tumors and tuning T cell response in 
situ.  
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 An important consideration that is often underappreciated in academic research 
laboratories is how market and regulatory forces shape the risk profile of particular drugs or 
therapies. For example, non-cell based drugs and biologics have a well-established regulatory 
framework for their development and approval. In contrast, the regulatory landscape for cell-
based therapies is poorly defined and likely to change, which translates to greater risk for 
pharmaceutical companies pursuing these therapies. These regulatory considerations will likely 
incentivize the development of more conventional therapies with better-defined risk profiles into 
the future. Therefore, it will be important to understand how ambitious cell-based 
immunotherapies interact and synergize with the pipeline of conventional drugs and biologics.   
 
 
Figure 5.5. Molecular tools for isolating and activating antigen-specific T cells. 
  
 Finally, as the information bottleneck shifts from data acquisition to data analysis, 
computational methods will likely play an increasingly prominent role in generating new 
insights. This paradigm shift toward high-dimensional data analysis has been catalyzed by 
129 
 
technological breakthroughs that substantially increase the number of parameters that can be 
studied in a single experiment (e.g. whole genome/exome sequencing and CyTOF). In Chapter 
1 and Chapter 2, we briefly discussed the promise demonstrated by machine learning methods 
using artificial neural networks in predicting peptide-MHC binding. Similar methods should 
continue to play an important role in analyzing and deconvoluting highly complex datasets as 
new high-dimensional tools like CyTOF and rapid whole-exome sequencing become more 
widely used.
354,355
 Further, because machine learning methods improve as the amount of relevant 
data increases, systematic studies that aim to fully characterize the space of possible T cell 
responses should be more valuable than previously thought. For example, a significant volume of 
phenotypic data correlating with ineffective, inappropriate, or counterintuitive T cell responses 
could generate profound insights – that would otherwise never occur – when fed into advanced 
artificial neural networks.    
 In this dissertation, we have introduced a novel set of molecular tools that are designed to 
address some of the more difficult challenges facing T cell immunotherapy (Figure 5.5). Like all 
tools, we cannot envision every possible application at the time of development. Similarly, the 
most appropriate application of each tool discussed will likely change over time. Nevertheless, 
we believe that protein-scaffold directed assembly is an exciting toolset that will continue to 
have a wide range of applications in molecular biology and immunology in the future.
356
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